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Cellular oncogenes form a class of evolutionary conserved genes which are 
thought to be involved in the control of cell proliferation and differentiation and 
also may play a role during development. Organisms with an established 
embryology may offer valuable prospects in our understanding of cellular 
oncogene function. In this thesis I describe my attempts to study cellular 
oncogenes in Xenopus as a means to the above end.
By the use of highly labeled probes from a variety of birds, mammals and their 
viruses and low stringency hybridisation conditions I have shown the presence 
of N-myc, c-myc, c-ha-ras, c-ki-ras, c-src, c-abl, c-erbB, c-fms, c-fos, c-sis 
and c-rel related sequences in Xenopus genomic DNA. Similar experiments also 
show the presence of N-myc, c-myc, c-ha-ras, c-ki-ras and c-fos related 
sequences in X.borealis RNA.
The c-myc gene was chosen for further analysis with the isolation of 
homologous clones from a X.borealis previtellogenic ovary cDNA library which I 
had constructed. DNA sequence analysis and southern blotting experiments 
suggest that there are two distinct classes (A and B) of c-myc genes in 
Xenopus and in addition at least one of these classes may be polymorphic. 
Sequence analysis of the class A c-myc genes show they are highly 
homologous to the c-myc genes of other species.
The Xenopus c-myc gene(s) are expressed in a variety of tissues at a low level 
but oocytes contain a large store of maternal c-myc mRNA (about 5 x 10 6 
copies per stage VI oocyte). After fertilisation the accumulated c-myc mRNA is 
degraded to less than 40 copies per cell by late blastula. New transcription of 
the c-myc gene(s) begins at late gastrula to maintain on average 30 - 130 
copies of c-myc mRNA per cell throughout the rest of embryoinic development. 
Preliminary evidence suggests that there is a localisation of c-myc expression 
during neural development. Attempts to generate an antiserum against the 
Xenopus c-myc protein are also described.
These results indicate Xenopus posseses a class of genes that are regarded as 
crucially important in other systems. In particular the Xenopus c-myc gene(s) 
are highly conserved throughout evolution and show an unusual regulation
during oogenesis and early development where high c-myc expression is 
uncoupled from cellular proliferation. In addition the c-myc gene(s) may be 
involved in neural differentiation.
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Although the causes of cancer are elusive it is the current belief in 
molecular oncology that a neoplastic cell develops from a normal progenitor 
cell as a result of mutations in a limited set of cellular genes. These mutant 
genes are known as active cellular oncogenes and their wild type counterparts 
as normal cellular oncogenes or proto-oncogenes (c-onc'$. Normal cellular 
oncogenes are strongly implicated in the growth control of cells hence they 
may be involved in differentiation and development. Oncogene research is one 
of the most intensively studied areas in modern molecular biology and as a 
result this introduction will neccessarily be selective. Many excellent reviews 
have been written which can be consulted for more detail (Bishop 1983, 1985, 
Deusberg 1983, Muller and Verma 1984, Varmus 1984, Bishop and Varmus 1985, 
Hall 1986). Xenopus was used as a model organism to study cellular 
oncogenes in this thesis therefore the final part of this introduction will discuss 
gene expression in Xenopus.
1.2 Discovery of Cellular Oncogenes
In 1911 Rous discovered, in chickens, Rous sarcoma virus (RSV) - the first 
acutely transforming retrovirus (Rous 1911). Over 20 such viruses have now 
been isolated from a variety of birds and mammals (table 1.1) each carrying a 
distinct piece of genetic information responsible for the rapid induction of 
tumours and neoplastic transformation of cultured cells i.e. the viral oncogene 
(v-ond). In the early 1970's it was felt that cellular DNA might contain the 
potential to create viral or (active) cellular oncogenes by somatic mutation 
and/or reverse transcription (Huebner and Todaro 1969, Temin 1971). Now we 
know that cells from a variety of organisms harbour genetic loci homologous 
to retroviral oncogenes and that these loci are cellular not viral in origin. Also 
some cellular oncogenes with no viral counterparts have been isolated hence 
there are probably many genes important in the genesis of cancer.
1.2.1 Proto-oncogenic progenitors of retroviral oncogenes
The largest group of cellular oncogenes have been identified by the 


























































Species of Conditional Non-conditional In vitro Multiple 
origin mutants mutants rccomlmtant * iraiistliiciion" '
chicken + + +
chicken + + 
chicken + -I- + 
chicken +
chicken + + + 
chicken +





mouse + + +
mouse + + +
mouse +
mouse + +
rat + + +
rat +
rat + +





cat, woolly + + 
monkey
Abbreviations: USV, Rous sarcoma virus: Y7.1. Yarnaguclii 73 sarcoma vims; USV. U-.li s:ircoma vinis; TuSV. Fujiiumi sarcomavirus; MC29. m)clix.-yli)n).ilosis-29 virus- Ml 12 
Mill Hill-2 virus; AMV. avian myclohl.isloM's virus; ACV. a\ian a>irmihla<tiiMS virus; KLV-T. rcticulo-cndothcliosis virus, strain T: Mo-MSV. Moloncy murinc sarcoma virus' 
Ah-MLV. Abclson murinc leukemia virus; Ila-MSV. Harvey inurine sarcoma virus; RaSV. Ra^hecd rai sarcoma virus; Ki-MSV. Kirslcn murinc sarcoma vinis;ST- GA- SM GR 
PI-FcSV, Snydcr-Thcilcn. Gardncr-Arnstcin, Susan McDonoujih. Gardner-Rasliccd, Parodi-lrpcns feline sarcoma viruses; SSV, simian sarcoma virus
+ means lliat the v-o/ic sequence has been found to have transforming activity when moved lo a new context by in vitro manipulation of cloned DNA
+ means that ihc one sequence Ims been encountered in two or more viruses that appear to have independently transduced the same c-onc from one or more host species
v-\cj and v-Jgr appear to be derived from the same cognate c-onc
v-y/ij and v-/c.! arc derived from the same cognate c-onc
\-mil (also known as v-mhi) and v-/v;/are derived from the same copnatc t-fiic
Ha-nii of UALU-MSV (also known as v-ixi.i), lla-ni.t of lla-MSV, mid Ra-n« of RaSV arc all derived from the same cognate c-onc. called c-Hz-ras
Pan of llie mammalian p-actin sequence is found in the pcnonie of GK-FcSV
Table 1.1 (From Varmus 1984)
oncogenes apparently have served as targets for genetic transduction by 
retroviruses. Mutations are introduced during the process rendering the 
cellular gene an active viral oncogene. The selective pressure for the evolution 
of oncogenic retroviruses remains unclear.
In 1976 it was established, by using cDNA specific for v-src of RSV, that 
closely related sequences existed in the genome of chickens (Stehelin et al 
1976). Subsequently src related sequences were detected in a variety of 
vertebrates from fish to man (Spector, Varmus and Bishop 1978). With the 
advent of molecular cloning it has now been confirmed that all the viral 
oncogenes in table 1.1 have cellular counterparts (Bishop 1983, Varmus 1984, 
Muller and Verma 1984). In fact cellular oncogene related sequences have been 
isolated from Drosophila for src, abl, erbB, ras and myb (Hoffman-Falk et al 
1983, Simon et al 1985, Hoffman et al 1983, Linveh et al 1985, 
Neumann-Silberberg et al 1984, Bishop et al 1985). Even yeast has ras related 
sequences (Defeo-Jones et al 1983, Powers et al 1984). Such high evolutionary 
conservation strongly implies that cellular oncogene products play an essential 
and basic role in normal cellular growth and development.
1.2.2 Functional tests identifying cellular oncogenes
An appropriate recipient cell line can by neoplastically transformed by the 
introduction of nuclear DNA from tumours or transformed cell lines (Cooper 
1982, Land, Parda and Weinberg 1983). This perceives the cellular oncogene as 
an active oncogene and that the recipient cells acquire a dominant mutant 
allele. For example the lesion in the ras family of oncogenes is a single point 
mutation at amino acids 12, 13 or 61 (Hall 1984, Levinson 1986). Table 1.2 
indicates the candidate oncogenes detected by this assay.
Two major limitations to this are that it examines oncogenic potential in a 
cell type and species that differ from the donor and that the recipient is 
already an established cell line. This may partly explain why 80% of 
spontaneous human tumours fail in this assay (Krontris and Cooper 1981, 
Copper 1982) and why many active genes identified belong to the ras family.
Primary cells have now been transformed using combinations of cloned 
oncogenes (Land, Parda and Weinberg 1983, Ruley 1983). Co-operation of a 
nuclear gene such as myc, adenovirus E1a, polyoma large T or p53 (with 
supposed immortotaation function) together with ras, adenovirus E1b or












Examples of cell types in which 
transforming activity is found 3
Bladder carcinoma cell line (human)
Urinary tract tumors (human)
Lung carcinoma cell line (human)
DMBA and NMU-induccd mammary carcinomas
(rat) 
DMBA/TPA-induced skin papillomas, benign and
malignant (mice) 
Melanoma cell line (human) 
Mammary carcinosarcoma line (human) 
MC, BP. DEN and MNNG-transformcd primary
cells (guinea pig) 
Mycloid tumor cell line (mouse) 
Lung carcinomas and cell lines (human) 
Colon carcinomas and cell lines (human) 
Pancreatic carcinoma cell line (human) 
Gall bladder carcinoma cell line (human) 
Rhabdomyosarcoma cell line (human) 
Ovarian carcinoma, primary' (human) 
Acute lymphocytic leukemia line (human) 
MC-induced fibrosarcomas and MC-transformcd
fibroblasts (mouse)
-/-irradiation induced thymoma (mouse) 
MC-induccd thymic lymphomu and macrophage
tumor lines (mouse) 
BP-induccd fibrosarcoma (mouse) 
Ncuroblastoma cell line (human) 
Burkitt lymphoma line (human) 
Fibrosarcoma and rhabdoniyosarcoma cell lines
(human)
Promyclocytic leukemia line (human) 
T cell leukemia line (human) 
Melanoma cell lines (human)
Teratocarcinoma line (human, late passage)
Lung carcinoma line (human)
Acute and chronic myeloblastic leukemia (human)
Lung carcinoma cell line (mouse)
Carcinogen-induced thymoma (mouse)
Plasmacytoma cell lines (mouse)
ENU-relaied neuroblastoma cell lines (rat)
ALV-indueed hursal lymphomas (chickens) 
Burkitt lymphoma lines (human)
Intermediate T cell lymphoma lines (human) 
MLV-induced T cell lymphomas (mouse)
Mammary carcinoma cell line (human)
MM TV and UMBA-induced mammary carcinomas
(mouse)
PreB tumor cell lines (human) 
AbMLV-induced prc B tumor cell lines (mouse) 
Myeloma and plasmacytoma cell lines (human.
mouse)
Mature T cell lymphoma lines (human, mouse) 
Pre B cell leukemia cell line (human) 
MNNG-treatcd osleosarcoma cell line
1 Abbreviations: MC. meln\ Icholanthrcnc: UMIiA. Jimellu Ihcn/.anlhracene: TPA. liMtailecano) I-1 3-plinrbnl 
acetate: NMU. niiroMiiuetlivlurea: MNNG. N-meili>l-N-niiro-N-nitrogu,inidine DC. bendalpwene; DUN. 
die(h)lnitro<.amine; LNU, cih)lnitro<;ourca.
Table 1.2 (From Varmus 1984)
polyoma middle T (with supposed transformation function) is sufficient to 
induce neoplastic transformation. It is unclear whether two oncogenes are 
inevitably required as very high levels of a mutant ha-ras allele alone can 
transform primary rodent cells (Spandidos and Wilkie 1984).
In vivo animal models using a variety of chemical carcinogens to generate 
tumours in a reproducible manner have identified active oncogenes (Table 1.3; 
Barbacid 1986). The ras family appear to predominate in this assay and table 
1.4 describes the reproducibility of lesions in the ha-ras activated tumours. It 
seems these agents generate adducts with bases in the ha-ras DNA leading to 
mutation which occurs shortly after application of the carcinogen. Therefore 
oncogene activation is concomitant with the initiation of carcinogenesis.
1.2.3 Proviral insertions activating cellular oncogenes
Most retroviruses lack a viral oncogene but still induce tumours after a 
latent period. These tumours appear to contain mutant cellular oncogenes that 
are activated by proviral insertions (Nusse 1986). The insertion event seems to 
be of prime importance causing an increase in the level of expression of the 
target gene influenced by strong promoter or enhancer elements present in the 
long terminal repeat (LTR) of the provirus but sometimes the coding sequences 
also get altered. The first gene identified by this means was the chicken 
c-myc gene which had avian leukosis virus DNA integrated next to it (Hayward, 
Neel and Astrin 1981, and later). Table 1.5 lists the other oncogenes that have 
been identified and it is interesting to note many are previously unknown. 
Note that the provirus in all the resulting tumours act in a dominant way as a 
consequence of selection by investigators though there is evidence to suggest 
mutations in tumour cells are recessive. In the future it is possible insertional 
mutagenesis by retroviruses will help in the isolation of such sequences.
1.2.4 Chromosomal translocations and cellular oncogenes
Chromosomal translocations frequently occur in tumour cells. In solid 
tumours these changes often are heterogeneous and not well defined but in 
hematopoietic malignancies specific translocations are common (Rowley 1980, 
1983). Interest has focused on whether any cellular oncogenes reside at the 
translocation breakpoints such that they undergo structural and functional 
alterations (Rowley 1983). Both the cellular myc and abl genes have been 
implicated as such oncogenes (myc will be discussed later). In chronic
Oncogcncs in carcinogen-induced animal tumors
Species Carcinogen Tumor Oncogene
aNumber in parentheses indicates number of tumors tested.
Table 1.3 (From Barbacid 1986)







































































Activating Incidence of activating 
mutation mutation in tumors
G 35 -*A













Table 1.4 (From Barbacid 1986)





















































































' Abhrcvuitions: ALV, ;ivi;m Icukosis virus; CSV, chicken s\ncyli.il * ills. RI'V, rinp-ncckcil |'|IC;I-..M>I \ iruv; MAV. iii\i'lnlil.is|osis-as'.oci:ilctl virus: Mo-MLV. Moloncy inurinc 
leukemia virus; ( rcLV. feline Icukcinu virus; IAI". inlraciMcrn.il A particle; MM TV. mouse mammary lumor virus; MCF-MLV, mink cell focus-rorniinj; murinc leukemia virus. 
b Cloned DNA containinc an MLV LI l< was used as an insertion imitajien via trunslecnon,
Table 1.5 (From Varmus 1984)
myelogenous leukemia the abl gene on chromosome 9 is translocated to a 
specific region of chromosome 22 called bcr (Heisterkamp et al 1983, Groffen 
et al 1984). Table 1.6 summarises the candidate oncogenes involved with 
chromosomal translocations.
1.2.5 Cellular oncogenes in amplified DNA
Many tumour cell lines manifest amplified cellular DNA detected 
cytologically as homogeneously staining regions (HSRs) in chromosomes or as 
small mini chromosomes called double minutes (DMs). It was hoped these 
regions might contain amplified cellular oncogenes that lead to unexpectedly 
high levels of the gene. Table 1.7 indicates the oncogenes detected in 
amplified DNA of tumour cells often such amplification does lead to the 
expression of the target gene but it should be noted that the amplified DNA 
spans a large region on either side of the gene and its effects on tumour 
formation are not clear. Most cases of amplified cellular oncogenes are 
sporadic but a consistent pattern of gene amplification has been found in 
human neuroblastomas of the N-myc gene and will be discussed later (Schwab 
1985).
1.3 Specific Cellular Oncogenes
Many different oncogenes have now been uncovered and how they act can 
only be answered for a few in some detail. Cellular oncogenes appear to carry 
out tasks in many aspects of cell growth-some are growth factors, some are 
growth factor receptors, some may mediate intracellular signalling and some 
may be involved in the control of transcription. Here I only briefly outline 
some of the details concerning some oncogenes and readers are asked to 
consult the relevant reviews and references therein for further details. Section
1.4 discusses the c-myc oncogene in more detail as the majority of the work 
carried out in this thesis concerns this gene.
1.3.1 Src
Both c-src and v-src are 60kD phosphoproteins that possess tyrosine 
kinase activity (see review by Sefton 1985). Src is one member of a family of 
oncogene products with tyrosine kinase activity which includes src, yes, abl, 
fgr, fps, ros, fms, and erbB. A stretch of about 250 amino acids in src 
responsible for the kinase activity has been found to be conserved in the other
Translocated cellular oncogenes
Tumor
Mouse plasmacytoma cell lines
Rat immunocytoma cell lines
Human Burkilt lymphoma cell 
lines
Human chronic myclogcnous 
leukemia cell lines













































Table 1.6 (From Varmus 1984)


















Promyclocylic leukemia cell line. IIL60 and
primary tumor1
APUDoma cell line, COLO320
Small cell lung carcinoma cell lines (variants)
CSV-induced bursal lymphoma
Primary ncuroblastomas (Stage III and IV)
and ncuroblastoma cell lines
Rctinoblastoma cell line, Y79, and primary
tumors
Small cell lung carcinoma cell lines and
tumor
Chronic mycloid leukemia cell line, K562
Colon carcinoma cell lines, COLO20 1/205
Acute mycloid leukemia
l-pidcrmoid carcinoma cell line, A43I
Primary carcinomas of lung, colon, bladder
and rectum
Colon carcinoma cell line, SW4HO
Adrenocortical carcinoma cell line, Yl
Mammary carcinoma line, MCF7
















































Table 1.7 (From Varmus 1984)
tyrosine kinases. The src protein (and yes, abl, fgr, fps, ros also) have been 
found to be localised on the inner plasma membrane (Courtneidge et al 1980). 
Tyrosine phosphorylation appears to be a normal event in the regulation of cell 
division as growth factor receptors possessing tyrosine kinase activity activate 
this activity on binding the appropriate growth factor. Since src is located on 
the inner side of the plasma membrane it makes it unlikely that src is a growth 
factor receptor. The targets for phosphorylation by src are unclear but in 
RSV-transformed cells cytoskeletal, glycolytic and unknown proteins all show 
increased levels of phosphotyrosine though it is not clear if this plays a role in 
transformation. Phosphorylation of a 42kD protein is a common response in 
normal cells exposed to a variety of mitogens (Cooper et al 1984). In vitro 
v-src can phosphorylate phosphatidylinositol which breaks down to yield 
diacylglycerol and inositoltriphosphate (Sugimoto et al 1984). Activation of the 
serine specific protein kinase C results by increased Ca 2+ levels mediated by 
inositoltriphosphate and by direct action of diacylglycerol. Protein kinase C is 
thought to play a central role in the various cellular responses to mitogenic 
stimulation including the phosphorylation of ribosomal protein S6 which seems 
to be a critical event in the mitogenic stimulation of quiescent cells. A cAMP 
dependent kinase can also activate protein kinase C in response to high cAMP 
levels generated by adenylate cyclase in response to growth factors receptors 
binding their agonist. It has been shown that v-src can phosphorylate cAMP 
dependent kinase (Graziani et al 1984) therefore there may be two distinct 
biochemical pathways by which src can play a role in mitogenic stimulation. 
Expression of src appears to be ubiquitous (Muller and Verma 1984) but high 
levels of src have been found in neural tissue during early development both in 
Drosophila and chickens (Simon et al 1985, Sorge et al 1985). Src appears to 
be expressed in non-proliferating but differentiating neural cells at high levels 
therefore maybe the role of c-src is not only as mitogenic signal but also a 
differentiation signal.
1.3.2 Erb B, fms and erb A
A connection between oncogenes and growth control was realised by the 
discovery that the v-erb B oncogene is almost certainly derived from the 
epidermal growth factor (EGF) receptor gene (Downward et al 1984, Ullrich et al 
1984). The EGF receptor (c-erb B) gene product which is an integral 
transmembrane protein is one of the best characterised growth factor 
receptors (see Carpenter 1984, Cohen 1984 for review). EGF is a small
polypeptide hormone which can induce DMA synthesis and cell proliferation. 
On binding EGF, by the external domain of the protein, the receptor will 
autophosphorylate at a tyrosine residue in the cytoplasmic carboxyl terminal of 
the protein and also will phosphorylate other unidentified proteins. The 
receptor then clusters and subsequently becomes internalised leading to its 
eventual degradation. It is not clear how cellular proliferation is signaled by 
EGF binding to its receptor but it is interesting that the highly purified receptor 
has DNA nicking activity (Mroczkowski, Mosig and Cohen 1984) and that the 
receptor can cause increased guanine nucleotide binding and phosphorylation 
of ras gene products (Kamata and Feramisco 1984).
The v-erb B oncogene appears to be truncated version of the EGF receptor 
such that it has sustained a large deletion of the heavily glycosylated amino 
terminal domain which lies external to the cell and a small deletion of the 
cytoplasmic domain removing the site of autophosphorylation (see Hunter 1985, 
Hayman 1986 for reviews). This suggests v-erb B mimics the occupied EGF 
receptor, but it is difficult to demonstrate that v-erb B has tyrosine kinase 
activity in vitro and also avian erythroblastosis virus (AEV) transformed cells 
show only small increases in cellular phosphotyrosine levels. AEV also 
transforms erythroblasts which do not possess EGF receptors (fibroblasts do) 
therefore if v-erb B is mimicing acot\*Vitutively activated EGF receptor it is not 
a normal signal for these cells. This suggests v-erb B protein transforms cells 
by a pleiotropic mechanism indeed it seems different domains of the protein 
appear to influence the transformation of different cell types.
Since rather few growth factor receptors have been characterised then it is 
possible that other oncogene products with tyrosine (or serine) kinase activity 
could be growth factor receptors. The v-fms gene product has properties 
similar to growth factor receptors (Hunter 1985). It is an integral 
transmembrane protein with a heavily glycosylated amino terminal domain 
outside the cell. Also it has tyrosine kinase activity and can be clustered into 
coated pits. Recently it has been shown that the c-fms gene product is almost 
certainly the growth factor receptor for colony stimulating factor (CSF) 1 (Sherr 
et al 1985). The macrophage growth factor, CSF 1, stimulates hematopoietic 
precursor cells to form colonies containing mononuclear phagocytes. CSF 1 is 
required by cells to enter DNA synthesis and stimulates precursors of 
mononuclear phagocytes to proliferate and differentiate. Although c-fms 
transcripts can be detected in a wide variety of organs this might reflect the
presence of tissue macrophages since the CSF 1 receptor is apparently 
restricted to mononuclear phagocytes. Transcripts of c-fms have also been 
found in the developing mouse placenta and extra embryonal membranes 
(Muller et al 1983) but it is not clear if this is a characteristic of cells other 
than that of the mononuclear phagocyte lineage. It is possible v-fms 
transforms cells by a similar mechanism to v-erb B.
Very recently it was discovered that the c-erb A gene of both human and 
chickens is a thyroid hormone receptor (Sap et al 1986, Weinberger et al 1986 
and review by Green and Chambon 1986). Sequence analysis shows c-erb A is 
similar to steroid hormone receptors even though steroid and thyroid 
hormones are not structurally or biosynthetically related hence their receptors 
probably evolved from common ancestors. Steroid hormone receptors can 
activate transcription by specific binding of Hormone-receptor complexes to 
enhancer elements of target genes. Thyroid hormone receptors are known to 
be localised in the nucleus and are believed to modulate gene expression in a 
similar manner to steroid hormone receptors. Sequence comparison shows the 
putative DNA binding domain is conserved between receptors. Thyroid 
hormones are known to have many effects on differentiation. The v-erb A 
gene cannot bind hormone and may be constitutively active. Therefore altered 
enhancer factors may be important in oncogenic transformation by interfering 
with target genes. Since both polypeptide and thyroid hormone receptors have 
turned out to be known oncogenes maybe steroid hormone receptors will also 
be found as oncogene products.
1.3.3 Sis
Another pathway at which oncogenic proteins could intercede is to mimic a 
growth factor which may stimulate cells in an autocrine manner. This potential 
was realised by the finding the v-sis gene from simian sarcoma virus (SSV) 
was highly related to the B chain of platelet derived growth factor (PDGF), 
(Waterfield et al 1983, Doolittle et al 1983 and reviews by Heldin and 
Westermark 1984, Hunter 1985). It has since been shown that c-sis does 
encode PDGF B chain. PDGF is a potent mitogen for connective tissue cells 
also it is secreted by many cell types and has many possible biological roles 
including wound healing, development, atherosclerosis and neoplasia (see Ross, 
Raines and Bowen-Pope 1986 for review).
PDGF probably forms a hetrodimer of an A and B chain whereas v-s/s only 
forms a homodimer. SSV transformed cells secrete a PDGF-like mitogen factor 
therefore it seems the transformed cell has escaped normal growth control by 
both secreting and responding to growth factors. Some non-SSV transformed 
cell lines also secrete a PDGF-like activity. The differences between v-sis and 
c-sis are probably unimportant since overexpression of c-sis can transform 
cells. Interestingly cytotrophoblastic cells from placenta which exhibit a 
pseudo-malignant phenotype express high levels of c-sis, produce PDGF and 
have PDGF receptors (Goustine et al 1985). Therefore autocrine stimulation 
may be important for growth of both transformed and normal cells. PDGF on 
binding to its receptor stimulates a tyrosine kinase activity which may then 
mediate mitogenic events through pathways similar to those of the EGF 
receptor. Shortly after PDGF binding c-fos then c-myc expression is also 
drastically increased (see later) hence many oncogene products may interact to 
produce the signals for mitosis.
1.3.4 Ras
The ras oncogenes appear to be involved in yet another level of growth 
control (see Hall 1984, Levinson 1986 for reviews). There are three types of ras 
genes: ha-ras, ki-ras which were discovered through homology to retroviral 
oncogenes and N-ras which was discovered to be the active oncogene in a 
neuroblastoma cell line. The great interest in the ras gene family began in 
1982 when it was found that a single point mutation in the ha-ras gene 
appeared to be the active lesion in a human bladder carcinoma (Reddy et al 
1982, Tabin et al 1982, Taparowsky et 3/1982). Subsequently it has been found 
that a single point mutation at positions 12, 13, 59, 61 or 63 can generate an 
active ras oncogene. Indeed using site directed mutagenesis of the ha-ras 
gene shows that any amino acid except proline or glycine at position 12 
generates an active oncogene; interestingly proline and glycine are known to 
be a-helix breaking residues. Similarly such somatic mutations of the ras 
oncogenes appear to be an important step in tumour development of chemical 
induced cancers. This step appears to be a general event in tumoocpgenesis but 
sometimes it occurs late hence pointing to multistep carcinogenesis. Therefore 
it appears qualitative changes are important in ras influenced cancers.
The mammalian ras proteins all are located on the inner side of the plasma 
membrane, bind guanine nucelotides, have GTPase activity and have molecular
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weights of ~21kD. It appears that activating mutations inhibit GTPase activity. 
Recent interest focuses on the homology of ras proteins with G proteins. G 
proteins signal hormone binding to receptors by coupling to the generation of 
intracellular second messages and by doing so stimulate their intrinsic GTPase 
activity. Two ras gene homologs, RAS1 and RAS2, have been isolated from 
yeast (Powers et al 1984). Neither yeast gene is essential but one gene is 
required for the viability of haploid spores (Tatchell et 5/1984). It has recently 
been shown that the yeast ras genes can function as GTP dependent regulators 
of adenylate cyclase (Toda et al 1985). Since a yeast ras gene can transform 
mammalian cells and a human ras gene can substitute for yeast ras genes this 
lead to the suggestion mammalian ras proteins might act in a similar fashion 
but apparently mammalian ras products have no effect on adenylate cyclase 
(Beckner et al 1986). Also microinjection of purified activated ras proteins into 
Xenopus oocytes leads to release from prophase arrest (i.e. maturation) 
through an apparently cAMP independent pathway whereas progesterone 
induced maturation leads to dramatic increase of cAMP levels (Birchmeier et al 
1985). Therefore if ras proteins in higher eukaryotes are acting as coupling 
proteins for signal transduction from the cell surface to intracellular targets 
they must achieve this by some mechanism other than cAMP control. Very 
recently it has been shown that N-ras couples the bombesin receptor to 
phospholipase C leading to an increase in intracellular second messages 
(Wakelam et a/1986) hence other ras proteins may couple other receptors in a 
similar manner.
1.3.5 Fos (see Verma 1986 for review)
The fos gene was first identified in two retroviruses, FBJ murine scucoma 
virus (MSV) and FBR-MSV and now both human and mouse c-fos genes have 
been isolated. Like myc the fos proteins are located in the nucleus. Both 
c-fos and v-fos proteins are similar but the last 48 carboxyl amino acids are 
different in c-fos due to a switch in reading frame. Interestingly although 
v-fos alone can transform cells c-fos must first be linked to a LTR and also 
have a deletion of 3' non-coding sequences such that constitutive expression 
can be maintained (Miller, Curran and Verma 1984), therefore c-fos might 
normally regulate its own synthesis mediated by 3'non-coding sequences.
The most remarkable feature of c-fos is its rapid induction on response to 
mitogen or differentiation specific agents. On differentiation of
myelomonocytic cells to mature macrophages (but not granulocytes) the c-fos 
gene is rapidly induced within a few minutes with maximal levels observed by 
30 minutes of induction which decline to 20% of this level and are maintained 
for the next 10 days (Muller et al 1985) though c-fos protein is only detected 
for 120 minutes after induction. Exogenously introduced c-fos into F9 
teratocarcinoma cells results in expression of c-fos mRNA and protein and 
which is accompained by the appearance of morphologically altered cells 
displaying characteristics of differentiated cells (Muller and Wagner 1984, Muller 
et al 1985 b). C-fos is also expressed at high levels in fetal membranes and 
the placenta, in bone marrow, in early fetal liver and in differentiated 
macrophages (Muller et al 1983, Muller, Muller, Guilbert 1984). Therefore these 
studies strongly implicate c-fos being involved in cellular differentiation; note 
this is the opposite response of c-myc which is down-regulated upon 
differentiation (see later).
When quiescent fibroblasts are treated with serum or growth factors c-fos 
is rapidly induced within 2-3 minutes with maximal levels of induction (around 
20 fold) occuring within 20 minutes and no transcripts can be detected by 240 
minutes (Muller et al 1985). This extremely rapid appearance and 
disappearance of c-fos contrasts that of c-myc which is induced later and 
declines gradually (Muller et al 1985 and later). The transient transcriptional 
activation of c-fos upon serum stimulation requires a DNA element 300bp 5' to 
the mRNA cap site and has been shown to bind a protein(s) from Hela cell 
nuceli specifically (Treisman 1986). Hence apparently c-fos is involved in two 
distinct pathways: one involving cellular differentiation and the other cellular 
proliferation. As to how the c-fos protein functions is unclear despite the 
many studies on the expression of the gene and protein but it is possible it is 
responsible for activation of other genes (including c-myc ?) in response to 
signals at the cell surface, more work will be required to elucidate its function.
1.3.6 Other oncogenes
In the previous sections I have highlighted some oncogenes about which 
alot is known and which reflect current research in the oncogene field. For the 
many other oncogenes much less is understood about their behaviour and 
function. It is possible that many of them reflect variants of the oncogenes I 
have described above. For example maybe ato/\s another kind of growth factor 
receptor since it is located on the plasma membrane and exhibits tyrosine
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kinase activity. Maybe the nuclear oncogenes such as myb and ski act in a 
similar manner to myc and fos. Other oncogenes such as re/ do not appear to 
have any parallels in the known oncogenes. The number and variety of 
potential oncogenic sequences should keep molecular and cellular biologists 
occupied for a fair number of years to come. What is surprising is that in the 
face of such potential adversity a cell can manage to remain "normal" so 
perhaps looking at single oncogenes is a bit naive and a more unified approach 
will be more useful in understanding normal cell growth.
1.4 The C-myc Oncogene
1.4.1 Introduction
Most of the work described in this thesis concerns the isolation, expression 
and sequences of c-myc related genes from X.borealis. In this section I outline 
the current interest in the c-myc (and other myc) gene(s). Recently a major 
review on the regulation and expression of c-myc in normal and malignant 
cells has appeared (Kelly and Siebenlist 1986) and another major review is due 
to appear in the 1986 volume of the Annual Review of Genetics but I was 
unable to obtain the latter review before writing this thesis.
1.4.2 V-myc and c-myc
The v-myc gene was first identified in the acutely transforming defective 
avian myelocytomatosis virus MC29 (Sheiness, Fanshier and Bishop 1978, 
Mellon et al 1978, Roussel et al 1979). Subsequently the v-myc gene was 
found in three other independently isolated acutely transforming retroviruses 
(CMII, OK10 and MH2 (Roussel et al 1979, Hayman 1983). MH2 contains an 
additional oncogene referred to v-mil or v-mht (Jansen et al 1983, Kan et al 
1983, Call et al 1983) and it is imagined each oncogene cooperates to alter the 
pathogenesis of the virus. The putative transforming gene products are hybrids 
composed of parts of the retroviral gene linked to the v-myc sequence, for 
example MC29 encodes a p110 A gag-myc fusion protein, CMII a p90 Lgag-myc 
fusion protein and MH2 a p200 kgag-pol-myc fusion protein (Abrams et al 
1982, Hann et al 1983, Hayman 1983). Additionally OK10 and MH2 have 
proteins expressed from subgenomic mRNAs (p62 v-myc OK10 and p61/63 
v-myc MH2). The v-myc proteins have been found localised in the nucleus 
(Abrams et a/1982, Donner, Greiser-Wilkie and Moelling 1982, Bunte et a/1982, 
Hann et a/1983) and can be shown to bind DNA in vitro (Donner, Greiser-Wilki«.
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and Moelling 1982, Bunte et a/1982).
Avian myelocytomatosis viruses induce a broad spectrum of malignancies 
in vivo including myelocytomas, endotheliomas, kidney and liver carcinomas 
and sarcomas. They also transform fibroblastic, myeloid and epitheloid cells in 
vitro (Graf and Beug 1978). Mutants have been isolated that have a reduced 
capacity to transform macrophages but still retain their ability to transform 
fibroblasts (Ramsay et al 1980). These mutants are useful in dissecting 
functionally important domains on the myc protein and it has been shown that 
small deletions in the 3' coding sequences are associated with the above 
phenotype but the protein still locates to the nucleus yet fails to bind DNA 
(Enrietto and Hayman 1985). Also it was shown that these mutations render 
the virus non-pathogenic in chickens. Hence there seems to be two domains 
in the v-myc protein: one responsible for transformation of macrophages and 
one for transformation of fibroblasts in vitro. Revertants of these mutants are 
similar to wild type MC29 in vitro but in vivo they have an altered pathogenic 
spectrum therefore it should be possible to analyse the specificity of tumour 
formation by the v-myc protein (Enrietto and Hayman 1985).
The cellular oncogene c-myc was first identified by its homology to the 
transforming gene (v-myc) of MC29 virus (Sheiness and Bishop 1979, Sheiness 
et al 1980, Robbins et al 1982). Nucleotide sequences of the c-myc gene are 
available from chickens, mice, human and trout (Papas et al 1984, Waston et al 
1983, Shih et al 1984, Bernard et al 1983, Stanton et al 1984, Gazin et al 1984, 
Waston et al 1983 b, Colby et al 1983, Watt et al 1983, Van Beneden et al 
1986). This sequence data for man, mouse and chicken has shown that the 
c-myc oncogene is composed of three exons with only the last two exons 
being translated into protein. The first exon suspected to play a role in the 
regulation of c-myc expression. The v-myc gene carried by the MC29 family 
of viruses is composed mainly of sequences derived from the last two exons of 
the chicken c-myc gene and presumably arose by recombination between avian 
leukosis virus and cellular myc sequences. The v-myc and c-myc coding 
sequences differ by only eight base pairs (Waston et a/1983).
1.4.3 C-myc gene structure
For human, mouse and chicken c-myc genes it has been shown that there 
are three exons and two introns (Papas et al 1984, Waston et al 1983, Shih et
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al 1984, Bernard et al 1983, Stanton et al 1984, Gazin et al 1984, Waston et al 
1983, Colby et al 1983, Watt et a/1983) and that trout c-myc gene has at least 
two exons (Van Beneden et al 1986). Exons 2 and 3 encode a protein product 
of about 439 amino acids. Immunological analysis using antisera generated to 
peptides homologous to parts of the predicted amino acid sequence as well as 
antisera generated to bacterial fusion proteins with portions of exon 2 and 3 
have confirmed that exon 2 and 3 are translated in normal cells to give protein 
products of ~62kd and ~65kd (Alitalo et al 1983, Hann et al 1983, Persson et 
al 1984, Evan et al 1986). Exons 2 and 3 are very highly conserved between 
different c-myc genes for example the human and mouse c-myc amino acid 
sequences are ~93% homologous, the chicken and human c-myc amino acid 
sequences are ~68% homologous and the human and trout c-myc amino acid 
sequences are ~62% homologous. Exon 3 appears to be slightly more 
conserved than exon 2 perhaps reflecting a functional constraint on the exon 3 
sequence such as DNA binding which has been suggested as a role for the 
exon 3 coding sequence (Persson and Leder 1984). C-myc protein coding 
regions have been conserved throughout evolution suggesting that it plays an 
important role in cellular growth, division and/or differentiation. The frequent 
alteration of c-myc gene structure and expression (see later sections) also 
reinforces the role of c-myc in growth control.
Exon 1 is about 600bp long and is ~70% conserved between humans and 
mice (Bernard et al 1983, Battey et al 1983, Gazin et al 1984). The mouse exon 
1 sequence appears not to have any coding capacity but the human exon 1 
sequence could give rise to a putative protein product of ~20kD (Gazin et al 
1984). This is somewhat controversial since other published c-myc sequences 
have differences which would make them untranslatable. Support for the 
presence of an exon 1 translation product has recently been obtained from 
Gazin and co-workers who showed that antisera raised to synthetic peptides 
homologous to the putative protein coding sequence will detect a 32 kD 
protein which can dimerise to a 58 kD protein in human cells (Gazin et a/1986). 
It is possible there is true polymorphism in the first exon sequence but maybe 
the sequence divergence arose through somatic mutation in the tissues that 
was used to clone the exon 1 sequence or maybe this region is particularly 
subject to cloning artifacts. Sequencing germ-line exon 1 sequences should 
help clarify this point. Interestingly the mouse exon 1 sequence is 
untranslatable even though it is quite homologous to the human sequence this
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suggests the coding capacity has been gained since the divergence of humans 
and mice but rudimentary conservation still exists. In the chicken, exon 1 is 
even more diverged; it is a lot shorter, bears no homology to human and 
mouse exon 1 sequences and cannot code for any protein (Linial and Groudine 
1985, Shin et al 1984). This may either mean that exon 1 sequences are 
unimportant in the regulation of c-myc or that different ways of regulating the 
gene have evolved. Possibly human type exon 1 sequences are present in 
chickens but are encoded by a different gene. Exon 1 has been proposed to be 
important in the regulation of c-myc expression and this will be discussed in 
the appropriate sections. Note a coding function of exon 1 does not preclude 
any role in regulation of c-myc expression associated with exon 1 but it is 
intriguing that two independent polypeptides could be encoded by the c-myc 
gene and may reflect some kind of translational control.
1.4.4 The c-myc protein
To help analyse the c-myc protein expression antisera have been generated 
against synthetic peptides of the c-myc protein or against c-myc protein 
sequences synthesised in E.coli either as a fusion protein or not (Hann et al 
1983, Ramsay, Evan and Bishop 1984, Evan et 3/1986, Sullivan et al 1986, Watt 
et al 1985, Alitalo et al 1983, Persson et al 1984). At least two proteins are 
synthesised by the c-myc gene which run on SDS polyacrylamide gels with 
anomolous molecular weights of ~64kD and ~67kD (the calculated molecular 
weight from the DNA sequence is ~47kQ). Bacterially synthesised c-myc 
protein also runs with an anomoJous molecular weight (Watt et al 1985) hence 
this may be a property inherent to the c-myc protein itself and may reflect a 
high proline content. Phosphorylation is the only known post-translational 
modification of the c-myc and v-myc proteins (Hann et al 1983, Ramsay, Evan 
and Bishop 1984, Evan et al 1986). The c-myc proteins are found to have a 
very short half life of ~20-30 minutes (Ramsay, Evan and Bishop 1984, Evan et 
3/1986) which suggests that they are under tight cellular control and they can 
be rapidly modulated. This also correlates with the short half life of c-myc 
mRNA, described later, hence changes in transcription rate can be immediately 
translated into changes of protein level.
The proteins specified by c-myc and v-myc are localised in the nucleus 
(Alitalo et al 1983, Hann et al 1983, Persson and Leder 1984, Eisenman et al 
1985, Evan et al 1986). Indeed microinjection of bacterially synthesised c-myc
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protein into cells efficiently localises it to the nucelus within 5 minutes after 
injection (Sullivan et al 1986). Immunofluorescence studies show that the 
c-myc proteins are located to discrete regions of the nucleus in a punctate 
fashion and are excluded from the nucleoli and nuclear membrane (Hann et al 
1983, Sullivan et al 1986, Eisenman et al 1985). Both c-myc and v-myc 
proteins have been shown to bind to DNA with a relatively high but 
non-specific affinity (Donner et al 1982, Persson and Leder 1984, Eisenman et al 
1985, Watt et al 1985). Initial studies suggested that the c-myc protein was 
firmly associated with the nuclear matrix (Eisenman et al 1985) but it now 
seems this is due to an artifact caused by insolublisation of the protein when 
exposed to temperatures of 37°C during the isolation procedure. The c-myc 
protein appears now to be in the nuclear soluble fraction bound there by a 
very salt labile interaction (Evan et al 1986). These results may point to c-myc 
functioning as a transcriptional regulatory protein or in DNA replication. The 
c-myc protein has some structural similarity to the E1a transforming protein of 
adenovirus (Ralston and Bishop 1984) which is known to stimulate the 
transcription of other genes. Also a c-myc construct transfected into cells can 
activate the expression of an endogenously introduced heat shock protein gene 
upon expression of c-myc (Kingston, Baldwin and Sharp 1984). It still remains 
to be determined if c-myc has a trans-activcfring role which would help explain 
the effects of this gene in transformed cells but it is interesting that the E1a 
protein does not bind DNA directly, rather it activates the transcription of 
genes indirectly (Green, Triesman and Maniatis 1983). The significance of 
homology between E1a and c-myc proteins has recently been challenged 
(Christ and Ricciardi 1986). Recent excitement has been generated with the 
possibility that c-myc be involved in RNA splicing or metabolsm. Of a variety 
treatments only actinomycin D causes any effect on the immunolocalisation of 
c-myc, the punctate pattern becoming more dispersed (Sullivan et al 1986). If 
these results are validated then they would open up extremely interesting 
possibilities for cell growth and transformation.
Recently using two different antisera to c-myc protein antigens four distinct 
human c-myc proteins have been detected (Persson et a/1986). Two of these 
proteins (~64kD and ~67kD) are probably the proteins described above; the 
other two have molecular weights of ~65kD and ~68kD and are not 
phosphorylated. The 64, 67 and 68kD proteins have short half lifes and may be 
precursors of a more stable 65kD protein which has a half life of ~8 hrs.
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Immunofluorescence shows the 65 and 68kD proteins, in addition to being 
located in the nucleus in a speckled fashion as previously described, are also 
found in the nucleoli and nuclear membranes. The significance of these results 
remains to be determined since previous models have focused on the short 
half life of c-myc RNA and protein and there may be important implications 
understanding c-myc function.
1.4.5 C-myc is expressed in many normal cell types
The c-myc gene is expressed in a wide variety of cells and tissues as a 
mRNA of about 2.5-2.7kb (Gonda, Sheiness and Bishop 1982, Westin et al 1982, 
Stewart, Bellve and Leder 1984). In somatic cells the level of c-myc 
transcription tends to be low although there appears to be a correlation of the 
number of c-myc transcripts with the overall rate of cellular proliferation. For 
example the thymus has a high degree of cell division and has many c-myc 
transcripts whereas skeletal muscle with few dividing cells has very little 
c-myc RNA. An exception to this is that proliferating spermatogonia appear to 
express very little c-myc RNA as compared with normally dividing somatic cells 
which might be because these cells are committed to terminal differentiation 
(Stewart, Bellve and Leder 1984). Elevated c-myc RNA levels have been 
reported in hematopoietic tissues compared with other tissues such as brain 
(Gonda, Sheiness and Bishop 1982) and readily detectable levels of c-myc RNA 
are found in many human leukemia cell lines which are similar to immature 
hematopoietic cells (Westin et al 1982). In human placental development 
c-myc expression occurs primarily in the proliferative cytotrophoblasts and 
decreases upon differentiation into syncytiotrophoblasts (Pfeifer-Ohlsson et al 
1984, Ohlsson and Pfeifer-Ohlsson 1986). Using in situ hybridisation it has 
been shown that c-myc expression is localised to only a subset of human 
embryonic cells such as brain, intenstine, kidney, lung and skin suggesting 
cellular proliferation is not always associated with c-myc activity 
(Pfeifer-Ohlsson et al 1985). In murine development it has been shown for 
many tissues that c-myc RNA is expressed at the same level for newborn as in 
adult tissues but for brain c-myc expression is virtually undetectable by day 15 
of postnatal development with hindbrain showing a more rapid decrease than 
forebrain (Zimmerman et 5/1986). Recently it has been shown that c-myc RNA 
expression is quite high in Purkinje cells and granule precursor cells in the 
postnatal development of the murine cerebellum (Ruppert, Goldowitz and Wille 
1986). From the expression patterns of c-myc described above it seems c-myc
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activity is not simply a marker of proliferative activity but also reflects 
additional tissue-specific gene regulation especially during embryogeney* hence 
it is possible the c-myc product has many functions.
1.4.6 C-myc uses two promoters
The c-myc gene is transcribed from two promoters located about 150bp 
apart at the 5' end of exon 1 (Bernard et al 1983, Stewart, Bellve and Leder 
1984, Battey et al 1983). The differential use of these promoters might be 
involved in processing or stability of c-myc RNA since the 5 X ends of 
transcripts can be drawn as short stem loop structures (Battey et al 1983, 
Leder et al 1983) also this might influence the translational efficiency of each 
transcript. The ratio of promoter usage in normal tissues is variable for 
example in spleen and thymus the ratio of longer to shorter transcripts is 1:4 
but in the preputial gland it is about 1:20 (Stewart, Bellve and Leder 1984). The 
relative promoter usage also changes during mouse cerebellar development. 
Before birth both promoters are used equally, at postnatal days 7-10 the ratio 
of longer to shorter transcripts is 1:4 and in mature cerebellar tissue 
transcription of c-myc is almost exclusively from the shorter promoter 
(Ruppert, Goldowitz and Wille 1986). In stimulated T and B cells induction of 
c-myc RNA can be up to 40 fold yet the promoter used does not change (Kelly 
et al 1983) also different tissues have individual promoter usage (Stewart, 
Bellve and Leder 1984). These observations suggest that each cell type 
analysed has a unique promoter usage of the c-myc gene. This may explain 
the change in promoter usage on mouse cerebellum development as the cell 
populations are changing from embryonic to mixed neonatal to adult cell 
populations.
1.4.7 Post-transcriptional and transcriptional controls in c-myc expression
In many cell lines containing chromosomal rearrangements of the c-myc 
gene where the breakpoint is within exon 1 or intron 1 high levels of truncated 
c-myc mRNA are produced whereas the unrearranged c-myc locus is 
transcriptionally silent which has led to a suggestion that a negative control 
element acting on exon one sequences regulates c-myc expression (Leder et al 
1983). The inhibition of protein synthesis superinduces c-myc transcription 
which may suggest a labile protein either acting as a represser or affecting 
c-myc mRNA stability regulates c-myc expression (Kelly et al 1983, Taub et al
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1984).
It has been established that in many normal and tumour cell lines that 
c-A7?KcmRNA has a half life of about 20 minutes (Dani et al 1984, Rabbitts et al
1985). In some cell lines there was no effect of protein synthesis inhibitors on 
c-myc mRNA stability but in others there was a dramatic stablisation 
suggesting some kind of post-transcriptional controls (Dani et al 1984). G 0 
arrested cells have low amounts of c-myc mRNA but on mitogenic stimulation 
c-myc mRNA levels increase dramatically (see later). One study has shown 
that this increase c-myc mRNA levels is not due to changes in the 
transcriptional rate of the c-myc gene but rather there is post-transcriptional 
regulation of c-myc expression at the level of mRNA degradation (Blanchard et 
5/1985). Another study using normal B cells suggests that the c-myc gene is 
not transcribed in quiescent cells (Smeland et al 1986). How these differences 
arise is not clear but may reflect changes in cells maintained in culture for a 
long time compared with fresh normal cells or may reflect epigenetic 
differences between cell types.
In many Burkitt's lymphoma and mouse plasmacytoma cell lines the 
truncated c-myc gene (lacking exon 1 sequences) gives rise to mRNA that is 
much more stable than normal c-myc mRNA (Piechaczyk et al 1985, Eick et al 
1985, Rabbitts et al 1985 b, Piechaczyk et al 1986). Therefore it may be that 
exon 1 sequences impart instability on the c-myc mRNA but it has been found 
that exon 1 sequences cannot confer instability upon any other message 
(Piechaczyk et al 1985) and other c-myc mRNAs bearing exon 1 sequences are 
stable (Eick et al 1985, Bauer et al 1986). Probably the mRNA structure is 
important for its rapid degradation but the role of 3' sequences remains to be 
determined. Recently a short sequence located in the 3'non-coding sequences 
of colony stimulating factor 1 mRNA has been implicated in the rapid 
degradation of its mRNA (Shaw and Kamen 1986). Interestingly a short 
conserved sequence, AUUUA, has been found conserved in the 3' non-coding 
sequences of many genes whose mRNA is unstable including c-myc. The role 
of these sequences in c-myc mRNA stability should be open to experimental 
analysis.
Putative regulatory regions of the c-myc gene have been identified by the 
presence of 5 distinct DNase I hypersensitive sites in the human and murine 
c-myc genes (Siebenlist et al 1984, Fahrlander et 5/1985). Two of these sites
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are associated with each of the c-myc gene promoters and another two have 
sequences similar to the consensus for the binding of nuclear factor 1. One of 
these sites binds nuclear factor 1 in vitro (Siebenlist et a/1984). The function 
of nuclear factor 1 is unclear but it is essential for adenovirus replication in 
vitro and it may bind upstream of other promoters though it remains to be 
determined if it has a role in transcriptional actw\V>j (Dynan 1986). The 
remaining DNase I hypersensitive site is 1.8kb 5'of the transcriptional start 
sites and lies in a region of strong homology between the human and mouse 
c-myc genes (Fahrlander et al 1985). This may be the binding site for a 
represser since this site is lost in many chromosomal translocations that 
deregulate the c-myc gene (Siebenlist et al 1984). The existence of a class of 
plasmacytomas which have chromosomal translocations lying ~400bp 
upstream of exon 1 has further defined the location of an upstream regulatory 
element (Yang et al 1985). By analysing the expression of 
c-/77j^chloramphenicol acetyl transferase vectors transfected into cells it has 
been shown that a 760bp segment of the murine c-myc gene lying 428bp 5' 
from the first promoter can act as a negative transcriptional control element 
(Remmers, Yang and Marcu 1986). This element has been termed a dehancer 
since it has the opposite properties of a transcriptional enhancer. It is 
interesting that the DNase I hypersensitive sites which binds nuclear factor 1 is 
located in this element and that it lies in a region of good homology between 
the human and murine c-myc genes.
Recently it has been shown that intragenic pausing (or premature 
termination) has a profound effect on c-myc transcription (Bentley and 
Groudine 1986, Nepveu and Marcu 1986). There appears to be a significant 
block to the elongation of transcription located in the vicinity of the exon 1 - 
intron 1 boundary which and as judged by the use of protein synthesis 
inhibitors, appears to be mediated by the action of a labile protein acting in a 
negative fashion (Nepveu and Marcu 1986). These studies also showed the 
existence of a very minor promoter lying ~600bp upstream from the first 
promoter giving rise to a 3.1kb transcript (Bentley and Groudine 1986). On 
differentiation of HL60 cells the decreased transcription of c-myc appears to be 
due to an increased block in elongation at the exon 1 - intron 1 boundary 
(Bentley and Groudine 1986). Therefore the control of production of full length 
c-myc mRNA appears to be mediated through exon 1 sequences. These 
results disagree with those of Blanchard et al, 1985 which suggested that
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transcription was constant through the gene and that other post-transcriptional 
mechanisms are important in c-myc regulation but this may be a cell type 
difference or a reflection on the fact a heterologous probe was used for this 
study. Interestingly there appears to significant antisense transcription of the 
c-myc gene (Bentley and Groudine 1986, Nepveu and Marcu 1986). The 
majority of antisense transcripts appear to begin about the 5'of exon 1 and 
these RNAs are very unstable. Their role in the regulation of c-myc 
transcription is unclear, maybe they are involved in the maturation of c-myc 
mRIMA. How c-myc mRIMA production is regulated appears to be a complex 
process involving both transcriptional and post-transcriptional controls and is 
likely to be finely balanced between the two mechanisms.
1.4.8 Regulation of c-myc expression in relation to the cell cycle
The regulation of c-myc expression during cellular proliferation has been 
investigated using systems that allow the manipulation of the cell cycle by 
growth inducing agents. Two separate signals are required for the entry of 
quiescent G 0 cells into DNA synthesis (S) phase. One control is an early 
priming event and is termed competence and the second acts at a later stage 
of G-|. Both signals are either mediated by growth factors or polyclonal 
mitogens. Hence if cellular oncogenes are involved in growth control they 
might be expected to be involved in these events.
Treatment of growth arrested G 0 B lymphocytes with lipopolysaccharide, or 
T lymphocytes with concanavilin A or fibroblasts with platelet derived growth 
factor, serum or phorbol esters leads to a dramatic induction of c-myc mRNA 
levels of at least 20 fold within 1-2 hours after treatment occuring before any 
DNA synthesis (Kelly et 5/1983, Campisi et 5/1984). This suggests that c-myc 
expression is one of the earliest biochemical events that occur in response to 
mitogen binding therefore c-myc may play a role in the competence of a cell 
to progress through the GQ-GT phase of the cell cycle. C-myc might be 
regarded as a cell cycle enabling signal whose presence is required either 
continuously or through a sensitive temporal window to allow a cell to progress 
through its cycle (Evan et al 1986). Since protein synthesis inhibitors 
superinduce c-myc expression it is suggested that a labile protein mediates 
these effects (Kelly et al 1983). Also it has been shown that, at least in part, 
that increased c-myc mRNA levels are due to transcriptional controls 
(Greenberg and Ziff 1984). It must be noted that increased c-myc mRNA levels
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alone are not sufficient to stimulate cellular proliferation in the absence of late 
acting growth factors (Smeland et a/1985). Late acting growth factors, such as 
EGF, can induce c-myc expression in those cells that can show a proliferitive 
response on binding the factor (Muller et al 1984). Therefore two 
post-receptor pathways, one mediated by protein kinase C (phorbol esters etc) 
and one mediated by EGF can induce c-myc activation (Ran et al 1986) and 
point to c-myc being an intracellular mediator of mitogen binding. In tumour 
cells there may be an inappropriate temporal expression of c-myc such that 
cells efficiently transit G-j. The high levels of c-myc mRNA in chemically 
transformed cells might suggest autocrine synthesis of growth factors leading 
to a continual activation of the c-myc gene (Campisi et al 1984).
Although there is a transient increase in c-myc expression by resting cells 
in response to growth factors it appears that in a variety of cell types the 
expression of both c-myc mRNA and protein are constant throughout the cell 
cycle in the continual presence of serum (Hann, Thompson and Eisenman 1985, 
Rabbitts et af\9Q5, Thompson et 5/1985). These studies showed that both the 
turnover rates of c-myc mRNA and protein appear to be similar at each stage 
in the cell cycle as do modifications to the c-myc protein. Hence the increase 
in c-myc expression on stimulation of resting cells is only transient with high 
levels of mRNA and protein falling to a basal level which is maintained through 
the cell cycle. These results still imply c-myc may play a role in the G 0 to G^ 
transition.
1.4.9 The regulation of c-myc expression in relation to differentiation
In a variety of cells that are induced to differentiate terminally there 
appears to be a downregulation of c-myc expression associated with cessation 
of proliferation upon differentiation. The promyelocytic leukemia cell line HL60 
(Westin et al 1982), the mouse erythroleukemia cell line MEL (Lachman and 
Skoultchi 1984), the mouse myeloid leukemia cell line WEH1-3B (Gonda and 
Metcalf 1984), the human histiocytic lymphoma cell line U937 (Einat, Resnitzky 
and Kimchi 1985) and a mouse teratocarcinoma cell line (Campi*t et al 1984) 
can by the action of a variety of agents be differentiated terminally in vitro and 
in each case there is corvcot«\vW\\ decrease in c-myc expression. This decrease 
occurs within a few hours but for MEL cells there is a transient re-expression 
of c-myc about 15 hours later and apparently these changes occur before any 
commitment to differentiation (Lachman and Skoultchi 1984). Constitutive
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expression of a transfected c-myc gene in MEL cells inhibits the ability of cells 
to terminally differentiate upon treatment with DMSO (Coppola and Cole 1986, 
Dmitrovsky et al 1986) but transient expression of c-myc before the second 
wave of endogenous c-myc expression causes cells to differentiate earlier 
(Lachman et a/1986). This suggests that c-myc has both positive and negative 
roles in the process of commitment of MEL cells. Low levels of c-myc mRNA 
may be due to the non-proliferative state of differentiated cells but recently it 
has been shown that in primary mouse keratinocytes c-myc expression 
remains high upon induction of differentiation with calcium but not with 
phorbol esters (Dotto et 5/1986). Again post-transcriptional (Knight et al 1985, 
Bente-ly and Groudine 1986) or transcriptional regulation (Einat, Resnitzky and 
Kimchi 1985) might be involved in these processes but it is clear that the 
pattern of DIMase I hypesensitive sites changes upon differentiation (Kelly and 
Siebenlist 1986, Bentley and Groudine 1986). Therefore it appears c-myc 
expression plays a role in both differentiation and proliferation of cells and will 
need to be analysed very carefully before assigning functions to the c-myc 
protein.
1.4.10 Activation of c-myc by retroviral insertion
A key discovery in oncogenesis was that in avian leukosis virus (ALV) 
induced B cell lymphomas a provirus was commonly integrated upstream of the 
c-myc gene (Neel et al 1981, Hayward, Neel and Astrin 1981). The ALV 
integration occurred mainly 5' of the second exon in the same transcriptional 
orientation leading to ~100 fold increase in c-myc expression (Hayward, Neel 
and Astrin 1981, Payne, Bishop and Varmus 1982). This is termed promoter 
insertion - activation due to readthrough of the powerful viral promoter leading 
to increased c-myc expression. In some cases the viral LTR is integrated 
upstream in the opposite transcription orientation or downstream of the c-myc 
gene suggesting increased c-myc expression is due to an enhancer element 
present in the viral LTR (Payne, Bishop and Varmus 1982). In some murine T 
cell lymphomas there appears to be an increase in c-myc expression due to 
integration by a retrovirus (Corcoran et al 1984, Selten et al 1984). Therefore 
the repeated isolation of retroviral insertions adjacent to the c-myc gene in T 
and B cell lymphomas strongly implicates c-myc in the genesis of tumour 
formation. Activation of c-myc is probably only one step in the development 
of these tumours and presumably other changes (in other cellular oncogenes?) 
are required. Since abherrent c-myc expression correlates with tumour
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formation this suggests that c-myc plays an important role in normal cell 
growth.
1.4.11 Amplification of c-myc in tumour cell lines
The first human cell line reported to contain an amplified oncogene was the 
promyelocytic leukaemia line HL60 (Collins and Groudine 1982). It appears that 
increased expression of c-myc in this cell line is due to the amplification of the 
c-myc gene by about 20 fold. Other cell lines such as COLO 320 (Alitalo et al 
1983) and SEWA(Schwab et a/1985) also show amplification of the c-myc gene 
with concomitant high levels of c-myc mRNA. It may be that c-myc 
amplification is a secondary event for increased tumouroyrv^city since 
amplification of c-myc is not often associated with tumour tissue from which 
the above cell types were derived and since the degree of amplification of 
c-myc in SEWA cells can be altered depending on whether they are grown in 
vivo or in in vitro (Schwab et al 1985). Also a greater degree of amplification 
of c-myc is found in highly malignant small cell lung carcinomas than less 
malignant variants (Little et al 1983). Again these studies point to a role of 
c-myc in tumouroaenesis though in these cases the role may be much more a 
secondary event than in retroviral insertion but this may reflect cell or tumour 
type specificity.
1.4.12 Chromosomal translocations involving the c-myc locus
Many human Burkitt lymphomas (BLs) and murine plasmacytomas (PCs) are 
characterised by consistent reciprocal chromosomal translocations involving 
the c-myc locus and one of the three immunoglobulin (Ig) loci (see reviews by 
Perry 1983, Leder et al 1983, Varmus 1984, Kelly and Siebenlist 1986). A single 
detailed model to account for the consequences of these translocations is 
probably unrealistic due to the wide variety of translocations involved. Here I 
briefly outline some salient facts concerning c-myc and chromosomal 
translocations; for further details see the reviews cited above and references 
therein.
The most predominant translocation is the juxtaposition of the c-myc gene 
with the heavy chain Ig gene. In BLs the c-myc gene on chromosome 8 is 
translocated to the heavy chain gene on chromosome 14 and similarly in PCs 
the c-myc gene on chromosome 15 is translocated to the heavy chain Ig gene 
on chromosome 12. Normally the chromosome breakpoint in both BL and PCs
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on the Ig carrying chromosome is located in the switch region. The breakpoint 
in the c-myc gene in BLs is normally 5'of the first exon but in PCs it can often 
include the first exon; note there is much variability in these locations. This 
generates a situation where both genes lie head to head in opposite 
transcriptional orientations hence the c-myc gene is expressed from its own or 
cryptic promoters. Since the reciprocal translocation event removes the Ig 
heavy chain enhancer then the transcription of c-myc is influenced by as of yet 
uncharacterised regulatory sequences in the 3' domain of the Ig heavy chain 
gene. Although BL cells have relatively high levels of c-myc mRNA they are 
apparently often not much greater than those in non-tumourooenic proliferating 
B cells therefore this points to other events involved in the genesis of tumour 
formation
The less well characterised variant translocations in BL and PCs involve the 
juxtaposition of c-myc to either of the light chain Ig loci. In these 
translocations the c-myc gene normally remains on its own chromosome and 
the Ig loci are translocated to it. For BLs this involves an 8:2 translocation for 
Kappa, 8:22 for lambda Ig light chain genes and in PCs a 15:6 translocation for 
Kappa Ig light chain genes resulting in the Ig genes located an indeterminate 
distance 3' to the c-myc gene. The c-myc mRNA levels appear to be no 
different in these tumours when compared with the other BL and PCs. 
Interestingly in many PCs bearing the 15:6 translocations a region called pvt-*\ 
is a common site for breakpoints on chromosome 15 and lies at least 94kb 3' 
of c-myc. Pvt-1 is also a common site of proviral integration in retroviralty 
induced T cell lymphomas. Therefore pvt 7 may represent a sequence that can 
act at a considerable distance from c-myc, since pvt 1 is not transcribed and 
has no homology to other oncogenes, it may act by influencing the chromatin 
structure of the c-myc gene (Graham and Adams 1986).
In the BL and PCs only the c-myc gene that resides on the translocated 
chromosome is actively transcribed, the unrearranged c-myc gene remains 
transcriptionally silent. These results suggest that c-myc expression is 
negatively regulated by a process that can repress the normal allele but not 
the translocated allele. It is supposed that the c-myc protein or a protein 
synthesised in response to high levels of c-myc protein represses c-myc 
expression by acting on sequences 5' of exon 2 (i.e where most of the 
alterations occur in the translocated gene). Indeed it recently has been shown 
that a negative acting element with the opposite properties of a transcriptional
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enhancer lies -400bp 5' to c-myc first exon. (See earlier and Remmers, Yang 
and Marcu 1986).
Changes in the promoter usage of the c-myc gene may also occur in BL 
and PCs; maybe this alters translation of efficiency the mRNA but no consistent 
pattern of promoter usage is clear. Somatic mutation of the Ig locus is known 
to occur in normal B cell development and in some of the translocatioo* 
described above mutations have been found in the translocated c-myc allele 
(Rabbitts, Hamlyn and Baer 1983). Few mutations occur in the coding 
sequences but many are observed in the first exon although they are 
inconsistent. These changes may alter putative represser binding, mRNA 
stability or utilisation. Possibly deletion or mutations of first exon sequences 
are unimportant for c-myc regulation in these tumours since BLs exist which 
have translocated c-myc genes without any changes but these BLs may have 
alterations in chromatin structure leading to the same effect. Indeed the 
regulatory regions defined by DNase I hypersensitive sites appear to be altered 
in many different PCs and BLs. Some translocation events leave the Ig 
enhancer on the same chromosome as the c-myc gene hence it is likely the 
enhancer has positive effects on c-myc expression in these tumours. In 
summary it appears that the c-myc gene is highly regulated but in BL and PC 
cells a variety of mechanisms have given rise to a deregulated c-myc gene 
though it is not clear what role this deregulation has in tumour formation.
1.4.13 Studies with transfected myc genes and transgenic mice
DNA mediated gene transfer has been utilised to manipulate the c-myc and 
v-myc genes in order to analyse their transformation potential. Although 
viruses carrying v-myc cause morphological transformation of cells in vitro 
they are not immortalised and do not cause tumours in nude mice 
(Lautenberger et al 1981). In contrast transfection of heterologous promoter 
driven c-myc sequences into immortalised fibroblasts (Armelin et al 1984) or 
cloned v-myc DNA into secondary rat embryo fibroblasts does not produce 
morphological transformation (Land, Parda and Weinberg 1983), suggesting that 
other phenotypic changes are required for the full transformed phenotype in 
such transfected cells. It was found that co-transfection of a mutant ha-ras 
gene and an SV40 promoter driven c-myc gene into normal rat embryo 
fibroblasts could result in morphological transformation whilst either alone 
could not (Land, Parda and Weinberg 1983), suggesting groups of co-operating
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oncogenes, one a nuclear gene supplying an immortalisation function (e.g. myc, 
E1a or SV40 large T) and the other a cytoplasmic gene supplying a 
transformation function (e.g. ras or polyoma middle T). An immortalisation 
function has been suggested for myc because transfected myc sequences alter 
the growth properties of cells. C-myc is induced by growth factors suggesting 
it is an intracellular mediator of mitogen binding. Balb/c3T3 cells transfected 
with myc sequences show an increased sensitivity to EGF and an increased 
probability of cell division in the absence of PDGF (Armelin et al 1984). 
Recently a model has been suggested in which the mechanism of co-operation 
between myc and ras oncogenes involves ras genes inducing growth factor 
production while myc genes increase the responsiveness of cells to these 
factors (Stern et al 1986) It should be noted that immortalised cell lines 
transfected with LTR promoter driven c-myc genes do result in tumouroo^enic 
cells even though they lack morphological transformation (Keath, Caimi and 
Cole 1984). Therefore constitutive myc expression leads to a variety of effects 
which probably relates to the genetic background of the cells but it could be 
indicative of a multi-functional c-myc protein.
Recently the transformation potential of c-myc has been analysed by the 
use of transgenic mice. When transgenic mice possess a c-myc gene under 
the control of the glucocorticoid inducible MMTV promoter they can develop 
monoclonal adenocarcinomas during one of their early pregnancies (Stewart et 
al 1984). F1 progeny of these mice inherit the predisposition to develop these 
tumours. Although the fusion gene in these mice can be expressed in a wide 
variety of tissues there is no obvious effect on early development. The active 
MMTV//77KC gene does not appear to be sufficient for the development of 
tumours since uniform development of tumour masses involving the entire 
bilateral mammary gland would have resulted. Therefore further transforming 
events are required - possible mutation giving clonal antecedents of tumours 
and also the hormonal environment related to pregnancy. A further study on 
these mouse lines shows the deregulated MMJV/myc gene contributes to an 
increased variety of tumours including those of testicular, breast, lymphoc^Ve, 
and mast cell origin (Leder et al 1986). Since tumours are not observed in 
every organ within the transgenic animal those which are tumourgenic begin to 
define the transformation spectrum of the c-myc gene which correlates with 
the pluripotent transformation ability of c-myc in other systems. In another 
study using transgenic mice different configurations of the c-myc gene linked
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to enhancer sequences from Ig genes were studied (Adams et al 1985). 
Injection of c-myc genes linked to either heavy chain or light chain enhancers 
led to the induction of multifocal lymphomas in 90% of mice. No neoplastic 
disease was found when the normal c-myc gene or truncated c-myc gene was 
injected observations which argue against a negative acting role of exon 1 
sequences in the normal regulation of c-myc In BL and PCs the Ig loci must 
have a positive effect on c-myc expression. Again this study suggests 
dysregulated c-myc expression is insufficient for malignancy due to the 
clonality of tumours produced. Interestingly in these tumours the endogenous 
c-myc gene is not expressed whereas the transgene is expressed, which might 
point to an autoregulation model similar to BL and PCs but it is not clear if the 
tumours arose from cells in which the c-myc gene is not normally expressed. 
Also some of MMTV/mvc carrying transgenic mice expressed both the 
endogenous gene and the transgene. It was suggested that maybe high levels 
of c-myc make cells that tend to proliferate rather than to generate 
differentiated progeny hence this will increase the proportion of less mature 
cells having a greater proliferative capacity. Presumably these cells are more 
susceptible to accidental events that would then create the malignant clone. 
Further studies on such transgenic mice should help define the role of c-myc 
in transformation and studies on the normal biochemistry of the protein should 
help in the design of future experiments with transgenic mice.
1.4.14 Myc gene families: N-myc and L-myc
Studies of tumour cell lines with gene amplifications has led to the 
identification of c-myc related genes (Schawb 1985). Initially it was shown by 
using a v-myc probe that amplified DMA from a neuroblastoma cell line 
contained a novel oncogene, termed N-myc, with limited homology to c-myc 
(Schwab et al 1983). The strongest similarity lies in two major domains 
separated by a heterologous sequence. These so called myc-boxes are 
extremely conserved: box A has 19 out 24 amino acids identical between 
N-myc and c-myc and box B has 13 out of 16 amino acids identical. The 
complete human N-myc nucleotide sequence shows that like c-myc \\\e N-myc 
gene is composed of three exons both having large untranslated first exons 
which bear no sequence homology to each other (Kohl et a/1986). The overall 
homology between N-myc and c-myc is about 70% with the strongest 
homology in exon 3. The N-myc gene maps to human chromosome 2 (Kohl et 
al 1983). Anti-peptide antiserum to the myc boxes detect a N-myc protein of
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~66kD which has a short half life and is located in the nucleus (Evan et al 
1986). Therefore N-myc appears to be a member of a myc gene family and 
has properties very similar to that of c-myc and may reflect similar functions.
Most neuroblastoma cell lines have a 10-700 fold amplification of the 
N-myc gene leading to increased N-myc expression (Schwab et al 1983), Kohl 
et al 1983, Schwab 1985). In a study of tumour patients it was found that 
amplification of N-myc only occurred in the later, more metastafo 
neuroblastomas (Brodeur et al 1984). 50% of advanced neuroblastomas had an 
amplification of the N-myc gene whereas no amplification of N-myc was 
detected in the earlier stages. Similarly N-myc amplification has been detected 
in cell lines derived from highly malignant small cell lung carcinomas (Nau et al
1984) and in retinoblastoma cell lines, though a high level of N-myc expression 
is independent of amplification in retinoblastoma cell lines (Lee, Murphee and 
Benedict 1984). N-myc amplification and increased expression may not be the 
only factor in the formation of the above tumours since 50% of the metastic 
neuroblastomas do not have such amplification. Indeed transfection of a 
N-myc construct driven by a viral enhancer into rat embryo cells results in 
established cell lines that are non-tumouro^efuc in animals (Schwab 1985, 
Schwab, Varmus and Bishop 1985) but in some cases co-transformation of 
N-myc with the mutated ha-ras gene can give rise to fully transformed cells 
which are tumouroc^emc in animals (Schwab 1985). This situation is very 
reminiscent of that described for the c-myc gene. Neuroblastomas and 
retinoblastomas are both of neural origin while small cell lung carcinomas are 
of endodermal origin they share common membrane proteins and express 
neuron specific enolase (Nau et al 1984) hence N-myc expression has only 
been found in tumours that have neural characteristics. In situ hybridisation 
suggests that high levels of N-myc expression are are limited to primary 
neuroblasts (Schawb et al 1984). Retinoic acid induced differentiation of a 
human neuroblastoma cell line results in decreased N-myc expression (Thiele, 
Reynolds and Israel 1985) as does differentiation of murine embryonal 
carcinoma cell lines which may reflect expression in normal early embryonic 
embryos (Jakobovits et al 1985). N-myc is only expressed in a limited number 
of adult tissues and is expressed at high levels in the murine mid-gestation 
embryo which decreases as the embryo approaches term (Jakobovits et al
1985). It may be N-myc expression is high in inner cell mass cells at around 
implantation but upon differentiation into endodermal cells expression
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decreases. High levels of N-myc expression have been also found to be 
restricted in the developing mouse to hindbrain, forebrain and kidney with 
mRNA levels decreasing drastically between day 15 of prenatal development to 
day 15 of postnatal development (Zimmerman et a/1986). Hence it appears the 
expression of N-myc is much more limited then c-myc and the N-myc gene 
product may play a role in multiple (but related) differentiation pathways.
A third myc related gene, termed L-mycwas identified in the amplified DNA 
of small cell lung carcinoma cell lines by virtue of its homology to N-myc (Nau 
et al 1985). In humans there is a restriction polymorphism associated with this 
gene and either allele becomes amplified in the small cell lung carcinoma cell 
lines. Using an L-myc specific probe a 2.2kb L-myc transcript is detected in 
cell lines containing an amplified L-myc gene. In any small cell lung carcinoma 
only one of the three myc genes is expressed which may reflect overlapping 
functionality of the gene products. Limited sequence analysis shows that the 
L-myc gene contains highly conserved myc boxes. The L-myc gene maps to 
human chromosome 1. Apparently anti-peptide antisera recognise a 64kD 
L-myc protein product (Evan et al 1986). During mouse development L-myc 
showed a very restricted expression pattern that was similar to that of N-myc 
(Zimmerman et al 1986). Therefore it seems there is a family of myc genes all 
of which play a part in the formation of some tumours. It could be they all 
have similar functions which have been tailored to a particular need, indeed 
restricted developmental expression and expression in certain tumour cells 
suggests such a role and it may be there as yet undiscovered myc related 
genes. Understanding the relationship of these genes in normal cell growth 
and tumour formation should be a fruitful area in the next few years.
1.5 Gene Expression During Xenopus Development 
1.5.1 Introduction
In this thesis the study of cellular oncogene function was carried out using 
Xenopus as a model system. Xenopus is an ideal organism for studying the 
molecular biology of development for a variety of reasons. Large numbers of 
oocytes and embryos are easily obtained and occur in well defined 
developmental stages (Dumont 1972, Neiuwkoop and Faber 1956). Development 
is extremely rapid, a fertilised egg reaches gastrulation in about 15 hr and by 
the time a Xenopus embryo has reached 80,000 cells the mouse embryo has
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only just completed its first division. Xenopus embryos have a well known 
histology and established methods exist for the micromanipulation of the 
embryos. Factors governing the maturation of the oocyte are easily studied in 
vitro (e.g. Wasserman et al 1984). Indeed the Xenopus oocyte has been used 
by many workers as a living test tube in the design of their experiments. As a 
vertebrate Xenopus provides a valuable model system for studying vertebrate 
developmental biology.
A great deal is known about gene organisation and expression in Xenopus 
(Dawid, Kay and Sargent 1983, Dawid et al 1985, Dawid and Sargent 1986) 
although it must be remembered that other organisms (e.g. Drosophila) have 
been studied extensively at the molecular level. Xenopus oocytes and embryos 
are very large hence the microinjection of molecules is simple. Microinjection 
of cloned DNA into fertilised eggs provides a powerful tool for studying 
mechanisms that underlie tissue specific gene expression since the cloned DNA 
will be inherited by daughter blastomeres that enter separate differentiation 
pathways. Also the microinjection of other molecules such as antibodies to try 
and block protein function (e.g. Scheer 1986) and antisense RNA to try and 
block mRNA function (Drummond and Colman 1986, Melton and Rebagliati 1986) 
are rapidly becoming possible. Many different genes have been studied during 
Xenopus development, for example histones (Woodland 1980), keratins (Dawid 
and Sargent 1986), actins (Gurdon et al 1985 a), ribosomal proteins 
(Pierandrei-Amaldi et al 1982), small nuclear RNAs (Mattaj et al 1985), 5S RNAs 
(Brown 1984), homeoboxes (Carrasco et 5/1984) and many other genes have all 
been studied during oocyte and embryo growth. Xenopus oocytes and eggs 
have also provided experiment systems for the study of RNA localisation 
( Pcebagliati et al 1985), meiosis (Miake-Lye and Kirschner 1985), nuclear 
assembly (Forbes et al 1983), transport of proteins to the nucleus (DeRobertis 
et 5/1983) and cell cycle events (Kirschner, Newport and Gerhart 1985) as well 
as other processes. Techniques such as in situ hybridisation to embryos using 
antibodies and antisense RNA are currently under development and should 
provide valuable information on the temporal and spacial controls during 
embryonic gene expression. Xenopus, as a system, has provided a few firsts in 
modern molecular biology such as the isolation of the first eukaryotic gene 
(Birnstiel et al 1968) and the cloning of the first eukaryotic transcription factor 
(Ginsberg, King and Roeder 1984) to name but a few.
Although Xenopus has a good grounding in molecular biology it is not a
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completely ideal organism to study developmental biology. The most important 
limitation is that Xenopus lacks standard genetics which severely hinders the 
study of gene activity and is better understood in Drosophila or mice. 
Transgenic Xenopus will be difficult to obtain because animals take 1-2 years 
to reach sexual maturity and since microinjected cloned DNA appears not to 
integrate into the host genome. Studying the biosynthesis of macromolecules 
is also difficult since Xenopus embryos are impermeable to radioactive 
precursors. Also blocking translation of mRNA with antisense RNA embryos is 
not yet completely satisfactory (Drummond and Colman 1986, Melton and 
Rebagliati 1986) though this is apparently not true in oocytes; for example 
antisense RNA to ribosomal protein L1 will block translation of L1 mRNA in 
oocytes (Wormington 1986).
1.5.2 Gene expression in oogenesis
The growth of Xenopus oocytes takes at least 6 months during which time 
the cells grows to a diameter of about 1.5mm and accumulates a stockpile of 
many substances for utilisation during early development (see Davidson 1976, 
for review). Oogenesis in Xenopus has been subdivided into six major stages, I 
to VI, based on morphological criteria such as oocyte diameter, pigmentation 
and the stage of meiotic prophase reached by the nucleus (Dumont 1972). 
Only fully grown stage VI oocytes are capable of responding to the steroid 
hormone progesterone and resuming mciosis from prophase arrest (e.g. 
Wasserman et al 1984). This culminates in the dissolution of the nuclear 
membrane, condensation of the chromosomes and reductive meiotic divisions 
prepare the egg for fertilization. The first polar body (one set of condensed 
chromosomes) is extruded at this point and meiosis becomes arrested at 
metaphase. On fertilisation of the egg by a sperm the second meiotic division 
is completed and the second polar body is extruded (Balinsky 1970). Further 
development of the egg thus ensues.
1.5.2.1 Yolk proteins
Quantitatively the largest accumulation of material by the growing oocyte is 
yolk protein and can be as much as 80% of the dry weight of an oocyte. Yolk 
proteins are synthesised in the female liver, under the hormonal control of 
oestrogen, as high molecular weight precursors known as vitellogenins (see 
reviews by Wahli et al 1981, Wahli and Ryffel 1985). Vitellogenins are secreted
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into the bloodstream and then taken up by the growing oocyte by 
receptor-mediated endocytosis. These precursor vitellogenins are cleaved to 
give phosphoproteins and lipoproteins which are assembled to form crystalline 
yolk platelets. Yolk proteins serve as a nutrient store during embryogenesis 
until the embryo reaches an independent feeding stage.
1.5.2.2 Ribosomes, rRNA and tRNA
Xenopus oocytes accumulate large amounts of the components of protein 
synthesising machinary during oogenesis. 5S RNA and tRNA are made very 
early in oogenesis representing about 70% of the total RNA in previtellogenic 
oocytes (Ford 1971, Mairy and Denis 1972). Enough 5S RNA is made during 
previtellogenesis to allow a hundred fold increase in ribosome content without 
need for further synthesis. At early stages of oogenesis tRNA and 5S RNA are 
stored in 42S ribonucleoprotein complexes (Ford 1971, Denis and Mairy 1972) 
and 5S RNA in 7S ribonucleoprotein complexes (Picard and Wegnez 1979). In 
fully grown oocytes 42S ribonucleoprotein complexes are undetectable (Dixon 
and Ford 1982) and much of the 5S RNA becomes recruited into ribosomes. 
Accumulation of 18S and 28S rRNA starts at the onset of vitellogenesis and 
continues throughout oogenesis such that in stage VI oocytes 18S and 28S 
rRNA represent -90% of the total RNA (Ford 1971, Mairy and Denis 1972). 
Ribosomal protein synthesis also begins at the onset of vitellogenesis and their 
accumulation parallels that of 18S and 28S rRNA (Dixon and Ford 1982). Stage 
VI oocytes are thought to have accumulated their full ribosome complement 
although continued synthesis and turnover can occur (Leonard and La Marca 
197S).
The differential accumulation of 18S and 28S rRNA compared with 5S RNA 
and tRNA is reflected in their gene organisation. There are about 200 genes 
for each tRNA, about 20,000 genes for oocyte specific 5S RNA and about 400 
genes for somatic specific 5S RNA. The oocyte specific 5S RNA differs by 6 
nucleotides from somatic 5S RNA (Ford and Southern 1973) and only oocyte 
specific 5S RNA is accumulated in oocytes although somatic 5S RNA is 
synthesised but not accumulated (Denis and Wegnez 1977). The 5S RNA and 
tRNA synthesised from these genes during previtellogenesis is stable for 1-2 
years (Ford, Mathieson and Rosbash 1977). The 18S and 28S rRNA genes are 
organised into repeating units containing 18S and 28S DNA interspersed with 
spacer DNA and are present in about 450 copies per haploid genome. During
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very early oogenesis these genes are selectively amplified to give many 
extrachromosomal nucleoli (see Lewin 1980 for review). This amplification 
gives a total number of ribosomal genes of about 10 6 which are utilised at the 
onset of oogenesis. The extra rDNA is not replicated during cleavage and 
either is diluted by nuclear replication or becomes degraded. Hence the oocyte 
uses two different mechanisms to accumulate the resources of 5S RNA and 
tRNA, 18S and 28S rRNA used during early development. 18S and 28S rRNA 
are synthesised from genes which are selectively amplified over a relatively 
short period whereas 5S RNA and tRNA are made on a fixed number of genes 
over a much more protracted period of time.
The transcription of 5S genes is developmental^ regulated and is 
reasonably well understood. Transcription of 5S genes requires three factors 
(TFIIIA, B and C) in addition ^o RNA polymerase III (Segall, Matsui and Roeder 
1980). TFIIIA is specifically required for the initiation of 5S gene transcription 
and is a protein of ~38kD which binds to a 50bp internal control region of 5S 
genes (Bogenhagen, Sakonju and Brown 1980, Engelke et al 1980). This 
complex is further stabilised by the sequential binding of factors INC and 1MB 
(see Brown 1984 for review). TFIIIA also interacts with 5S RNA to form 7S 
ribonucleoprotein complexes which serve as storage particles during oogenesis 
(Pelham and Brown 1980), therefore it is possible an autoregulatory mechanism 
exists for 5S gene expression during oogenesis. The activation of all 5S genes 
during early oogenesis is ensured by the very high levels of TFIIIA protein 
(~10 12 molecules/cell). The decrease in 5S gene transcription during 
oogenesis can be accounted by the decreased expression of the TFIIIA gene 
(Ginsberg, King and Roeder 1984) and the recruitment of TFIIIA into 7S 
ribonucleoprotein particles in the face of the accumulating 5S RNA. In somatic 
cells 95% of the 5S RNA arises from somatic type genes and in cell free 
extracts from oocytes or somatic cells cloned somatic 5S genes are transcribed 
more efficiently than cloned oocyte specific genes (Pelham, Wormington and 
Brown 1981). Oocyte 5S RNA genes appear only to be transcribed when there 
is is a large excess of TFIIIA. In somatic cell chromatin repressed oocyte 5S 
genes lack transcription complexes and this repression appears to be mediated 
by histone H1 (Schlissel and Brown 1984). During embryogenesis there is 
transient expression of both kinds of 5S gene at midblastula due to TFIIIA 
inherited by the egg but as cell division continues and the concentration of 
TFIIIA drops only the somatic 5S genes become transcribed (Wormington and
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Brown 1983). Injection of TFIIIA protein into cleaving embryos greatly increases 
the transcription of endogenous oocyte 5S genes whereas injection of mixture 
of cloned 5S genes lead to the preferential transcription of somatic 5S genes 
(Brown and Schlissel 1985). Hence it seems the preference of somatic over 
oocyte 5S gene transcription in somatic cells is due to the differences in 
binding constants of TFIIIA for the somatic and oocyte 5S genes and to the 
concentration of TFIIIA protein in the cell.
1.5.2.3 mRNA
A particularly interesting group of materials accumulated by oocytes is the 
relatively large amount of poly(A) + RNA. The total amount of poly(A)* RNA has 
reached its final abundance in previtellogenic oocytes (Rosbash and Ford 1974, 
Cabada et al 1977, Dolecki and Smith 1979). This RNA population comprises 
about 20,000 different sequences and apparently lacks a high abundance class 
which is present in tadpole or adult tissues (Perlman and Rosbash 1978, 
Rosbash 1981). Of these sequences 5% are about 15 times more adundant 
than the remaining 95%; the majority of sequences being present at ~0.005% 
of the poly(A) + population. These results have been extended to show that 
several individual poly(A)+ species, as measured by cloned probes, cease to 
accumulate after stage II of oogenesis (Golden, Schafer and Rosbash 1980). 
The poly(A) + RNA synthesised in previtellogenic oocytes is stable over a 18 
month period (Ford, Mathieson and Rosbash 1977) hence poly(A) + RNA is 
accumulated before the onset of maximum extension of lampbrush 
chromosomes. Although RNA synthesis continues throughout oogenesis most 
is ribosomal but some poly(A)+ RNA is synthesised. Since the poly(A)+ RNA 
made early in oogenesis does not turnover then this suggests the poly(A) + RNA 
made later turns over differentially. The significance of this is unclear but it is 
interesting that the poly(A)+ RNA made earlier has a larger poly(A)+ tail than 
that made later (Cabada et al 1977).
What is the nature and function of the poly(A) + in oocytes? A simple 
interpretation is that it is mRNA of which most is stored during oogenesis for 
subsequent translation in the course of oocyte maturation and early 
embryogenesis since only a small fraction of the RNA is found in polysomes 
(Woodland 1974). Undoubtably some of the oocyte mRNAs are translated in 
the oocyte to synthesise many stored products and to support its own 
metabolism e.g. ribosomal proteins (Pierandrei-Amaldi et a/1982). Most of the
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poly(A)+ RNA is never translated in the oocvte and will only be used during 
embryogenesis many weeks after its synthesis. This storage of mRNA in 
Xenopus oocytes is probably one of the clearest examples of the translational 
regulation of gene expression known.
There are a number of ways that this translational regulation could arise. 
Fully grown oocytes could have a limited translational capacity due to some 
factor lacking in the translational machinery. Apparently this is partly true 
since the injection of heterologous mRNAs only results in protein synthesis at 
the expense of proteins translated from endogenous mRNAs (Laskey et a/1977, 
Richter and Smith 1981). Hence the oocyte has only the capacity to translate 
the mRNA actually loaded on polysomes even though this noay be less than 5% 
of the total poly(A)* RNA. There is no direct evidence in support of this due to 
the absence of the isolation of the limiting components.
Another hypothesis is that proteins bind to the poly(A) + RNA and mask its 
translation prior to maturation and embryogenesis. In previtellogenic oocytes 
the majority of the poly(A) + RNA is located in the cytoplasm and up to 70% is 
polysome associated (Darnbrough and Ford 1976) but less than 10% is 
polysome associated in full grown oocytes (Rosbash and Ford 1974). The 
remainder is complexed with protein sedimenting heterogeneously over the SOS 
to 120S range. Specific poly(A)+ RNA binding proteins have been identified in 
oocytes and cannot be detected in liver or reticulocytes (Darnbrough and Ford 
1981, Dixon and Ford 1982). These proteins are independently regulated during 
oogenesis and their accumulation follows that of poly(A) + RNA. Using a cell 
free translation assay it has been shown that the poly(A) + RNA in 
ribonucleoprotein complexes can be translated as effic»e^r\>f as free poly(A) + 
RNA and that their coding capacities are similar (Darnbrough and Ford 1976). A 
contrasting result has been obtained by Smith and co-workers who found that 
when globin mRNA is mixed with RNA binding proteins from stage I and II 
oocytes then injected into oocytes that the globin mRNA is inhibited for 
translation (Smith, Richter and Taylor 1984). Therefore the role of masking 
proteins suppressing the translation of maternal mRNA remains unclear.
An additional possibility is that the poly(A) + RNA molecules in oocytes 
possess structural features which inhibit their own translation. Up to 70% of 
the oocyte poly(A) + RNA displays an interspersed sequence organisation in 
which regions transcribed from single copy and repetitive sequences are
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covalently associated whereas only 15% of tadpole poly(A) + RNA displays this 
organisation (Anderson et al 1982). Recently it has been shown that poly(A) + 
RNAs which lack a renaturable repeat are translated efficiently in both in vitro 
and in vivo assays whereas interspersed poly(A)+ RNAs are translationally 
inactive (Richter et al 1984). There may be a number of reasons why the 
interspersed polv(A) + RNAs which lack a renaturable repeat are translated 
efficiently in both in vitro and in vivo assays whereas ^^cspersed poly(A) + 
RNAs are translationally inactive (Richter et al 1984). There may be a number 
of reasons why the interspersed poly(A) + RNAs are translationally inactive such 
as the separation of ribosome binding sites from start codon, the translation 
start signals could be preceded by repeated elements which contain stop 
codons, they could contain unprocessed intervening sequences which inhibit 
translatignor they could provide binding sites for oocyte proteins that prevent 
translation. This might suggest a precursor role for much of the oocyte 
poly(A) + RNA but the finding that many individual RNAs have the same size in 
oocytes and tadpoles tends to argue against this (Golden, ScVaffer and Rosbash 
1980, Dworkin et al 1984).
Therefore it is most unclear how the translational regulation of the poly(A) + 
RNA arises but it is likely to involve the co-ordinate control of all the 
mechanisms described above. A calculation described in Richter et al 1984 
might suggest that the mass of translatable maternal mRNA present in oocytes 
excluding the interspersed poly(A) + RNA might be sufficient to support protein 
synthesis until the midblastula stage when new RNA synthesis begins (see 
below) but it must be borne in mind there are many uncertainties in this 
calculation. Also it remains to be determined whether the poly(A)+ interspersed 
RNAs are processed in later development (maybe in particular tissues or at 
different developmental stages) to render them translatable. It is worth noting 
no one has yet reported the presence of an interspersed repeated sequence 
within the body of a coding region in cDNA clones derived from oocyte 
libraries.
1.5.3 Gene expression during embryogenesis
The previous section described that the fully grown Xenopus oocyte 
contains a large store of poly(A) + RNA some of which is mRNA. This maternal 
mRNA is used to support protein synthesis during the first hours of 
development before the onset of embryonic transcription which begins around
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midblastula (see below). About 2% of ribosomes are found in polysomes in 
stage VI oocytes then during the first 5 hours of development this figure 
increases to 20% which then remains constant for the next 24 hours and then 
ribosome recruitment increases to a somatic level of 70% by the feeding 
tadpole stage (Woodland 1974). Because there is little accumulation of new 
mRNA during the first hours of Aev/elopment (see below) then some of the 
maternal poly(A) + RNA must be recruited into polysomes and hence does 
represent stored RNA. Indeed it has been shownthat the 2-4 fold increase in 
protein synthesis during oocyte maturation is due to the recruitment of mRNA 
onto polysomes (Richter, Wasserman and Smith 1982). Also using cloned cDNA 
probes it has been shown that many sequences that are non-polysomal in the 
stage VI oocyte become mobilised onto polysomes by the 16 cell stage 
although some (5/18) are mobilised poorly (Dworkin, Shrutkowski and 
Dworkin-Rastl 1985). This study also suggested there is a class of moderately 
expressed maternal mRNA in the oocyte which decreases in titre during 
development but is loaded onto polysomes and is perhaps involved basic 
physiological processess during early development or related to pattern 
formation or differentiation.
1.5.3.1 RNA synthesis and the midblastula transition
The first 12 cleavage divisions proceed synchronously and take the single 
cell egg to the 4000 cell midblastula in about 7 hours. No RNA synthesis is 
detectable in the embryo until the midblastula stage (Brown Littna 1966a, 
Brown and Littna 1966 b, Shiokawa et 5/1981, Newport and Kirschner 1982 a). 
The specific time this occurs is termed the midblastula transition since many 
other changes occur in the embryo at this time (Newport and Kirsch«\er 1982 b) 
cell division becoming asynchronous, cells becoming motile and the cell cycle 
slowing down. During the first 12 cleavages the cell cycle is ascribed to an 
endogenous free running oscillator present in each blastomere and operating 
independent of the nucleus (K^schner, Newport and Gerhart 1985). It is not 
clear what activates the midblastula transition but it may be due to nuclear to 
cytoplasmic volume or recruitment of maternal factors (Kirschner, Newport and 
Gerhart 1985).
It appears that many different classes of RNA begin to accumulate at or 
shortly after the midblastula transition. Amongst the most rapid are the small 
nuclear RNAs, 5S RNA and tRNAs (Newport and Kirschner 1982, Brown and
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Littna 1966 b). Ribosomal RNAs also begin to accumulate after the midblastula 
transition (Shiokawa, Misumi and Yamana 1981) though this experiment used 
dissociated embryos which may affect synthetic behaviour. Poly(A) + RNAs 
undoubtedly begin to accumulate soon after the midblastula transition 
(Shiokawa et al 1981). It has been calculated that about 40% of the poly(A) + 
RNA in gastrula polysomes and in whole embryos is newly synthesised. Since 
the majority of poly(A)+ RNA does not vary (see below) between the egg and 
gastrula embryo then this suggests that the embryo resynthesises RNAs that 
were already present.
1.5.3.2 RNA populations during embryogenesis
Using cDNA::RNA hybridisation it has been concluded that oocyte and 
tadpole poly(A)+ RNA populations are very similar except that the oocyte 
population lacks a high abundance class present in tadpole RNA (Perlman and 
Rosbash 1978). Only a small fraction of poly(A)+ RNAs are newly synthesised 
during development. This has been extended using in vitro protein translation 
assays and is in agreement with previous results (Rosbash 1981). It has also 
been shown that oocyte poly(A) + RNA is larger than tadpole poly(A) + RNA 
(Rosbash 1981). Perhaps this decrease in size is partly due to the synthesis of 
shorter molecules and partly due to the loss of interspersed repeat elements 
described earlier. Analysis of RNA populations in embryos has also been 
studied by using labeled poly(A) + RNA from different developmental stages to 
screen several hundred cloned sequences from gastrula and tadpole cDNA 
libraries (Dworkin and Dawid 1980 a, Dworkin and Dawid 1980 b, Dworkin et al 
1981). These studies confirmed the previous results and suggested that 
oocyte, egg and gastrula poly(A) + RNA populations are similar, changes only 
become apparent from the tailbud stage onwards with some RNA species 
increasing in concentration from undetectable levels which also leads to the 
presence, in tadpoles, of the highly abundant poly(A) + RNA species. Also this 
showed in early embryos that mitochondrial RNAs were the most abundant 
poly(A) + RNAs. A study of individual cloned cDNA probes showed that the 
accumulation of prominent tadpole poly(A) + RNAs that are rare in eggs starts to 
increase in titre at the beginning of neurulation suggesting in the late gastrula 
there is a major transition in gene expression which accompanies cellular 
differentiation and morphogenesis (Dworkin et al 1984). Abundant RNAs which 
appeared in polysomes during later development were found to be newly 
synthesised RNA (Dworkin and Hershey 1981). Hence this result and the results
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described earlier implies that initially during development polysomes are 
assembled using stored maternal mRNA and then later in development 
polysome assembly involves newly made RNAs some of which may be 
qualitatively different from the RNAs in the egg.
Since total poly(A)"1" RNA levels remain constant during gastrulation but 
newly synthesised mRNA begins to accumulate from blastula onwards the 
poly(A) + RNA in the embryo must turnover. It has been estimated that 40% of 
the mass of gastrula poly(A)+ RNA is newly synthesised (Shiokawa et al 1981). 
It has been shown that stored histone mRNA turns over during early 
development such that by gastrulation it is entirely replaced by newly 
synthesised mRNA (Woodland 1980). For other endogenous mRNAs turn over 
rates are not clear but it is interesting to note that injected mouse globin 
mRNA is stable through embryogenesis (Gurdon et al 1974). Therefore turn 
over rates may be a property of the individual mRNAs.
1.5.4 Developmental Decisions during embryogenesis
The information described above is at a general level and refers to 
population classes of RNA molecules. Much insight has been brought into the 
expression of individual genes by the application of recombinant DNA 
technology and, much is understood about the developmental regulation of 
known gene products such as histone, actin and tubulin. A number of 
approaches have been adopted to try and identify genes or factors that play 
critical roles in developmental decisions. In other words the initial information 
that differentiates populations of blastomeres must come from somewhere.
1.5.4.1 Homeobox containing genes
One approach to isolate genes that are deveAopmentaly important is by 
virtue of their homology to genes that are important in pattern forma&oo in 
other systems. The homeotic and segmentation genes in Drosophila are 
important in specifying body segment identify, number and polarity and it is 
thought these genes function by selecting between different developmental 
pathways. The homeobox is a protein coding domain that is conserved in 
many of the homeotic and segmentation genes (see Gehring 1985 for review). 
It is most striking that this conserved sequence resides on proteins that are 
involved in important features of Drosophila embryogenesis. The function of 
these proteins remains to be determined but the homology of homeoboxes
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with yeast mating type regulatory proteins and bacterial DNA binding proteins 
has lead to the suggestion that regulatory proteins are directed to binding sites 
on DNA by the homeobox domain (Shepherd et al 1984, Laughon and Scott 
1984 DiNardo et al 1986). This has been supported by the fact homeobox 
proteins are located in the nucleus (White and Wilcox 1984, Beachy et al 1985, 
DiNardo et al 1986) and since the engrailed gene product can bind DNA 
(Desplain, Theis and O'Farrel 1985). There is genetic evidence that homeobox 
proteins can regulate the transcription of other homeotic genes (Struhl and 
White 1985); indeed a hierarchy of when these gene products are required by 
the Drosophila embryo has been recently described (MacDonald, Ingham and 
Struhl 1986). That the homeobox plays an important role in developmental 
events has been reinforced by the discovery that the sequences are conserved 
in frogs (Carrasco et al 1984, Muller, Carrasco and DeRobertis 1984, Harvey, 
Tabin and Melton 1986), mice (McGinnis et 5/1984, Rabin et 5/1985, Hart et al 
1985) and humans (Levine, Robin and Tijan 1985, Hauser et 5/1985) all of which 
display a segmented body plan. Most homeobox containing genes appear to 
be developmentally regulated or expressed in a cell type specific manner hence 
this predicts a role for homeoboxes in development. The isolation of a 
homeobox gene in a non-segmented organism, the sea urchin, which is also 
developmental expressed (Dolecki et al 1986) suggests homeobox genes are 
not simply involved in the establishment of body plan per se but rather they 
might be the regulatory genes that choose between different developmental 
programs.
The fact homeobox genes appear to be developroentaly important has led to 
the isolation of a number of homeobox containing genes from Xenopus 
(Carrasco et al 1984, Muller, Carrasco and De Robertis 1984, Harvey, Tabin and 
Melton 1986). The homeobox containing domain is very highly conserved 
(greater than 65% when compared to Drosophila sequences). Interestingly two 
homeoboxes were isolated on the same genomic clone (Xhox-1). The 
sequences outside the Xhox-IB homeobox are similar to the human Hu-1 and 
mouse Mu-1 homeobox containing genes hence it will be of great interest to 
identify the function of this gene. Both Xhox-1 A and B transcripts can first be 
detected in gastrula stage embryos and are expressed through to the 
swimming tadpole stage. The Xhox-1A transcript is present at very low levels 
in unfertilised eggs whereas the MM3 homeobox transcript is expressed 
maternally at a very high level. During cleavage the MM3 transcript disappears
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rapidly but it is re-expressed from gastrulation onwards with an additional 
transcript. So the MM3 gene product might determine the fate of cells during 
the initial stages of development. The AC-1 homeobox is expressed from the 
beginnift^of neurulation through to the swimming tadpole. The AC-1 probe 
also detects two other transcripts which are only expressed transiently during 
neurulation. Injection of Xhox-1A RNA into Xenopus oocytes shows that the 
protein encoded by this gene is located in the nucleus. Deletion of 13 amino 
acids from the homeobox domains as well as 32 carboxyl-terminal amino acids 
of the Xhox-1A protein produces a protein which no longer localises to the 
nucleus. Therefore the Xenopus homeobox genes have features whkU might 
say they are important in developmental decisions but much more work will be 
required in order to elucidate their function.
1.5.4.2 Localised factors
It has been a long standing hypothesis in developmental biology that 
embryo^c cells acquire specific developmental fates by the inheritence of 
maternal factory which are differentially distributed among cleavage cells. The 
localisation of maternal factors in the egg which are inherited by specific 
blastomeres provides an attractive explanation of how cell fate (gene 
expression) is determined. The nature of these determinants is unknown but it 
is often suggested that maternal mRNA could fulfill such a function, indeed it is 
implicated in insect development (Anderson and Nusslein-Volhard 1984). If 
maternal mRNA is such a cytoplasmic determinant then some of the mRNAs 
should be regionally localised within the egg. cDNA:RNA hybridisation 
suggests that small number (3-5%) of poly(A) + RNA sequences are enriched in 
the vegetal third of Xenopus eggs and embryos (Carpenter and Klein 1982). 
Also concentrations of both total and poly(A) + RNA are known to change along 
the animal-vegetal axis of oocytes and embryos (Capco and Jeffery 1982, 
Capco and Jackle 1982). A group of abundant soluble proteins have been 
found to be localised along the animal-vegetal axis but their relationship to 
localised RNAs is unknown.
Two recent studies have shown the existence of localised RNAs in frog 
eggs. In the first study poly(A) + RNA isolated from different regions of oocytes 
was translated in vitro and analysed by two-dimensional gel electrophoresis 
(King and Barklis 1985). A comparison of the resulting protein products 
showed that at least 17 specific translatable mRNA are regionally localised in
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the oocyte. The second study used a differential screening procedure to 
isolate cDNA clones for localised mRNAs (Rebagliati et al 1985). This showed 
most maternal mRNAs are uniformly distributed but a rare class of localised 
mRNAs existed. Three of these localise to the animal pole (An1,2,3) and one to 
the vegetal pole (Vg1) and they are all locally inherited in cleaving blastomeres. 
An1 and Vg1 are only synthesised in oogenesis and during development this 
mRNA disappears by gastrula. An2 and An3 are similarly expressed in 
oogenesis but their mRNAs are re-expressed in late gastrula and neurula 
respectively. Thus their expression is consistant with a role in cell 
determination. Each of these mRNAs appear to be located on polysomes 
during development and hence probably encode proteins (Weeks et al 1985). 
There are many ways how these mRNAs could affect the developmental fates 
of embryoinic cells. A simple idea would be their protein products might turn 
on genes in one region of the embryo. Further work should elucidate the roles 
of localised mRNA in cell determination.
Another way to analyse how cells acquire their developmental fates is to 
use genes that are known to be activated in restricted cell types during 
embryogenesis. The cardiac actin gene is transcriptionally activated at the end 
of gastrulation only in those cells that will subsequently form muscle (Mohun 
et al 1985, Gurdon et al 1985 a). Ligation experiments with fertilised but 
uncleaved eggs showed that all the materials required for the eventual 
activation of the cardiac actin genes are localised in a subequatorial region of 
the egg (Gurdon et al 1985 a, Gurdon et al 1985 b). It is suggested that some 
muscle cells of an embryo might be formed by the activity of cytoplasmic 
determinants localised in the uncleaved egg and partitioned by cleavage to the 
third tier of a 32 cell embryo. It is possible to argue that inductive processes 
rather than cytoplasmic determinants are involved in producing muscle cells 
from the the tier-3 cells. It has been shown that vegetal cells can induce 
animal cells to activate the cardiac actin genes (Gurdon et al 1985 a, Gurdon et 
al 1985 c). The induction signal does not require cell contacts but the ability 
of cells to induce and respond is strictly limited in time (Gurdon et al 1985 a, 
Gurdon et #/1985c) also cell division is not required for the signal (Gurdon and 
Fairman 1986). Recently it has been demonstrated that upstream sequences 
are required for the temporal and tissue specific expression of the cardiac actin 
gene as shown by the microinjection of chimeric plasmids containing cardiac 
actin promoter - bacterial chloramphenicol acetyl transferase gene constructs
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into fertilised eggs (Mohun, Garrett and Gurdon 1986). Therefore it appears 
that the developmental regulation of cardiac actin expression (i.e. muscle cell 
differentiation) is influenced by many parameters and hence it could be difficult 
to obtain an overall picture of how muscle cells are determined.
1.5.4.3 Expression at particular developmental stages
Although the RNA populations of eggs and gastrula embryos are similar 
some qualitatively new mRNAs are synthesised immediately after the 
midblastula transition. These genes might encode products that are important 
in the formation of germ layers and tissue anlagen and might also be involved 
in gastrulation processes. There are a few ways that this class of gene 
sequence can be isolated. The first approach is to use labeled poly(A) + RNA 
from eggs and gastrula embryos to differentially screen a gastrula cDNA \\Warvj 
but only relatively abundant sequences will be isolated by this method. One 
such clone, called GS17, was isolated by this procedure (Krieg and Melton 
1985). GS17 is one of the first genes to be expressed by the embryonic 
genome exactly at the midblastula transition and is only expressed transiently 
during gastrulation. It is interesting to note, as judged by micrcnnjection of 
recombinant plasm! ds, that only about 2kb at the 5'end of the GS17 gene are 
required for both the correct switch on and off of transcription during 
development. No function has yet been assigned to the GS17 gene product 
but its promoter will certainly be useful in studying the function of other genes 
during development.
The second approach is to use cDNA libraries that have been enriched in 
the sequences of interest. By employing a subtractive cDNA cloning procedure 
a library containing sequences that are differentially expressed in gastrula 
(called DG genes) has been obtained (Sargent and Dawid 1983). Each DG gene 
is activated in a specific temporal manner during early development and none 
are expressed in adult (Jamrich, Sargent and Dawid 1985). Sequence analysis 
of many of the clones has revealed two families (Jonas, Sargent and Dawid 
1985, Dawid and Sargent 1986). One family represents cytokeratins which form 
the intermediate filament system of epidermal and epithelial cells. These genes 
appear to be embryonic forms of adult cytokeratins and in the gastrula their 
mRNA is located exclusively in the ectoderm. The second family represents 
sequences that accumulate rapidly after the midblastula transition and the 
decay during neurulation. One sequence, DG 42, has no sequence homology to
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any other known gene and its mRNA is exclusively located in the endoderm of 
the gastrula.
Both classes of genes have been used as molecular markers to analyse 
inductive events during early differentiation (Jamrich, Sargent and Dawid 1985, 
Dawid and Sargent 1986). Using exogastrula embryos it has been shown that 
the correct shape of the embryo is not important for the expression of the DG 
genes or cardiac actin. Suppression of mesoderm formation by UV treatment 
(which is a purely positional effect) or the interruption of cell communication 
by the use of calcium and magnesium free medium and dissociation of cells 
does not inhibit the expression of the DG genes but does cardiac actin. The 
keratin genes are switched off but not other DG genes and cardiac actin genes 
when the cells are in close proximity yet have lost tight adhesivity. All these 
results suggest that the regulatory substances which cause the activation of 
the DG genes could be maternally derived but the activation of cardiac actin 
(and other muscle specific genes) requires substances to be formed in early 
development. Since expression of ectodermal and endodermal markers is cell 
autonomous the endoderm/ectoderm dichotomy is determined by the polarity 
of components in the egg. The mesoderm orignates from an interaction 
between ectodermal and endodermal cells which is independent of calcium 
mediated tight adhesion and expression of mesodermal markers is suppressed 
when cell interactions during the blastula stage are inhibited. Elucidation of 
the nature of these cell interactions and how the differentiated state arises will 
be a very exciting area in future studies on molecular biology of development.
1.6 Objectives of this Thesis
Initially I wanted to make use of the observation that cellular oncogenes are 
highly conserved in evolution to encompass the genus Xenopus. Since cellular 
oncogenes are strongly implicated in regulation of normal cell growth, division 
and differentiation and during development it should be possible to exploit the 
potential of Xenopus\o analyse cellular oncogenes during oogenesis, very early 
embryogenesis and cellular differentiation.
Interest would focus on one particular oncogene (c-myd) with the isolation 
on homologous sequences from Xenopus gene libraries helping in the analysis. 
Sequence analysis of such clones would then establish the Xenopus sequences 
relationship with other sequences and may point to important functional
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domains in the protein. Clues to the function of these genes might be found 
by analysing their expression during oogenesis and development. Also parallels 
with other systems might become apparent and unique features peculiar to 
aspects of Xenopus development might be found. Antisera to putative gene 
products could be generated to try and study aspects of protein expression. 
Also clues to the evolution of the Xenopus genus might be gained. In 
summary I would hope to have begun an initial characterisation of a gene that 
plays an important role in development - the choice of this gene having been 






Generally solutions were made sterile and RNase/DNase free where possible 
by autoclaving (15psi/15 minutes) or by treating with 0.01%(v/v) diethyl 
pyrocarbonate overnight at 65°C. Stocks solutions were made in sterile, baked 
glassware and were also filtered through a 0.45pm cellulose nitrate filter to 





Barth X (Barth and Barth 1954)
MS222
10x high salt restriction buffer
10mM Tris-CI, 1mM EDTA pH 7.4 - 8.0 
0.4M diaminoethanetetra-acetic acid pH 8.0
0.11M NaCI, 1.3mM KCI, 0.44mM CaCI pH 7.2 
with NaHC0 3
solution A: 51.50g NaCI, 0.75g KCI, 2.04g 
MgSO4.7H 2O 0.62g Ca(NO 3)2.H 2O, 0.60g 
CaCI 2 .2H 2O made to 1 litre divided into 100ml
solution B: 2g NaHCO 3 made to 500ml and 
divided into 50ml aliquots
solution C: 24.22g Tris, 20mg phenol red pH 
to 7.6 with HCI made to 500ml and divided 
into 50ml aliquots
1x Barth X is made by mixing 1 aliquot of 
solution A, B and C then made to 
1 litre
10 - 20%(w/v) ethyl-M aminobenzoate in ddH 2O
1M NaCI, 0.5M Tris-CI pH 7.5, 0.1M 
MgC1 2, 10mM DTT
10x medium salt restriction buffer 0.5M NaCI, 0.1M Tris-CI pH 7.5,
0.1M MgCI 2, 10mM DTT
10x low salt restriction buffer
10x universal restriction buffer
0.1M Tris-CI pH 7.5, 
0.1M MgCI 2, 10mM DTT
0.33M Tris-acetate pH 7.9, 0.1 M 
Mg-acetate, 0.66M K-acetate, 10mM DTT, 
1mg/ml gelatin
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10x TAE gel buffer 
10x TBE gel buffer
DNA gel sample buffer
IQx MOPS gel buffer
RNA sample buffer
10x T4 DNA ligase buffer
STET
Kirby salts








0.4M Tris-acetate pH 8.3, 20mM EDTA
0.89M Tris-borate-0.89M 
boric acid, 10mM EDTA
50%(v/v) glycerol, 0.25%(w/v)
bromophenol blue, 0.25%(w/v) xylene cyanol FF
in ddH 20
0.2M Na-MOPS pH 7.0,
50mM sodium acetate, 10mM EDTA
50% formamide, 2.2M formaldehyde, 
1x MOPS gel buffer
0.66M Tris-CI pH 7.6, 
50mM MgCI 2, 50mM DTT
8%(w/v) sucrose, 0.5%(v/v) Triton X-100, 50mM 
EDTA pH 8.0, 10mM Tris-CI pH 8.0
0.1M Tris-CI pH 9.0, 10mM EDTA, 0.5%(w/v) SDS, 
1.0%(w/v) tris-iso-propylnaphtalene sulphonic 
acid, 6.0%(w/v) 4-aminosalicylic acid, 1.0%(w/v) 
NaCI, 6.0%(w/v) phenol
0.7M Tris-CI pH 7.6, 0.1M MgCI 2 , 
50mM DTT
30%(w/v) acrylamide,
1%(w/v) IM-N- methlyene bis-acrylamide,




10 or 25%(w/v) ammonium persulphate 
in ddH 20
100ng/ml DNase I, 50mM Tris-CI 
pH 8.0, 5mM MgCI 2
50mM KP04 pH 7.4, 7mM MgCI 2,
1mM DTT, 0.33mM dATP 0.33mM dGTP,
0.33mM dTTP
solution 0: 0.125M MgCI 2, 1.25M 
Tris-CI pH 8.0
solution A: 0.95ml solution 0,
18ul 2-mercaptoethanol, 25ul 20mM dATP,
25ul 20mM dTTP, 25ul 20mM dGTP










2x Second strand salts
Packaging buffer A
Packaging buffer Ml
5x Laemmli gel buffer 





solution C: Hexadeoxyribonucleotides 
(Pharmacia) suspended in TE at 90 OD U/ml
OLB is made up by mixing solution A, B, 
and C in the ratio 2:5:3 and stored at 
-20°C
0.4M Tris-Cl pH 7.9, 0.1M NaCI,
0.1M DTT, 0.06M MgCI 2 0.02mM spermidine.
5mM rATP, 5mM rGTP, 
5mM rTTP,120uM UTP
3.6M NaCI, 0.2M NaH 2P04 pH 7.4, 0.02M EDTA
1%(w/v) Ficoll, 1%(w/v) polyvinyl pyrrolidone, 
1%(w/v) BSA (pentax fraction V)
Is made up as a 5mg/ml stock and sonicated 
till the viscosity is reduced. It is also phenol 
extracted as in 2.4.1
50ul 1M Tris-Cl pH 8.3 (measured at 37°C), 
40ul DTT 30ul 0.2M MgCI 2, 20ul 3M NaCI, 
50ul 20mM dATP, 50ul 20mM dGTP, 20mM dTTP, 
lOOug/ml p(dT) 12- 18 460ul ddH 2 O. 
Stored at -20°C
40mM Tris-Cl pH 7.5, 10mM MgCI 2, 20mM 
ammonium sulphate, 200mM KCI
20mM Tris-Cl pH 8.0, 3mM MgCI 2, 0.05%(v/v) 
2-mercaptoethanol, 1mM EDTA
110ul ddH 2O, 6ul 0.5M Tris-Cl pH 7.5, 300ul 
0.05M spermidine, 0.1M putrescine 9ul 1M MgCI 2
144g glycine, 30g Tris, 5g SDS made to 1 litre
0.125M Tris-Cl pH 6.8, 20%(w/v) glycerol, 
5%(v/v) 2-mercaptoethanol, 2%(w/v) SDS, 
0.01%(w/v) bromophenol blue.
0.25M sucrose, 50mM Tris-Cl pH 7.5, 50mM 
KCI 10mM MgCI 2, 1mM DTT with 150ug/ml 
PMSF added just before use
0.1M Sodium phosphate pH 7.5, 1.3M NaCI
20mg/ml 5-bromo-4-chloro-3-indoyl-|3 
galactoside in dimethyl formamide




Xenopus borealis, Xenopus laevis and Xenopus tropicalis frogs were kept in 
large aquaria and maintained in a constant environment at 22°C. Animals were 
raised from our own matings and were fed on pellets supplied by Xenopus Ltd. 
Aquaria were cleaned weekly.
2.2.2 Egg and embryo production 
2.2.2.1 Live matings
Mature male and female frogs are injected with 150-300 units of human 
chorionic gonadotrophin (Pregnyl, Organon) and a couple allowed to mate in 
small aquaria. Eggs are laid 8-12 hr later. Fertilised eggs are harvested and 
allowed to develop to the required stage (Nieuwkoop and Faber 1956). Stages 
1-6 are cleavage, stages 7-9 are blastula, stages 10-13 are gastrula, stages 
14-20 are neurula and stages 23-24 are tailbud. embryos are dejellied in 
2%(w/v) cysteine-hydrochloride pH 8.0 before use.
2.2.2.2 Artificial fertilisation
Females are injected as in 2.2.2.1 and eggs collected 8-12 hr later in to 1x 
DeBoers by gentle squeezing of the animal. Sperm are obtained from males by 
macerating testes in 1x DeBoers (Wolf and Hedrick 1971). Eggs and sperm are 
mixed in a small volume of 0.05x DeBoers and fertilisation monitored by 
rotation of the eggs. Developing eggs are transfered to 1x DeBoers. Upon 
reading blastula embryos are transfered to 0.05x DeBoers to allow gastrulation 
to proceed correctly.
2.2.3 Oocytes and other tissues
Frogs are anesthetised with a lethal dose of MS222. Ovaries and other 
tissues are dissected, washed in Barth X and used immediately or stored at 
-70°C. Previtellogenic ovaries are isolated from immature frogs. Blood is 
obtained by heart puncture; injection of a little Barth X containing heparin helps 
stop coagulation. Aneamic frogs are made by the injection, on three 
consecutive days, of 6-10mg of phenylhydrazine in Barth X into the dorsal 
lymph sac. These animals are bled 10 days after the final injection. Embryos
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are dissected under a microscope using fine tungsten needles.
Oocytes are obtained from adult ovaries by treatment of 1mg/ml 
collagenase in Barth X plus 20mM EDTA. After gentle stirring dissociated 
oocytes are washed in Barth X. These oocytes are essentially free of 
surrounding follicle cells and are staged as described by Dumont (Dumont 
1972). Table 2.1 summarises these stages.
2.3 Microbiological Strains and Media
2.3.1 Microbiological strains
All bacterial strains, plasmid vectors and bacteriophage vectors used in this 
study are described in table 2.2. Oncogene and other plasmids are described 
in Table 2.3. Bacterial stocks are stored at -70°C in freezing media and are 
also maintained on the appropriate plates. Lambda bacteriophage are stored in 
phage buffer with a few drops of CHC1 3 at 4°C. M13 bacteriophage are stored 
as DNA in sequencing TE at -20°C or in M13 phage buffer.
2.3.2 Media
Media is sterilized by autoclaving. Antibiotics, vitamins and sugars are 
made up in sterile water than filter sterilised. Where appropriate antibiotics are 
added to plates and media : ampicillin to 50ug/ml, streptomycin to 200yg/ml, 
tetracycline to 50]ig/ml and chloramphenicol to 100ug/ml.
L broth 10g Difco bacto Tryptone, 5g Difco Bacto yeast extract,
5g NaCI per litre, pH 7.2
L agar As L broth plus 15g Difco agar per litre
BBL agar lOg Baltimore Biological Laboratories trypticase, 5g NaCI,
10g Difco agar per litre, pH unaltered
BBL top agar As BBL agar but only 6.5g Difco agar per litre
Spitzen minimal salts lOg (NH 4) 2SO4, 20g K2 HP04/ 30gKH 2P04/
5g tri-sodium citrate, 1g MgSO4 per litre
Minimal medium 80ml spitzen minimal salts, 4mls 20% (w/v) glucose
0.2ml 1mg/ml vitamin B1 per 400ml
Minimal agar As minimal medium plus 6g Difco Bacto agar 
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Table 2.1 (From Dumont 1972)




20mM Tris-CI pH 7.5, 20mM NaCI, 1mM EDTA
6.3g K2 HPO4 , 1.8g KH 2 PO4, 
0.45g Na citrate, 0.09g MgSO4.7H 20, 
0.9g (NH 4) 2S04, 44ml glycerol to 




















thi,/F'proA+ B +,lacl q ,lacZAM15, traD36
MM294 (F~endA,thi,hsdR)with mail, 
Prcl857, mal PQ. This was constructed 
by Dr.Raibaud using pOM40 to transfer 
Pr,CI857 onto C600 (by Mal~Tet r 
selection) then by PI 
cotransduction using the marker 
araB onto MM294 
(Personal communication)
Iyc7, hsdM +S +R"hfl

















Amp r, Tet r (cloning vector) 
Amp 1", Tet r (cloning vector)
Amp r(lacZ colour selection,
cloning vector)
Amp 1", (T7/SP6 transcription)









































































Table 2.3 Oncogene and other plasmids
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2.4 General Methods
2.4.1 Deproteinisation of nucleic acids
Phenol was first redistilled under N 2, adjusted to 0.1%(w/v) 
8-hydroxyquinoline and saturated with TE. Purified phenol is stored at -20°C 
until required.
Nucleic acids are extracted as follows. 5ug of E.coli tRNA is added as 
carrier if required then the aqueous phase is adjusted to 0.4M NaCI, 20mM 
EDTA. An equal volume of phenol is added, incubated at 37°C for 5 minutes 
and occasionally vortexed to maintain the emulsion. After cooling on ice an 
equal volume of CHCI 3/isoamyl alcohol (24:1) is added and incubated for 5 
minutes vortexing occasionally. The phases are separated under centrifugation 
and the aqueous phase removed. The organic phase is back-extracted with an 
equal volume of TE and the aqueous phases combined then re-extracted with 
an equal volume of CHCI 3/isoamyl alcohol (24:1) on ice. After centrifugation 
the aqueous phases are precipitated as required.
2.4.2 Precipitation of nucleic acids
The aqueous phase is adjusted to 0.3M sodium acetate (pH 5.2) or 0.4M 
NaCI then 2 volumes (for DNA) or 2.5 volumes (for RNA) of ethanol or 1 volume 
of isopropanol (for DNA) is added and incubated at -20°C for at least 1hr. For 
small quantities of material (<5ug/ml) carrier tRNA may be added to 5-10ug/ml 
and the precipitation left overnight. The precipitate is recovered under 
centrifugation at 4°C in a Sorvall centrifuge (10K rpm, 20 minutes, HB4) or 
microfuge (12Krpm, 10 minutes). The pellet is washed in 70% ethanol, air dried 
and redissolved in ddH 2O or TE.
DNA can also be precipitated by the addition of an equal volume of 4M 
ammonium acetate and 2 volumes of ethanol or 1 volume of isopropanol. After 
incubating on dry/ice ethanol for 15 minutes the DNA is recovered as above. 
Two such precipitations remove >99% of unincorporated nucleotides from 
reactions (Okayama and Berg 1982).
2.4.3 Autoradiography
Autoradiography was performed using Cronex 4 X-ray film and cassettes. 
For 32 P film were preflashed and exposed at -70°C using intensifying screens
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(Laskey and Mills 1977). Films were developed in a Agfa X1 automatic film 
processor.
2.4.4 Deionised formamide
100ml formamide was deionised with 10g BioRad analytical grade mixed bed 
resin AG 501-X8(D), 20-50 mesh by stirring at room temperature for 30 
minutes. Formamide was then filtered through Whatman No.1 filter paper and 
stored at -20 °C.
2.4.5 Restriction endonuclease digestion of DNA
In general DNA was digested with a 2-4 fold excess of enzyme for at least 
2hr in conditions recommended by the manufacturer. Genomic DNA was 
digested for at least 6hr with a 4 fold excess of enzyme. Alternative reaction 
conditions used high salt, medium salt or low salt restriction buffers (Maniatis 
et al 1982) or universal buffer (O'Farrel et al 1980). Multiple enzyme digests 
were carried out in the same buffer where possible, otherwise after completion 
of one digest the salt conditions are altered for the next or the sample phenol 
extracted and precipitated before the next reaction.
2.4.6 Quantitation of nucleic acids
The optical density at 260nm was used to quantify nucleic acids. An OD 2 eo 
of 1.0 is 50ug/ml for DNA or 40ug/ml for RNA. Nucleic acid was free of 
contaminating protein if OD 26o/OD 280 was 1.8-2.0. The background value at 
OD 32o was subtracted from all readings. A rough estimate of nucleic acid 
concentration can be obtained by ethidium bromide staining of agarose gels 
with known quantities of material.
2.4.7 Agarose gel electrophoresis 
2.4.7.1 DNA gels
DNA was size fractionated by submerged agarose gel electrophoresis. 
Molten Pharmacia agarose (0.3-2.0%w/v in 1x TAE gel buffer) was cooled to 
60°C and poured into horizontal gel formers. Set gels were submerged in 
homemade electrophoretic tanks containing 1x TAE gel buffer. 1/5th volume of 
DNA gel sample buffer was added to the DNA sample and then applied to the 
sample well. Electrophoresis was performed at various voltages (5-100 V/cm)
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and times (0.5-18 hr) at room temperature until the required separation was 
achieved. Restriction digests of bacteriophage lambda c!857 or pAT153 were 
used as molecular weight markers. Gels were stained with 5ug/ml ethidium 
bromide in ddH 20 for 0.5hr and destained in ddH 20 for 2hr at room 
temperature. Low melting point agarose (BRL) gels were poured and run at 
4°C, 7.5V/cm in 1x TAE gel buffer containing 0.5 ug/ml ethidium bromide.
2.4.7.2 RNA gels (Lehrach et al 1977)
RNA was similarly size fractionated by electrophoresis through 1.2% 
agarose (Pharmacia) gels. Molten agarose was cooled to 60°C and adjusted to 
1x MOPS gel buffer, 2.2M formaldehyde before pouring into gel formers. Dried 
RNA samples were redissolved in 20ul RNA sample buffer and heated to 65°C 
for 5 minutes. After cooling on ice 2ul of 50% glycerol, 0.2%(w/v) 
bromophenol blue was added and the sample applied to the gel well. 
Electrophoresis was at 5V/cm for 18hr in 1x MOPS gel buffer at room 
temperature. Gels were stained for 20 minutes with 5ug/ml ethidium bromide 
in 0.1M ammonium acetate at room temperature and destained for 2hr in 0.1M 
ammonium acetate. Xenopus borealis 18S and 28S ribosomal RNA was used as 
markers.
2.4.8 Gel photography
Nucleic acid was visualised in stained gels using an ultraviolet 
transilluminator (254nm). Photographs were taken through a red (A1) filter onto 
llford HP5 film (f4.5, 20s). Films were developed in llford microphen (5 min), 
stopped in 3%(v/v) acetic acid (30s) and fixed in llford hypem (5 min) at room 
temperature. Films were washed well in water, dried and the relative mobilities 
of the sample measured directly from the negative (distance proportional to 
Iog 10 mwt).
2.4.9 Ctab precipitation
The incorporation of radiolabeled nucleotides into nucleic acids was 
monitored by ctab precipitation. A sample is added to 1ml of 1mg/ml yeast 
tRNA in 0.5M sodium acetate pH 4.6 and 0.5ml 4% (w/v) ctab is added, mixed 
and left at room temperature for 5 minutes. The precipitate is collected by 
vacuum filtration onto Whatman GF/C filters prewetted in 5% (w/v) sodium 
pyrophosphate. The precipitates are then washed 1ml 5%(w/v) sodium
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pyrophosphate and 2ml ddH 20. The filters are dried at 80°C put into 
scintillation vials, covered in scintillojit (8g/litre butyl-PBD in toluene) and 
counted.
2.5 Transformation of E.coli (Mandel and Higa 1970)
A single colony of E.coli is picked into 5ml L broth and grown up overnight 
at 37°C. 1ml of this overnight culture is used to innoculate a 100ml culture and 
is grown till OD650=0.2. Cells are chilled on ice then spun down. The cell 
pellet is gently resuspended in 50ml of cold lOOmM CaCI 2 and kept on ice for 
15 minutes. Cells are respun and the pellet resuspended in 10ml of cold 
100mM CaCI 2 and kept on ice at least 1hr before use.
0.2ml of competent cells are added to the DNA sample (<100ng) in glass 
tubes and left on ice for 1hr. The tubes are heat shocked for 2 minutes at 
42°C and 1ml L broth added and incubated at 37°C for 1hr. 2.5ml of molten 
BBL top agar at 45°C is added and poured onto appropriate plates, inverted 
and incubated at the correct temperature. If lacZ colour selection is used 30jal 
X-gal and 30ul of IPTG is added before pouring. This method gives 10 5-10 7 
transformants/jjg DNA.
2.6 Ligation of DNA
The vector and insert DNA are cut to completion with the appropriate 
restriction endonucleases but 5 minutes before completion 1 unit of calf 
intestinal phosphatase (Boehringer) is added. Samples are phenol extracted, 
precipitated and dissolved in ddH 2O. Ligation conditions are chosen such that 
the vector to insert DNA concentrations are at a 2:1 molar ratio. Typically 
100ng vector and 20ng insert DNA are ligated in 15ul reactions containing 1x 
T4 DNA ligase buffer, 1mM ATP and 1 unit T4 DNA ligase at 16°C for 18hr. 
The ligation mixes are transformed into E.coli or in vitro packaged into lambda.
2.7 Extraction of DNA from Agarose Gels
2.7.1 Low melting point agarose gel (Weislander 1979)
Low melting point agarose gels are run as in section 2.4.7.1 and the 
required DNA fragment is excised cleanly from the gel. 5 volumes of 0.1M 
NaCI, 10mM Tris-CI pHS.O, 1mM EDTA are added and heated to 65°C to melt 
the gel. The gel is phenol extracted (no CHCI 3) once at 65°C then the aqueous
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phase is phenol extracted as in section 2.4.1 and precipitated with addition of 
5pg carrier £.co//tRNA.
2.7.2 Electroelution
Pharmacia agarose gels are run as in section 2.4.7.1 and a small trough is 
cut in front of the desired fragment. The trough is then lined with dialysis 
tubing and the fragment electrophoresed into the trough. The current is 
reversed for 30 seconds and the DNA is sucked off with a pasteur pipette. 
DNA is then phenol extracted as in section 2.4.1 and precipitated with addition 
of 5ug carrier Ec0//tRNA.
2.8 Elutip-d Column Purification of DNA
For some purposes (e.g. nick translation of insert DNA) it is found that 
further purification of DNA is required. Elutip-d columns (Schleicher and 
Schull) are used exactly as described by the manufacturer. Briefly columns are 
primed by washing in high salt buffer (1.0M NaCI, 20mM Tris-CI pH 7.5, ImM 
EDTA) then low salt buffer (0.2M NaCI, 20mM Tris pH 7.5, ImM EDTA). DNA, in 
low salt buffer, is applied to the column (which has a 0.45um cellulose acetate 
filter attached to remove particulate matter). The DNA is then eluted in high 
salt buffer (no filter attached) and the sample precipitated.
2.9 Plasmid DNA Preparation
2.9.1 Mini-preperation of plasmid DNA (Holmes and Quigley 1981)
This method can yield 5-10ug of plasmid DNA. It is convenient to prepare 
multiples of twelve as required. Single bacterial colonies are used to 
innoculate 2ml cultures in L broth with appropriate antibiotics and grown 
overnight at the correct temperature. Cultures are transfered to microfuge 
tubes and the cells collected by centrifugation for 30 seconds. Supernatants 
are removed and 90uJ of cold STET and 10uJ of 10mg/ml lysozyme (made fresh 
in STET) are added to the pellet and mixed thoroughly. The tubes are boiled 
for 40 seconds and the cellular debris is immediately pelleted by centrifugation 
for 10 minutes. Supernatants are removed, deproteinised (2.4.1) and 
isopropanol precipitated. The DNA pellet is redissolved in 30ul ddH 2O and 
5-10ul are used for restriction analysis including RNase A at 50ug/ml to 
destroy contaminating RNA.
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2.9.2 Maxi-preparation of plasmid DNA (modified from Maniatis et al 1984)
A single bacterial colony was used to innoculate a 2ml culture in L broth 
(with antibiotics) and grown overnight (normally 37°C). A fresh 25ml culture 
was grown for 3hr using 1ml of the overnight culture. The 25ml culture was 
used to start a 500ml culture and after 2hr 75mg chloramphenicol was added 
and the culture grown overnight. Cells were harvested by centrifugation in a 
Sorvall GSA rotor (4Krpm, 5 minutes, 4°C) and resuspended in 5ml sucrose 
buffer (25%(w/v) sucrose, 50mM Tris-CI pH 8.1, 40mM EDTA) on ice. 1ml 
10mg/ml lysozyme (in sucrose buffer) and 1ml 0.5 M EDTA added and 
incubated for 15 minutes on ice. Lysis was achieved by the addition of 13 ml 
Triton buffer (0.1%(w/v) Triton X-100, 60mM EDTA, 50mM Tris-CI pH 8.0) and 
incubated on ice for a further 10 minutes. Chromosomal DNA and cellular 
debris was removed by centrifugation in a Sorvall SS34 rotor (17Krpm, 1hr, 
4°C). The supernatant was recovered, deproteinised (2.4.1) and ethanol 
precipitated.
Nucleic acids were recovered by centrifugation and resuspended in TE 
containing 100ug/ml RNase A, 5U/ml RNase T1 and incubated at 37°C for 30 
minutes followed by deproteinisation and ethanol precipitation. Plasmid DNA 
was recovered and redissolved in 3ml TE, 3g of caesium chloride and 0.15ml 
5mg/ml ethidium bromide in TE were added. Exactly 6.15g were removed to a 
vertical rotor centrifuge tube and plasmid DNA was banded under 
centrifugation in an OTD50 Sorvall ultracentrifuge (45Krpm, 18°C, TV-865) for 
18hr. The supercoiled plasmid DNA band was recovered via a syringe needle 
pushed through the centrifuge tube wall. Plasmid DNA was extracted four 
times with butan-2-ol (saturated in 4 NaCI, TE) to remove ethidium bromide. 
The plasmid DNA was diluted to 2ml with TE, precipitated with 2ml isopropanol, 
recovered and precipitated twice more from ammonium acetate. Plasmid DNA 
was stored at -20°C in ddH 2O.
2.10 Bacteriophage Lambda DNA Preparation 
2.10.1 Plating of phages
An overnight culture of NM514 (recombinant phage) or NM259 (non 
recombinant phage) was grown in L broth supplemented with 0.4% (w/v) 
maltose, and harvested by centrifugation then resuspended in 1/2 volume of 
10mM MgSO4 . Appropriate dilutions of phage are mixed with 0.2ml of plating
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cells and incubated on ice for 20 minutes then at 37°C for 20 minutes. 3ml of 
molten top agar supplemented with 10mM MgS04 is added and poured onto 
9cm BBL agar plates. Set plates are inverted and incubated at 37° for 6-12hr.
2.10.2 Plate lysates
A well isolated phage plaque was picked into 1ml phage buffer. 50ul phage 
were incubated with 100ul plating cells and plated onto freshly poured L plates. 
Phage are grown (non-inverted) for 12hr at 37°C then 4ml L broth 
supplemented with 10mM MgSO4 was added. The top layer and liquid were 
removed, vortexed briefly and cells and agar removed under centrifugation. 
The supernatant was removed, titred and stored at 4°C with the addition of a 
few drops of CHCI 3 .
2.10.3 Liquid lysates
A 100ml culture of NM259 or NM514 was grown at 37°C to OD650=0.5 in L 
broth supplemented with 10mM MgSO4 . Cultures were infected with 25ul of 
plate lysate (moi=0.1) and incubated till OD650 reached a minimum (5-7 hr). 4g 
NaCI, 100jag RNase A and lOOug DIMase I were added and incubated at room 
temperature per 1hr. Phages were left to precipitate overnight at 4°C by the 
addition of 25ml of 50%(w/v) PEG-6000. The phage particles were recovered 
by centrifugation at SKrpm in a Sorvall GSA rotor. The phage particles are 
gently resuspended in 5ml phage buffer.
2.10.4 CsCI step gradients
The phage particles were further purified on a CsCI step gradient. Three 
2ml CsCI steps (in phage buffer) were used with densities of 1.3, 1.5 and 
1.7g/ml. The phage sample was carefully layered onto the step gradient in 
14ml MSE centrifuge tubes and phage banded at 35Krpm at 20°C for 2hrs in a 
6 x 14ml Ti swing out rotor. The bluish phage band was collected through the 
side of the tube with a syringe. The phage suspension was then dialysed twice 
for Ihr at room temperature against 1 litre of 10mM MgCI 2, 10mM NaCI, 50mM 
Tris-CI pH 8.0.
2.10.5 Phage DNA extraction
The dialysed phage suspension was diluted to 2ml with TE and 100ul 0.4ml 
EDTA, lOOul 10%(w/v) SDS and 10ul 20mg/ml proteinase K added and
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incubated at 65°C for 1hr. The phage DNA was then deproteinised and 
precipitated with ethanol. The DNA pellet was left to redissolve in 500ul ddH 2 O 
overnight at 4°C before storing at -20°C.
2.11 Xenopus DNA Preparation (Blin and Stafford 1976)
Xenopus erythrocyte cells are pelleted and resuspended in 1 volume of 
0.1 M NaCI. Cells are pelleted and resuspended in 10 volumes of lysis buffer 
(0.5M EDTA, 0.5%(w/v) sarkosyl, 100ug/ml proteinase K) then incubated at 50°C 
with gentle swirling for 3hr. The DNA is gently extracted three times with one 
volume of phenol at 50°C then extracted with two volumes of CHCI 3/isoamyl 
alcohol (24:1) on ice. DNA is then dialysed extensively against TE then treated 
with RNaseA (to 100ug/ml) at 37°C for 3hrs. Proteinase K is added to 50ug/ml 
and incubated for 1hr at 37°C before extracting three times with phenol and 
twice with CHCI 3/isoamyl alcohol (24:1). The DNA is precipitated and the pellet 
left to redissolve in ddH 2 O at 4°C overnight before storing at -20°C.
2.12 Xenopus RNA Preparation
2.12.1 Ovary RNA (Darnbrough and Ford 1976)
Dissected ovary tissue is homogenised in Kirby salts (10ml/g tissue) until 
no large tissue fragments could be observed. An equal volume of phenol is 
added, vortexed and incubated at 37°C for 15 minutes. The emulsion is spun 
in a Sorvall HB4 rotor (10Krpm, 4°C, 15 minutes). The upper phase is 
recovered and 1/10 volume 3M NaCI and one volume phenol is added and 
shaken then incubated a 37°C for 15 minutes. After respinmna the aqueous 
phase is extracted with two volumes of CHCI 3/isoamyl alcohol (24:1) on ice. 
Following centrifugation the aqueous phase is precipitated twice from ethanol 
and the RNA is stored as an ethanol precipitate at -70°C.
2.12.2 Blood RNA
Isolated blood cells are washed twice in Barth X and resuspended in five 
cell volumes of lysis buffer (0.1M NaCI, 5mM MgCI 2, 20mM Tris-CI pH 7.5). 
Lysis is achieved by the addition of another five cell volumes of lysis buffer 
containing 1/40th volume of 10% (v/v) NP40. Nuclei are removed by 
centrifugation in a Sorvall HB4 rotor (10Krpm, 10 minutes, 4°C). The 
supernatant is removed adjusted to 20mM EDTA, 0.5% SDS and added to ten
60
cell volumes of 0.1 M NaCI, 0.2% SDS in TE. The RNA is deproteinised as in 
section 2.4.1, ethanol precipitated and stored as for ovary RNA.
2.12.3 Other tissue RNA (Feramisco et al 1982)
Tissue fragments are frozen in liquid N 2 and then powdered in dry ice 
before homogenisation in guanidinium mix (4M guanidinium isothiocyanate, 
10mM EDTA 50mM Tris-CI pH 7.6, 10% (w/v) sarkosyl, 1% (v/v) 
2-mercaptoethanol). The mixture is brought to 60°C and is passed through a 
19 gauge needle until the viscosity of the solution is reduced. An equal 
volume of phenol is added and the solution again passed through the needle. 
After cooling the mixture on ice, 0.1 volume of 0.1M sodium acetate pH 5.2, 
10mM Tris-CI pH 7.4, 1mM EDTA and an equal volume of CHCI 3/isoamyl alcohol 
(24:1) is added then mixed well. The aqueous phase is recovered by 
centrifugation in a Sorvall HB4 rotor (10Krpm, 10 minutes 4°C) and is 
re-extracted once with an equal volume of phenol/CHCI 3/isoamyl alcohol 
(25:24:1) and twice with an equal volume of CHCI 3/isoamyl alcohol (24:1). Two 
volumes of ethanol are added to the supernatant and after storing at -20°C for 
2hr the RNA is recovered by centrifugation (10Krpm, 20 minutes, 4°C, HB4) and 
the pellet redissolved to the original volume in 0.1 M Tris-CI pH 7.4, 50mM NaCI, 
10mM EDTA, 0.2% (w/v) SDS. Proteinase K is added to 200yg/ml and the 
mixture incubated at 37°C for 2hr before heating to 60°C. 0.5 volumes of 
phenol are added and mixed at 60°C for 10 minutes then cooled on ice and 0.5 
volumes of CHCI 3/isoamyl alcohol (24:1) is added and mixed. The aqueous 
phase is recovered by centrifugation and the extraction repeated once more. 
The aqueous phase is extracted twice with CHCI 3/isoamyl alcohol (24:1) and the 
RNA is ethotnol precipitated and stored as for ovary RNA.
2.12.4 Staged oocyte and embryo RNA
Total RNA is prepared from staged oocytes and embryos by a modification 
of the previous method. Ten oocytes or embryos are vortexed hard in 100ul of 
guanidinium mix, then 100ul phenol and lOOyl 0.1M sodium acetate pH 5.2, 
10mM Tris-CI pH 7.4, 1mM EDTA are added and vortexing continued until the 
mixture is homogenous. The mixture is spun in a microfuge for 5 minutes and 
the supernatant removed and re-extracted with 200^1 phenol/CHCI 3/isoamyl 
alcohol (25:24:1). The aqueous phase is precipitated with ethanol and the pellet 
redissolved in 200ul of ddH 2 O. To remove contaminating polysaccharides 200ul
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8M LiCI is added, left overnight a -20°C and the RNA recovered by spinning in 
a microfuge for 10 minutes at 4°C. The RNA pellet is redissolved in 20ul ddH 2O 
and stored at -70°C.
2.13 Poly (A)+ RNA Preparation (Aviv and Leder 1972)
Poly (A) + RNA is selected from total RNA by affinity chromatography on 
oligo (dT)-cellulose columns. The column is equilibrated in sterile loading 
buffer (20mM Tris-CI pH 7.6, 0.5M NaCI, 1mM EDTA, 0.1% (w/v) SDS). RNA in 
ddH 2O is heated to 65°C for 5 minutes, cooled on ice and an equal volume of 
2x loading buffer is added then the RNA is applied to the column. The flow 
through is collected, heated to 65°C, cooled and reapplied to the column. 
Bound RNA is washed with 10 column volumes of loading buffer then eluted 
with 2-3 column volumes of sterile elotion buffer (10mM Tris-CI pH 7.5, 1mM 
EDTA, 0.05% (w/v) SDS). The column is re-equilibrated in loading buffer and 
the bound RNA put through a second cycle of chromatography after adjusting 
the bound RNA to loading buffer conditions. The poly (A) + RNA is ethanol 
precipitated and then stored as for ovary RNA. Oligo (dT)-cellulose columns 
are regenerated by washing in 0.1M NaOH, ddH 20 then loading buffer checking 
the pH of the column effluent is less than 8.0
2.14 Poly(A) Content of RNA (Rosbash and Ford 1974)
To measure the poly(A) content of RNA a standard 3 H poly(U) hybridisation 
assay was performed. Dilutions of RNA (in 100jil ddH 2O) were added to 400ul 
annealing buffer (50mM Tris-CI pH 7.0, 0.3M NaCI, ImM EDTA) containing 
excess 3 H poly(U) (2-5ul of 3 H poly(U) specific activity 2 x 10 6 cpm/ug). 
Annealing was allowed to take place at 45°C for 30 minutes then the annealed 
RNA was cooled on ice for 5 minutes and incubated with 10ug RNase A for 20 
minuses. Ribonuclease resistant material was ctab precipitated, counted and 
the poly(A) content calculated as in Appendix 1.
2.15 Labeling of Nucleic Acids
2.15.1 End labeling and filling in of restriction sites (Maniatis et al 1982)
For end labelling of restriction sites the following simple method is 
employed. After 2hr of restriction digestion of DNA 10uCi a 32 P dNTP 
(complementary to the protruding 5' termini), 2 U klenow are added directly to
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the reaction and incubated at room temperature for 30 minutes. The end 
labelled DNA is precipttob^ twice from ammonium acetate/ethanol to remove 
unincorporated nucleotides.
Filling in of recessed 3' termini is carried out as above except 10uCi of the 
appropriate 3 H dNTPs are used and after 30 minutes incubation all four dNTPs 
are added to 0.25mM then incubated for a further 30 minutes. Successful 
filling in is monitored by ctab precipitation. Such filled in fragments can be 
used in blunt end ligations.
2.15.2 Kinasing of Linkers (Maniatis et al 1982)
Commercially available linkers, were resuspended at 0.5ug/ul in TE and 
stored at -20°C. 4ul linkers, 20uCi a32 P ATP, 1ul 10x linker kinase buffer, 10U 
T4 polynucleotide kinase and ddH 2O (to 10|il) were incubated at 37°C for 15 
minutes. Then 1yl 10x linker kinase buffer, 1\i\ 10mM ATP, 10U T4 
polynucleotide kinase and ddH 20 (to 20ul) were added and incubated at 37°C 
for a further 30 minutes before storing at -20°C.
The kinased linkers were checked they could be ligated as follows. 5ul 
kinased linkers were self ligated as in section 2.6 but at 4°C for 4hr then 
heated to 65°C for 10 minutes to inactivate the ligase, 5ul of ligated linkers 
were removed and digested with 10U of the appropriate restriction enzyme as 
in section 2.4.5. Finally samples of the kinased, ligated and restricted linkers 
were electrophoresed through a 10% polyacrylamide gel prepared as follows. 
16.7ml 30% acrylamide stock, 2.5ml 10x TBE, lOOul 25%(w/v) APS, 100ul TEMED 
and ddH 2O (to 50ml) were mixed and allowed to polymerise in a vertical gel 
apparatus. 2ul 50% glycerol, 0.2% (w/v) bromophenol blue were added to the 
samples before loading onto the gel. The gel was run in 0.5x TBE until the dye 
had run half way. The gel is then dried down and exposed to X-ray film.
2.15.3 Kinasing of RNA (Donis-Keller et al 1977)
RNA is first treated as follows to increase the number of 5'ends available to 
accept a labeled phosphate. 2.5yg RNA is taken up in 50yl 0.1M NaOH and left 
on ice for Ihr before neutralising with 5ul 1M Tris-CI pH 8.0, 5ul 1M HCI. The 
RNA is ethanol precipitated, redissolved in 25ul 10mM Tris-CI pH 7.4 1mM 
spermidine, 0.1mM EDTA and heated to 50°C for 3 minutes before chilling on 
ice. 10yl RNA (1)jg) is added to 15yl 2x RNA kinase buffer (100mM Tris-CI pH
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9.0, 20mM MgCI 2, 10mM DTT 5ul a 32 P ATP (10mCi/ml SOOOCi/mmol and 4U T4 
polynucleotide kinase. The reaction is incubated for 1 hr at 37°C, a further 4U 
T4 polynucleotide kinase added and incubated for one more hour (monitoring 
incorporation by ctab precipitation). The labeled RNA is ethanol precipitated, 
redissolved in 50ul ddH 20 and unincorporated nucleotides removed by passing 
over a 15cm x 0.4cm Sephadex G-75 gel filtration column in ddH 20. The peak 
fractions are pooled and used as a hybridisation probe, heating to 65°C for 3 
minutes and cooling on ice before use.
2.15.4 Nick translation (Rigby et al 1977)
10ug plasmid DNA (in lOul ddH 20) plus 50ul DNase I mix are incubated at 
37°C for 20 minutes then phenol extracted as in section 2.4.1. The supernatant 
is ethanol precipitated and the DNA redissolved at 0.1ug/ul in ddH 2O. For DNA 
fragments the optimium DNase I treatment must be determined empirically. 
Successful nicking can be checked by running on agarose gel or by a trial 
labeling reaction.
Nicked DNA is labeled as follows: 50ul Pol I mix-C, 5ul a 32 P dCTP 
(10mCi/ml, SOOOCi/mmol), 200ng DNA and 2U E.coli DNA polymerase I are 
mixed and incubated at 16°C for 90 minutes. The reaction is monitored by 
ctab precipitation and if necessary the incubation continued with the addition 
of more DNA polymerase.Unincorporated nucleotides are removed either by gel 
filtration chromatography over Sephadex G-75 (see 2.15.3) or by two 
precipitations from ammonium acetate/ethanol with the addition of 5ug E.coli 
tRNA. The labeled DNA is redissolved in 100ul ddH 2 O, boiled for 10 minutes 
then cooled on ice before use.
2.15.5 Oligolabeling (Feinberg and Vogelstein 1983, 1984)
Highly labelled insert probes with a specific activity of 5x108 - 2x109 
cpm/ug can be generated by this procedure. 5-10yg plasmid or phage DNA is 
cleaved with restriction endonucleases and the fragments separated on one 
lane of a 0.8-1.5% low melting point agarose gel. The desired fragment is 
located by uv visualisation of the stained gel and excised cleanly. 3ml ddH 20/g 
is added to the gel fragment and then boiled for 7 minutes to denature the 
DNA. 50pl aliquots are then stored at -20°C boiling for 3 minutes before use.
The reaction is carried out at room temperature by adding in the following
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order: ddH 2O (to 50ul), 10vil OLB, 2\i\ 10mg/ml BSA (pentax fraction V), 30ul 
DNA 2-5ul a 32 P dCTP (lOmCi/ml, 3000Ci/mmol) and klenow (40U home made 
stock).
After 5-6hr the reaction is normally completed with 70-100% of the label 
getting incorporated. The reaction is stopped by heating to 65°C for 5 
minutes. An equal volume of ddH 20 is added and the labeled DNA precipitated 
twice from ammonium acetate/ethanol (using 5pg carrier Eco// tRNA) to 
remove unincorporated nucleotides. The DNA is redissolved in 100ul ddH 2O 
and boiled for 10 minutes then chilled on ice before use.
2.15.6 M13 single stranded probes (Hu and Messing 1982)
Single stranded M13 probes are generated by using the M13 universal 
probe primer pHM235 (NEB, 5-GAAATTGTTATCC-3'). 5ul template DNA (see 
section 2.19.3), 1ul 10x medium salt buffer, 1ul primer and 3ul ddH 2 O are 
drawn into a capillary. The ends are sealed and the sample boiled for 3 
minutes then allowed to cool slowly to room temperature. The annealed 
primer/template are added to 3ul ddH 20, 3ul a 32 P a dCTP (10mCi/ml, 
3000Ci/mmol), 3ul 0.5mM dNTP-C (dATP, dTTP, dGTP), 1ul klenow (5 units) and 
the reaction incubated at room temperature for 90 minutes then terminated by 
addition of 2ul 0.4M EDTA. Unincorporated nucleotides are removed as for nick 
translation. The sample is not denatured before using.
2.15.7 T7 RNA polymerase probes (Melton et al 1984, Krieg and Melton 1986)
DNA cloned into the pGEM 1/2 vectors (Promega Biotech) is suitable for 
transcribing T7 or SP6 RNA polymerase transcripts. Bug of plasmid DNA is 
linearised with the appropriate restriction enzyme then phenol extracted (2.4.1) 
and redissolved in ddH 2O at 0.25pg/ul. At room temperature 2ul 10x 
transcription buffer, 2ul lOx transcription rNTPs, 1ul RNasin (20 units, 
Amersham), 2ul linearised plasmid DNA, 3yl a 32 P DTP (10mCi/ml, 410Ci/mmol) 
or 30uCi 3 H UTP (13.6Ci/mmol dried down and redissolved in 3ul ddH 2O), 1ul 
T7 RNA polymerase (10U, Boehringer), 9pl ddH 20 are mixed and then incubated 
at 37°C for 1hr. 1ul of RNase free DNase I (0.5ug) is added and incubated for 
15 minutes at 37°C then the reaction phenol extracted and the RNA ethanol 
precipitated. This procedure generates RNA of high specific activity 
(>2x108cpm/ug) or large amounts of 3 H labelled RNA ( >1ug).
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2.16 Transfer of Nucleic Acids to Membrane Filters 
2.16.1 Southern blots
This procedure is essentially as described by Southern (1975), Wahl et al 
(1979) and Maniatis et al (1982). Genomic DNA gels are first treated before 
transfer. The gel is soaked in 0.25 HCI for 15 minutes to depurinate the DNA, 
then in 0.5M NaOH, 1.5M NaCI for 1 hr to denature the DNA and then in 1M 
Tris-CI pH 8.0, 1.5M NaCI for 1hr to neutralize the gel. DNA is transfered to 
nitrocellulose (Schleicher and Schull) by capillary action for 18 hr using 20x 
SSPE as transfer buffer in a blotting sandwich as previously described. The 
blot is dismantled and the nitrocellulose filter air dried and then baked at 80°C 
for 2hr before use. Gels other than genomic gels are transfered similarly 
except that the gels are neutralised in 1M ammonium acetate, 0.02M NaOH and 
the gel transfered without a reservoVof transfer buffer. This can be modified 
to bidirectionally transfer the gel to two filters simultaneously.
2.16.2 Northern blots (Thomas 1983)
RNA gels are transfered by capillary action in a similar manner to that of 
southern blots. After running the gel the marker track is cut off and stained (it 
is important not to stain RNA gels before transfer). The gel is rinsed briefly in 
ddH 2O then the transfer set up using a nylon membrane (Hybond-N, 
Amersham) instead of nitrocellulose. After 18hr the blot is dismantled, the 
filter air dried, exposed to a uv transilluminator (254 nm, RNA side down) for 5 
minutes and then baked at 80°C for 1hr before use.
2.16.3 Phage lifts (Benton and Davis 1977)
DNA from phage plaques can be transfered to nitrocellulose filters by the 
following procedure. Phage are plated onto dry BBL bottom plates using 0.7% 
agarose in 10mM MgSO4 instead of BBL top agar and allowed to grow for 
6-12hr. after cooling at 4°C for 1hr a single sheet of nitrocellulose, cut to the 
dimensions of the plate, is laid on the agarose surface for 1 minute marking 
with needle holes for subsequent orientation. The nitrocellulose was removed 
and laid, plaque side up, on blotting paper soaked in 0.5M NaOH, 1.5M NaCI for 
5 minutes, then immersed in 0.5M Tris-CI pH 8.0, 1.5M NaCI for 5 minutes, then 
2x SSPE for 5 minutes and finally air dried and baked at 80°C for 2hr. Multiple 
filters can be prepared from each plate in this manner.
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2.16.4 Dot blots
Sometimes in testing hybridisation conditions it is useful to directly spot 
nucleic acid onto nitrocellulose filters presoaked in 20x SSPE. RNA if first 
heated to 65°C for 5 minutes and cooled on ice before applying in a small 
volume (<1.5jil). DNA is first denatured by heating to 60°C in 0.1 M NaOH for 
1hr then neutralising with 0.1M HCI before spotting on to the filter. Filters are 
air dried then baked at 80°C before use.
2.17 Hybridisation of membrane Filters with Radioactive Probes
Filters were first prehybridised in either high or low stringency conditions 
shaking for 4-12hr (0.2ml/cm 2) at 37°C. Hybridisation was then carried out for 
18-20hr in the same solution (~0.1ml/cm2) but with the addition of denatured 
radiolabeled probe. High stringency conditions were 50% formamide, 5x SSPE, 
5x Denhardts, 0.1% (w/v) SDS and 100ug/ml denatured herring sperm DNA. 
Low stringency conditions were similar but using 35-40% formamide and 6x 
SSPE. Poly (U) (Sigma) was added to 5ug/ml if the probe contained a poly (A) 
tail. Also if a nylon filter was used then 0.5% (w/v) SDS was used.
Filters were then washed four times at room temperature in 2x SSPE, 0.1% 
(w/v) SDS (10 minutes each wash). The filters were then washed for 1hr at the 
required final stringency. This stringency depended on the nature of the probe. 
Homologous probes had a final stringency of 0.2x SSPE, 0.1% (w/v) SDS at 
65°C whereas for heterologous probes the stringency varied from 2x SSPE, 0.1 
(w/v) SDS at 37 °C to 0.5x SSPE, 0.1% (w/v) SDS at 50°C If bad background 
was a problem it was found that treatment of the filter with proteinase K at 
25ug/ml at 37°C (or 65°C for bad background) for 1hr would solve the 
problem. Filters were then air dried and exposed to preflashed X-ray film. 
Filters were reused by adding them to boiling ddH 2O which was allowed to 
cool to room temperature.
2.18 Preparation of a Previtellogenic Ovary cDNA Library
The general methods for this technique have recently been described by 
Huynh et al (1985) and Watson and Jackson (1985). I have modified the 
methods to my own requirements as described below.
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2.18.1 First strand synthesis
lOug poly(A)+ RNA (inlOul ddH 2 0) is denatured at 65°C for 5 minutes and 
cooled rapidly on ice. 100ul cDNA mix-C, 2ul RNasin (Amersham), 6ul 20mM 
dCTP, 20uCi a 32 P dCTP (SOOOCi/mmol) or 20uCi 3 H dCTP (26.5Ci/mmol), 2yl 
AMV reverse transcriptase (BioRad, 40 units) are added, incubated at 42°C for 
2hr then 20U reverse transcriptase added and the incubation continued for a 
further 2hr. The reaction is then phenol extracted (2.4.1) and precipitated twice 
from ammonium acetate/ethanol. It is calculated that 30-50% of the RNA input 
mass was converted to cDNA (see Appendix 2). The size distribution is 
checked by running 32 P labelled cDNA on an alkaline agarose gel (McDonnell 
1977). This is a normal DNA type gel but is poured in 50mM NaCI, 1mM EDTA 
and run in 30mM NaOH, 1mM EDTA. The gel is dried down and exposed to 
X-ray film. This shows the average size of the cDNA is about 2.0kb (see figure 
4.1).
2.18.2 Second strand synthesis (Gubler and Hoffman 1983)
Optimum second strand synthesis is achieved by processing <200ng of 
cDNA/RNA hybrid in 100ul reactions as follows: 200ng cDNA/RNA hybrid, 50y,l 
2x second strand salts, 5.0ul S.OmM NAD (Sigma), 10yl 1mM dNTPs, 1ul 5ug/jil 
BSA (BRL), 0.8ul RNase H (IU, Pharmacia), lul E.coli DNA ligase (0.4ug, 
Pharmacia) 20uCi a 32 P dCTP (3000Ci/mmol) and ddH 2O to 100ul are mixed and 
kept on ice for 4 minutes. 0.4jjl E.Coli DNA polymerase 1(159U/uJ,home made 
stock) is added and incubated at 12°C for 1hr then at 23°C for 2hr. A further 
50U DNA polymerase I is added and the reaction incubated 23°C for 2hr more 
before phenol extracting and precipitating from ammonium acetate/ethanol. it 
is calculated 90-100% of input hybrid is converted to double stranded cDNA 
(Appendix 2). The size distribution is checking by running a sample on a DNA 
agarose gel, drying down and exposing to X-ray film. This shows the average 
size of the double stranded cDNA is at least 2.0kb (figure 4.1).
2.18.3 EcoRI methylation and end repair
1-2ug of double stranded cDNA are methylated using EcoRI methylase(NEB). 
106.5ul cDNA in ddH20, 30ul 5x methylase buffer, 12ul 5ug/ul BSA (BRL), 0.4ul 
32mM SAM (in 5mM H 2S04, 10% ethanol, NEB). 2ul EcoRI methylase (40U) are 
mixed and incubated at 37°C for 2hr. The reaction is heated at 65°C for 10 
minutes then phenol extracted and precipitated. The cDNA can then be tested
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to see if it is protected to EcoRI digestion.
The methylated cDNA is end repaired as follows: the cDNA is redissolved in 
21 ul ddH 20 then 5uJ 1mM dNTPs, 3ul 10x T4 DNA ligase buffer and 1ul Klenow 
(5U) are added and incubated at room temperature for 30 minutes. Following 
phenol extraction the cDNA is precipitated from ethanol.
2.18.4 EcoRI linker ligation and size fractionation
1ug methylated, end repaired cDNA is redissolved in 10ul ddH 2 O and added 
to 5yl phosphorylated EcoRI linkers (0.5ug, prepared as in 2.15.2), 2^1 10x T4 
DNA ligase buffer, 1ul 20mM ATP, 2ul T4 DNA ligase (6U, Pharmacia) and 
incubated at 15°C for 2 days. After terminating the reaction at 65°C for 10 
minutes the cDNA is precipitated once from ammonium acetate/ethanol and 
digested with 240U EcoRI (120U/ul, Boehringer) for 2hr at 37°C in a 50ul 
reaction. The reaction is then phenol extracted, precipitated from ammonium 
acetate/ethanol and redissolved in 20pl ddH 20.
Removal of unincorporated linkers and size fractionation of the cDNA is 
carried out by gel filtration chromatography essentially as described by Huynh 
et a/(1985). A 1ml bio-gel A 50m, 100-200 mesh (BioRad) column is poured in 
a serological pipette (250 x 3mm). The column is run in 0.1M NaCI, 10mM 
Tris-CI pH 7.4, 1mM EDTA and is first calibrated by running end labelled DNA 
markers through the column collecting 4 drop (lOOul) fractions. After extensive 
washing of the column 2ul 50% glycerol, 0.2% (w/v) bromophenol blue is 
added to the cDNA and applied to the column. Fractions containing cDNA 
greater than 500-700bp (Figure 4.1) are pooled and stored at -20°C for future 
cloning. Size fractionation can be checked by running a sample on a DNA gel, 
drying down end exposing to X-ray film.
2.18.5 Cloning of cDNA into bacteriophage lambda NM1149
A 50ug EcoRI restricted stock of NM1149 DNA is prepared such that the 
titre of restricted DNA drops by at least 103 on in vitro packaging and also that 
no recombinant phages are generated by self ligation of the vector (checked by 
plating on NM514). 20ng cDNA is co-precipitated with 1yg restricted NM1149 
DNA and redissolved in 9ul ddH 20. 1.2yl 10x T4 DNA ligase buffer, 0.6ul 20mM 
rATP, 1.2ul T4 DNA ligase (4U) are added and incubated at 15°C for 18hr.
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The ligated lambda DNA is packaged in vitro essentially as described by 
Hohn and Murray (1977). The sonicated extract and the freeze thaw lysate 
were gifts from Dr. N.Hunter. DNA is packaged as follows: 7ul packaging buffer 
A is mixed with lambda DNA (up to 0.5ug in volume of 3ul), 1ul packaging 
buffer Ml, 6yl sonicated extract and 10ul freeze thaw lysate then incubated at 
20°C for 1hr. Maximum packaging efficiency (5x107-1x108pfu/ug) is obtained 
by adding lOul freeze thaw lysate, 1ul packaging buffer M1 and incubating for 
a further 2hr. The packaging is terminated by adding 0.5ml phage buffer and a 
drop of CHCI 3 . The packaged DNA is stored at 4°C.
The percentage of recombinant phages is determined by plating dilutions on 
NM514 (only recombinant clear plaques grow) and NM259 (both recombinant 
clear plaques and non-recombinant turbid plaques grow). Using these 
procedures a library of approximately 5x104 recombinant phages was actually 
produced (with 1% total recombinants) which was used successfully.
2.18.6 Screening of phage cDNA libraries
Approximately 1.5x104 phages are used to infect 0.8ml NM514 plating cells 
(see 2.10.1) and plated onto warm 12x12cm BBL bottom agar plates (using 8ml 
of 0.7% (w/v) agarose in 10mM MgS04). The plaques are left to grow until the 
plaques are just touching each other (7-10hr). Plaque lifts are performed as in 
2,16.3 and the filters hybridised as in 2.17. Positive plaques are picked with the 
blunt end of a pasteur pipette into 1ml phage buffer and then are rescreened 
until a positive signal corresponds to an individual well isolated plaque.
After use the library is recovered by overlaying each plate with 25ml L 
broth plus 10mM MgS04 and leaving overnight at 4°C. The liquid is taken off, 
debris spun out and the supernatant stored at 4°C over 2ml CHCI 3 . The 
amplified library has to be titred before use, typically it has 6.5x105pfu/jjl.
2.19 Dideoxynucleotide DNA Sequencing 
2.19.1 General
DNA sequencing is performed by the dideoxynucleotide chain termination 
method as described by Sanger et #7(1977), Sanger and Coulson (1978), Biggen 
















20mg/ml lsoproyl-8-D-thiogalactoside in ddH 20 
20mM Tris-CI pH 7.5, 20mM NaCI, 1mM EDTA 
100mM Tris-CI pH 8.5, 50mM MgCI 2 
10mM Tris-CI pH 8.5, Ol.mM EDTA
5'-GTAAAACGACGGCCAGT-3' 
2.5ug lyophilite(NEB) resuspended in 
1000yl sequence TE
5'-TGGGAACGTGACACCGC-3'
a gift from M.Bownes, at 2.5ng/pl in ddH 2O
deoxyadenosine 5'a35 S thiotriphosphate 
8.0mCi/ml, 410 Ci/mmol (Amersham)
10mM of each dNTP (Sigma) in sequencing TE 
10mM of each ddNTP (Boehringer) in sequencing TE
ddNTP termination mixes The composition of each ddNTP termination mix is given
below, all values are in microlitres.
































0.25mM dGTP, 0.25mM dCTP, 0.25mM, dATP, 0.25mM 
dTTP in ddH 2 O
10ml deionised formamide, 0.01g xylene cyanol FF, 
0.01g bromophenol blue, 0.25 ml 0.4M EDTA
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IQx TBE o.9M Tris-borate pH 8.3, 25mM EDTA
40% Acrylamide 380g Acrylamide, 20g bis-acrylamide made to 1 litre
with ddH 20, deionised with 20g MB-1 (BDH) 
and filtered
0.5x TBE gel mix 150ml 40% acrylamide, 50ml 10xTBE, 460g urea made
to 1 litre with ddH 20 and filtered
2.5x TBE gel mix 150ml 40% acrylamide, 250ml 10xTBE, 460g Urea, 50g
Sucrose, 50g bromophenol blue made to 1 litre with 
ddH 20 and filtered
Gel fix 250ml glacial acetic acid, 250ml methanol made
to 2.5 litre with ddH 20.
2.19.2 Cloning into M13mp18 and M13mp19
An insert DNA preparation of the fragment to be sequenced is first prepared 
as in 2.7.1. To sequence each fragment entirely it is necessary to clone 
sub-fragments of less than 350bp into the M13 vectors. This is achieved by 
restriction of the fragment with a battery of 4bp and 6bp recognition restriction 
enzymes then cloning into the appropriate site in the polylinker of the vector. 
Ligation of the fragment to vector is carried out as in 2.6 and transformation of 
NM522 is carried out using lacZ colour selection as described in 2.5 but with 
the addition of 50ul of an overnight culture of NM522 to each plate and no 
addition of L broth and incubation before plating. Recombinant white plaques 
are picked into 0.5ml M13 phage buffer or used to produce templates 
immediately.
2.19.3 M13 template preparation
1ml of a fresh NM522 overnight culture is diluted into 100ml L broth and 
2ml aliquoted into 1.5x15cm tubes. White M13 plaques are picked into the 
tubes and grown with vigorous shaking at 37°C for 5-6hr. 1.5ml are 
transfered to microfuge tubes and spun for 5 minutes. 1.2ml of the 
supernatants are transfered to tubes containing 150ul 2.5M NaCI, 20% (w/v) 
PEG-6000, mixed and stored at 4°C for 30 minutes. The precipitated phages 
are spun for 10 minutes and the supernatants removed. Tubes are then respun 
and the remaining supernatants removed. The phage pellets are resuspended 
in 100ul of 0.1M NaCI, sequencing TE and 50ul phenol added, vortexed 
extensively then spun. The supernatants are removed and precipitated with
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sodium acetate/ethanol. DNA pellets are recovered by centrifugation, washed 
in 70% ethanol, air dried and redissolved in 30ul sequencing TE.
2.19.4 Sequencing reactions
Primer mix/template: 1ul M13 sequencing primer or 1^1 oligonucleotide 
sequencing primer, lul TM buffer, 3ul ddH 2O
Annealing mix/template: 5ul primer mix, 5ul template DNA
Enzyme mix/template: 0.62ul 35S thio dATP, lul 80mM Tris-CI pH 8.5, 1uJ 
80mM DTT, 5.1 ul ddH 2 0, 0.31 ul Klenow (5U/pl Boehringer), made up on ice just 
before use.
Templates are annealed in annealing mix at 60°C for 1hr then allowed to 
room temperature for 15 minutes. 2ul of the annealed template is added to 4 
wells of a round bottomed siliconised microtitre plate. 2ul of ddTTP 
termination mix is added to one well, similarly 2ul of the remaining ddNTP 
termination mixes are added to each of the other wells. 2ul of enzyme mix is 
added to each well and the plate tapped ^ertfly to mix the components then 
incubated at room temperature for 25 minutes. Finally 2ul of sequencing chase 
is added to each well and incubated at room temperature for a further 20 
minutes before freezing at -20°C. Before loading onto a gel the samples are 
first denatured by adding 2ul of formamide dyes, floating the plate on a 80°C 
water bath for 10 minutes and cooling on ice.
2.19.5 Polyacrylamide gel electrophoresis
Two alternative gel systems are used to analyse the products of the 
sequencing reactions. The gradient gel system resolves bases 0-250 from the 
sequencing primer binding site whereas the straight gel can resolve bases 
150-350 or more depending on the run time.
The gradient gel is prepared as follows: 70ul 25%(w/v) APS, 70ul TEMED 
and 35ml 0.5x TBE gel mix are mixed. 14ul 25%(w/v) APS, 14ul TEMED, and 
7ml 2.5x TBE gel mix are mixed. 4ml of the polymerising 0.5x TBE gel mix are 
taken up in a 10ml pipette, a crude gradient is formed by introducing 3-4 air 
bubbles, then pouring it quickly into a glass gel former (40 x 20 x 0.035cm). 
the rest of the polymerising 0.5x TBE gel mix is added, a well former is inserted 
and the gel allowed to polymerise. Similarly a straight gel is poured as above
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but it is made only with 0.5x TBE gel mix. (i.e. it does not have a gradient)
The gels are then assembled into an electrophorevskit with 1x TBE gel buffer 
in both upper and lower gel tanks. If sharkstooth combs(BRL) are used they 
are inserted now. The wells are flushed clear of urea and half the denatured 
sequencing reactions are loaded onto the gels in the order TCGA. Gradient 
gels are run at 25 watts constant power until the bromophenol blue has just 
ran off the bottom (2.5-3hr) and straight gels are run at 25 watts constant 
power for 6-9hr. The gels are dismantled such that they remain attached to 
one plate (non-siliconised) then transfered to a tray of gel fix for 15 minutes. 
Gels are transfered to prewetted blotting paper, covered in Saran Wrap and 
dried under vacuum at 80°C on a gel drier. Dried gels are placed directly in 
contact with X-ray film for 1-3 days before developing. Sequence information 
is read off the autoradiograph and compiled by version 2.0 of the programs of 
Staden (Staden 1980) and analysed by version 4.0 of the programs of the 
University of Wisconsin Genetic Computer Group (Devereux et al 1984).
2.20 Protein Methods
2.20.1 Laemmli polyacrylamide gels (Laemmli 1970)
A stock solution of 30% (w/v) acrylamide, 1% (w/v) N, 
N'-methylene-bis-acrylamide is deionised and stored at 4°C. Gels are cast 
between 25 x 20cm glass plates separated by 1mm perspex spacers. The 
separating gel (see below) is poured, overlayed with ddH 20 and allowed to 
polymerise for 2hr. The ddH 2O is poured off and the stacking gel poured then 
a comb inserted. After allowing to polymehse for 1hr the comb is removed 
and assembled into a vertical get kit. 1x Laemmli buffer is used in top and 
bottom tanks. An equal volume of 2x protein sample buffer is added to the 
sample, boiled for 5 minutes then loaded onto the gel and run at 7mA for 18hr 
or at 20mA for 30 minutes then 50mA till completed. The gel is then either 
stained or immor\oblotted (2.20.2). To stain gels they are first fixed in 50% (v/v) 
methanol, 10% (v/v) acetic acid then stained in 50% (v/v) methanol, 10% (v/v) 
acetic acid plus 0.1% (w/v) Coomassie brilliant blue R250. Gels are then 
destained in several changes of 5% (v/v) methanol, 7% (v/v) acetic acid. 
Markers for protein gel electrophoresis are obtained from BRL and are 200, 
97.4, 68, 43, 25.7, 18.4, and 14.3KD.
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Polyacrylamide gels (volume in ml):
Separating Stacking
	7.5% 10%
0.75M Tris-CI pH 8.8 15.0 15.0
0.625M Tris-CI pH 6.8 - - 2.0
30% Acrylamide Stock 7.5 10.0 1.67
ddH 2O 7.5 5.0 6.33
10% SDS 0.3 0.3 0.1
TEMED 0.015 0.015 0.005
10% APS 0.15 0.15 0.05
2.20.2 Immunoblotting
This method for transfering proteins from polyacrylamide gels to 
nitrocellulose is a modification of Towbin et a/(1979). the gel is run as above 
then soaked for 30 minutes in transfer buffer (20% methanol, 25mM Tris, 
192mM glycine pH 8.3). A gel sandwich is constructed in a BioRad transfer 
cassette as follows: all components are first prewetted in transfer buffer then 
layered on to the cassette in this order, removing bubbles between layers; a 
Scotch brite pad, blotting paper cut to same size as the gel, the gel, 
nitrocellulose (0.45um Schleicher and Schull) cut 10% large than the gel, more 
blotting paper and finally another Scotch brite pad. The cassette is closed and 
then added to a BioRad electrotransfer kit filled with 3 litres of transfer buffer 
such that the nitrocellulose faces the anode. Proteins are then transfered at 
250mA overnight or at 600mA for 4hr. After transfer the nitrocellulose sheet 
can be stained with 0.5% Ponceau S (Sigma) in 3% TCA and washed in ddH 20 
to visualise the transfered proteins.
Nitrocellulose strips are blocked in MTS (5% (w/v) skimmed milk 50mM 
Tris-CI pH 7.8, 150mM NaCI) for 2hr at room temperature then probed with the 
appropriate dilution of rabbit antiserum (typically 1:200) in MTS for 2-4hr at 
room temperature or overnight at 4°C with gentle shaking. The strips are 
washed 4 times, 10 minutes each wash, in TS (50mM Tris-CI pH 7.8, 150mM 
NaCI). To visualise the antibody-antigen interactions the filter is next incubated
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with goat anti-rabbit immunoglobulins (1gG fraction) conjugated with 
horseradish peroxidase (Sigma) at a 1:500 dilution in MTS for 2hr at room 
temperature. The filters are then washed again extensively in TS and 
developed with 10mM Imidazole pH 7.4, 0.25mg/ml dianisidine hydrochloride 
(Sigma), 0.37% (v/v) hydrogen peroxide (BDH) until the bands are viable. 
Filters are washed in plenty ddH 2 O and stored away from the light until 
photographed.
2.20.3 Preparation of B galactosidase-fusion proteins
DNA fragments containing protein coding sequences are cloned into the 
appropriate restriction site of one of the pEX series of vectors (Stanley and 
Luzio 1984) such that the coding sequence to be expressed is in the correct 
reading frame fused onto the 3' end of B galactosidase. Plasmids are than 
transformed (2.5) into the E.coli strain pop 2136 and grown at 30°C on plates 
containing ampicillin. Mini-preparations of plasmid DNA (2.9.1) are done and 
analysed by restriction digestion. Cells containing the appropriate plasmid are 
use to make proteins as follows: Colonies are grown up at 30°C overnight in L 
broth plus ampicillin then a 1:100 dilution is made and grown up for 6hr at 
30°C. This culture is then transfered to a 42°C water bath and shaken 
vigorously for 90 minutes. 1.5ml of the culture is spun down in a microfuge 
tube; resuspended in 75ul PBS and 75ul 2x protein sample buffer is added then 
vortexed hard. After boiling for 5 minutes the cell debris is spun down and the 
supernatant removed and stored at -70°C. 5-10ul are then used for one track 
of a protein gel, boiling for 3 minutes before loading. This procedure is simply 
modified for cells without plasmids (no antibiotics), no induction of fusion 
proteins (no heat shock) or large preparation of proteins (increase volumes 
appropriately).
2.20.4 Preparation of Xenopus ovary proteins
This method is modified from Darnbrough and Ford (1981). A piece of 
ovary tissue containing about 1000-5000 oocytes is homogenised in 1ml of 
protein extraction buffer on ice. the homogenate is spun in a Sorvall HB4 rotor 
for 20 minutes (10Krpm, 4°C) then the supernatant is removed, avoiding the fat 
layer and stored at -70°C. Before use an equal volume of protein sample buffer 
is added then boiled for 5 minutes. About 2-5 oocyte equivalents are loaded 
on one track of a gel.
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2.20.5 Generation of rabbit anti-fusion antiserum
A preparative gel of the required fusion protein was prepared by running 
0.75-1.5ml of the induced E.coli cell extract on the whole width of a protein 
gel. The fusion protein was localised by staining two small strips from the gel 
and the protein band was cut out, then homogenised in 3-5 volumes of PBS. 
One third of this homogenate (about 100ug protein) was used for one rabbit on 
each day of injection.
Three young half lop rabbits (Redhill Farm, Surrey) were subcutaneously 
injected at 6 sites on the back as follows: Before any injection about 20ml 
blood was taken from the ear as a preimmune control. The first injection was 
with (1:1) homogenate/complete freunds adjuvant (Difco) emulsion. The second 
injection was with (1:1) homogenate/incomplete freunds adjuvant (Difco) 
emulsion 3 weeks later. The subsequent injections were with homogenate 
alone at approximately 2 week intervals. 20ml ear bleeds were taken after the 
4th and 5th injection. All rabbits were bled from the heart 16 weeks after the 
first injection.
The blood collected from the rabbits was allowed to clot overnight at 4°C 
then the serum was removed, clarified by centrifugation in a Sorvall HB4 
(lOKrpm, 5 minutes, 4°C) and stored at -20°C or purified further by ammonium 
sulphate precipitation as follows: 1/2 volume of saturated NH 4SO4 pH 7.8 was 
added drop by drop to the serum and allowed to stir at room temperature for 
3hr. the precipitate is collected by centrifugation (HB4, lOKrpm, 30 minutes, 
room temperature) and then redissolved in 1/2 volume saline. The purified 
serum is then dialysed extensively against borate buffered saline at 
4°C. Cryoglobulins were spun out (HB4, lOKrpm, 30 minutes, 4°C) and the 
supernatant removed then stored at -20°C.
2.20.6 Affinity purification of antiserum
Affinity purification of antiserum against antigen can be done by a simple 
modification to the immunoblotting technique (2.20.2) as follows. The antigen 
is run on 1/3 width of a protein gel, transfered and stained with Ponceau 
S. The band containing (or thought to contain) the antigen is cut out, blocked 
and probed with 1:20 dilution of antiserum for 2hr at room temperature. After 
extensive washing in TS the bound antibody is eluted from the nitrocellulose 
with 1ml 0.2M glycine-CI pH 2.2 for 5 minutes at 4°C. 150ul of 2M Tris base is
77
added to neutralize the glycine. An equal volume of 2x TS is added, the 
supernatant removed and stored at -20°C.
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CHAPTER 3
IDENTIFICATION OF ONCOGENE RELATED SEQUENCES IN XENOPUS
3.1 Introduction
As discussed in Chapter 1 cellular oncogenes have been detected in a wide 
variety of organisms from yeast to man. An analysis of cellular oncogenes in 
different organisms (exploiting the special potential of each) may lead to clues 
about their function in normal cells which cannot be obtained in other ways 
and hence may help us to understand their roles in carcinogenesis. This kind 
of analysis has been dramatically illustrated by the biochemical and genetic 
analysis of the yeast ras gene products which appear to be G proteins that act 
as GTP dependent positive regulators of adenylate cyclase (Toda et al 1985). 
Also the Drosophila src gene product may play a role in the early development 
of neural tissue and smooth muscle (Simon et al 1985). Although studying 
cellular oncogene functions in different organisms sometimes gives misleading 
results (for example adenylate cyclase is unaffected by ras proteins in 
mammalian systems, Beckner, Hattori and Shih 1985) the general mechanisms 
of how these proteins act and how they interact with other proteins is still a 
valid scientific approach in the dissection of how normal cells behave.
Initially I wanted to see if it was possible to detect cellular oncogene 
related sequences in Xenopus DNA using a variety of oncogene probes from 
viruses and vertebrates. As a vertebrate with an established embryology, 
Xenopus is an ideal organism to study cellular oncogene function during 
development. Large numbers of oocytes and embryos are readily available 
which are amenable to micromanipulation. Gene expression during Xenopus 
development is reasonably well understood (Chapter 1). Modern techniques 
such as in situ hybridisation to oocytes and embryos and the blocking of 
translation of specific mRIMAs with antisense RNA in Xenopus are rapidly 
becoming commonplace (Melton 1985, Melton and Rebagliati 1986, Colman and 
Drummond 1986). Switching on of genes at specific developmental timepoints 
to assess their function will also soon be possible (Krieg and Melton 1985).
Closely related proteins that are encoded by small gene families are 
sometimes differentially expressed. For example the best characterised gene 
family is the globin family whose members are expressed at different times
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during the development of an individual. Apparently these gene families have 
arisen by duplication of an ancestral gene. Studies on DNA content, number of 
chromosomes and immunological distances between albumins of different 
species of the genus Xenopus suggest a whole genome duplication has 
occurred in X.laevis and X.borealis about 30 million years ago (Bisbee et 5/1977, 
Thiebaud and Fischberg 1977). X.laevis and X.borealis have 36 chromosomes 
whereas X.tropicalis, with 20 chromosomes and half the DNA content of 
X.laevis and X.borealis, probably is a modern representative of an original 
diploid ancestral form. Clues to the evolution of cellular oncogenes might 
therefore become apparent by studying various species of Xenopus.
Cellular oncogenes are known to be expressed in a variety of normal 
tissues (Chapter 1, Muller and Verma 1984) therefore it might be possible to 
detect expression of these sequences in Xenopus RNA using heterologous 
probes. If so this may provide further clues for cellular oncogene function and 
a starting point for the examination of cellular oncogene expression during 
development. In this thesis all RNA studies were performed using X.borealis. 
X.borealis was used instead of the more commonly used X.laevis for a number 
of reasons. Oncogene research is highly competitive hence it is likely that 
X.laevis would be chosen by others for study. So by using X.borealis, I would 
not directly repeat anyone else's work and also provide the basis for a 
comparative species analysis which may be informative and useful. In our 
hands X.borealis are easier to rear, can be kept at higher densities and the 
tadpoles are much larger than X.laevis. Eventually experiments could be 
designed using interspecies hybrids to follow the expression of specific 
molecules in the developing egg. In retrospect it may have been more sensible 
to use X.tropicalis since analysis can be difficult in X.laevis and X.borealis due 
to the increased gene number.
3.2 Detection of Oncogene Related Sequences in Xenopus DNA
A variety of oncogene probes from mammals, birds and their viruses (table 
2.3) were obtained and used to probe southern blots of genomic DNA from 
X.borealis, X.laevis and X.tropicalis (also human and chicken DNA as positive 
controls when appropriate) to see if any related sequences could be detected. 
Initially probes were made from complete plasmid DNA, labeled by nick 
translation (Chapter 2). Routinely 50% of the label (50uCi was used for each 
reaction) would be incorporated giving probes of specific activities between
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~107 - 108 cpm/ug. Since the vector DNA sequences can represent up to 
90% of the labeled DNA the DNA fragment of interest has only incorporated 
~5% of the label used in the reaction. Using these probes under standard 
high stringency hybridisation conditions (50% formamide, 5x SSPE, 37°C) and 
moderately high washing conditions (2-1x SSPE at 65°C) no homologies were 
detected in Xenopus DNA.
X./aev/shas a haploid DNA content of 3.1x106 kbp which is similar to that of 
humans (Lewin 1980). To detect gene sequences that are present in roughly 
single copy it is therefore essential that the probes are labeled to as high a 
specific activity as possible since the molar ratio of each gene is very low 
compared with that of Drosophila (~20x less) or yeast (~ 140x less). Loading 
high amounts of DNA helps to increase sensitivity by increasing the mass of 
each DNA fragment to be detected. Sensitivity is also increased by long 
exposures of the X-ray film. Therefore to try and increase the specific activity 
of the fragment of interest insert DNA preparations were made as described in 
Chapter 2 and used in standard nick translation reactions. It was found, even 
after elutip-d column chromatography, that nick translation of insert DNA was 
extremely unreliable. Anywhere between 5-50% of the label would be 
incorporated representing specific activities of ~10 7 - 2.0x108cpm/yg. When 
these probes were used under standard high stringency hybridisation 
conditions and moderately high washing conditions any homologies in Xenopus 
DNA were detected inconsistently although bands were frequently detected in 
the positive control chicken DNA.
Oligolabeling was found to be the most consistent and reliable technique 
for producing probes of high specific activity (see Chapter 2). Routinely greater 
than 80% of the label would become incorporated into the probe giving 
specific activities of the fragment of ~ 5x108 - 1.5x10 9cpm/ug (20-50ng of 
fragment DNA was used for each reaction). Even with Oligolabeling detection 
of oncogene related sequences in Xenopus DNA. under standard high stringency 
conditions and moderately high washing conditions was inconsistent using 
heterologous probes. When homologous probes were used on Xenopus DNA 
bands of homology were detected with relative ease, band intensities were 
strong, there were few non-specific bands and the exposures required were 
reasonably short (see following chapter for examples).
The heterologous oncogene probes probably have a high degree of
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sequence divergence from the Xenopus sequences hence hybridisation rates 
and the stability of partially matched duplexes would be effected. Many 
parameters govern the formation and stability of hybrid duplexes in filter 
hybridisation (see Anderson and Young 1985 for discussion) but in general the 
use of high salt, reduced formamide concentrations and low -V-e^peratures aids 
the detection of diverged sequences. It must be borne in mind, however, that 
each probe used was unique - mismatching between duplexes formed may be 
localised leaving large regions of good pairing or it may be dispersed leaving 
the overall duplex unstable, the base compositions and probe lengths were 
different also the specific activities varied by roughly 2-3 fold. Routinely I used 
probes made by oligolabeling (specific activities of 5x108 - 1.5x10 9 cpm/ug 
DNA) and hybridisation conditions of 35-40% formamide, 6x SSPE at 37°C for 
at least 18hr (no advantage is gained by leaving the hybridisation longer due to 
renaturation of the probe) to try and detect oncogene related sequences in 
Xenopus DNA. Washing of filters was done differentially to try and preserve 
the bona fide hybrids over the inevitable non-specific hybrids. This was done 
by washing initially at low temperatures and high salt (37°C, 1x SSPE) and then 
washing at higher temperature and/or lower salt (e.g. 50°C, 1x SSPE then 
50°C, 0.5x SSPE) exposing the filters between each wash. When this strategy 
was adopted I could consistently find oncogene related sequences in the 
genomic DNA of Xenopus as illustrated in figures 3.1, 3.2 and 3.3.
Figure 3.1(a) shows the result when human N-myc is used as a probe. The 
high degree of divergence between the probe and the Xenopus sequences is 
illustrated because only 5ug of human DNA (which is homologous for this 
probe) gives rise to a very intense expected ~2.1kb EcoRI band (Schwab et al 
1983) compared with the weak bands in 15ug of Xenopus DNA.
If the whole genome duplication theory is correct for Xenopus genome 
evolution then in the simplest case one gene in X.tropicalis would become 
duplicated in X.borealis and X.laevis. Both these genes being on different 
chromosomes may then evolve independently giving rise to two detectably 
separate genes which may eventually acquire slightly different functions. The 
practical consequences for southern hybridisations is that when equal amounts 
of DNA are loaded there should be two bands of equal intensity in X.borealis 
and X.laevis and one band of twice the intensity in X.tropicalis DNA since 
effectively twice the number of genome equivalents of X.tropicalis DNA have 

















































Genomic southern blots with heterologous oncogene probes. H = Bug human 
DNA, C = 5ug chicken DNA, B = 15ug X.borealis DNA, L = 15yg X.laevis DNA, T 
= 15ug X.tropicalis DNA. All DNAs were digested with Ecorl. Size markers were 
Hind3 digested X DNA. All probes had specific activties of ~7 x 10 8 - 1.5 x 10 9 
cpm/ug. (a) N-myc probe, stringency 2x SSPE, 65°C, 3 day exposure; (b) v-erb 
B probe, stringency 2x SSPE, 65°C, 8 day exposure; (c) human c-myc third exon 
probe, stringency 0.5x SSPE, 50°C, 1 day exposure; (d) filter from (c) washed at 
0.5x SSPE, 65°C, 5 day exposure; (e) chicken c-myc second exon probe, 












































Genomic southern blots with heterologous oncogene probes. B = 15ug 
X.borealis DNA, L = 15ug X.laevis DNA, T = 15ug X.tropicalis DNA, D = 5ug 
Drosophila DNA, Y = Bug yeast DNA. All DNAs were Ecorl digested. Size 
markers were Hind3 digested X DNA. Ch = chicken c-myc second exon probe, 
Hu = human c-myc third exon probe, Xe = X.borealis 3' c-myc probe. All 
probes had specific activities of ~7 x 10 8 - 1.5 x 10 9 cpm/ug. (a) v-fms probe, 
stringency 1x SSPE, 50°C, 21 day exposure; (b) v-fos probe, stringency 1x SSPE, 
50°C, 21 day exposure; (c) v-sis probe, stringency 1x SSPE, 50°C, 7 day 
exposure; (d) c-myc probe, stringency 0.5x SSPE, 65°C, 12 day exposure; (e) 
c-myc probes, stringency 1x SSPE, 25°C, 1 day exposure.
region of homology spanned by the probe and that both alleles at each locus 
are identical.
When a multigene family is involved the analysis becomes more 
complicated especially when heterologous probes are used. This would appear 
to be the case for N-myc although there are fewer more intense bands in 
X.tropicalis DNA. The presence of many bands in Xenopus DNA may reflect a 
multigene family but some might be non-specific hybridisation, although myc 
has been described as a small multigene family. Also the presence of introns 
may complicate analysis of this pattern.
Figure 3.1(b) shows the result using chicken v-erb B as a probe. Remember 
it is difficult to compare the results between different filters for the reasons 
described previously. Again Bug of chicken DNA was used as a positive 
homologous control compared with 15ug of Xenopus DNA hence it is easier to 
detect the chicken sequence even though the probe is actually from a chicken 
virus. There are two c-erb B alleles (a and B) in chickens (Raines et al 1985) 
and they can have either or both alleles. The ~6.6kb £co/?/band I detect is in 
agreement with a ~6.4kb EcoRI band from the (3 allele. It would appear the 
X.tropicalis c-erb B gene is single copy and has evolved in a simple doubling 
fashion in X.borealis and X.laevis as described above.
Figures 3.1(c) and (d) shows the results when a human c-myc probe 
containing the third exon is used as a probe. The effect of differential washing 
is shown here : figure 3.1(c) is a lower stringency wash compared with the 
same filter washed at higher stringency in figure 3.1(d), which is exposed for 
longer. Notice the presence of many non-specific bands (especially in X.laevi^ 
that disappear on washing at higher stringency. A common problem is a 
background smear in the DNA which obscures bands and appears to have 
occurred in the X.borealis track.
Figure 3.1(e) illustrates the hybridisation of a chicken c-myc probe which 
contains the second exon. The hybridisation is clear with stronger intensity in 
X.tropicalis DNA. This pattern of bands is different from figure 3.1(d), a result 
expected assuming the presence of EcoRI sites in an intron and or in the 
coding sequences. The chicken c-myc sequence may be more closely related 
to Xenopus DNA than the human c-myc sequence due to the clearer 
hybridisation but each species probe used was a different exon. It is difficult
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to interpret these results with the evolution of the Xenopus genus but the 
general impression is that the pattern of bands is simpler in X.tropicalis and 
the bands are stronger supporting the genome doubling notion. The multiple 
bands again hint at the presence of myc being a multigene family.
Figures 3.2(a) and (b) shows the hybridisation of v-ha-ras and v-ki-ras to 
Xenopus DNA. Under these low stringency hybridisation condition both probes 
pick up a similar pattern of bands with some differences whereas under high 
stringency in human and rat DNA they pick up separate bands (Hall 1984). This 
suggests the homology between the two probes is high enough to cross 
hybridise to related sequences in Xenopus DNA. The presence of so many 
bands can be partly explained by the fact that in other systems ras is a 
multigene family (e.g. human DNA has at least 5 members, 2 of which are 
pseudogenes, Hall 1984). Also since the probes used span the compete coding 
domain of ras and since human ras genes can have up to 4 introns, assuming 
the same to be true in Xenopus this might give rise up to 4 bands for each 
gene in the family. Each species of Xenopus shows a different band pattern 
implying a different genomic organisation of the ras genes.
Hybridisation patterns obtained when v-src is used as a probe are shown in 
figures 3.2(c). Src related sequences have already been cloned from X.laevis 
(Steele 1985). The ~ 10.0kb and ~2.3kbp EcoRI fragments I detect on southern 
analysis agrees well with the restriction map of a X genomic clone and is good 
evidence that the conditions adopted, which are similar to Steele's, are 
detecting bona fide oncogene related sequences in Xenopus DNA. Steele 
suggests on the basis of cDNA clones and southern analysis, that X.laevis has 
two src genes. My results suggest this is probably also true for X.borealis, and 
X.tropicalis probably has just one gene although there a number of weak bands 
in addition to the single strong 23kbp band.
Figure 3.2(d) shows the pattern of hybridisation obtained when a v-abl 
probe that spans the tyrosine kinase domain (a 1.7kbp Pvull fragment) is used. 
A common progenitor sequence to both src and abl (cDash) has been isolated 
from Drosophila DNA as well as a src specific sequence (cDsrc2, Hoffman-Falk 
et al 1983, Hoffman et al 1983) suggesting src and abl have evolved from the 
same ancestral gene. The hybridisation pattern of v-src and v-abl \Q Xenopus 
DNA is quite different implying cDash and cDsrc2 have diverged to give rise to 
distinct src and abl genes in the lineage leading to vertebrates. Note that the
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— 2.3kb band common to both the src and abl filters in X.tropicalis may be a 
progenitor sequence but this is unlikely since the X.borealis and X.laevis 
patterns are so different. Further southern blot analysis is required to 
determine the relationship of SAC and abl genes in X.tropicalis DNA.
Weak hybridisation in all three species of Xenopus to a rel probe is shown 
is figure 3.3(e). When v-fms, v-fos and v-sis are used as probes only very 
weak hybridisation is detected (figure 3.3 a,b,c). Definite weak bands can be 
detected in all the Xenopus DNAs with each of the probes used. In general 
X.tropicalis DNA has stronger bands than X.laevis or X.borealis which probably 
reflects the genome doubling event, however I cannot be sure these 
homologies are real because they are so weak. Also I am unaware of the 
detection of these sequences in any organism other than a mammal.
Chapter 1 describes why the myc genes are an interesting class of 
oncogene to study. Therefore as background I wanted to see if I could detect 
c-myc related genes in Drosophila and yeast DNA. Since the genomes of 
these organisms are much smaller it is possible to load more genome 
equivalents per track, which may aid detection compared with Xenopus. Figure 
3.3(d) shows the hybridisation of a human c-myc third exon probe to 
Drosophila DNA showing a weak band (Xenopus DNA is used as a control). 
Figure 3.3(e) shows the hybridisation of a human c-myc third exon probe, a 
chicken second exon c-myc probe and Xenopus 3' c-myc probe (Xbmyc A1 see 
later) to yeast DNA. Second and third exon probes detect similar bands while 
the Xenopus probe detects a single band strongly which is also detected by 
the other probes but is weaker. It is unclear if these truly represent detection 
of c-myc homologies or are just spurious hybridisations. Note that a 
Drosophila c-myc related sequence has been reported (Madhavan et al 1985). 
The bands of hybridisation in yeast DNA appear to be close to repeated 
sequences that generate bands on EcoRI digestion and can be seen on an 
ethidium stained gel. Therefore these hybridisations may be fortuitous. It is 
encouraging that the Xenopus probe, wV«e,K contains 300bp of 3' coding 
sequence, detects strongly a band that is moderately strong with the human 
third exon probe and weaker with the chicken second exon probe. It would be 
premature to interpret these results any further.
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3.3 Detection of Oncogene Related Sequences in X.borealis RNA
Having detected the presence of oncogene related sequences in Xenopus 
DNA I wanted to see if I could extend these observations to see if I could 
detect the presence of any transcripts in X.borealis RNA using heterologous 
probes. If I could find the presence of transcripts it would provide more 
evidence that the homologies I see in Xenopus DNA are in fact real. The 
detection of any transcripts using heVecalogous probes depends on parameters 
similar to those described for southern blots and therefore similar hybridisation 
conditions were used. A major difference though, is that the detection of 
transcripts depends very much on the level of gene expression in the tissues 
of interest. A combination of factors may lead to an apparently negative but 
incorrect result especially if the probe used is highly diverged and the mRNA is 
not highly expressed. So it is difficult to quantitate gene expression using 
heterologous oncogene probes. These results may be only used as a guide to 
examine which tissues are expressing particular sequences.
Initially to determine rapidly what if any oncogene sequences were 
expressed in adult ovary RNA, southern blots of a variety of oncogene plasmids 
digested with appropriate restriction endonucleases were probed with 32 P 
kinased labeled poly(A) + RNA. This technique will only detect reasonably 
abundant mRNAs (estimated to be >0.06% of the total, Dworkin and Dawid 
1980), also there may be fortuitous hybridisation because heterologous probes 
are used, hence this experiment only gives a guide to which oncogenes might 
be expressed allowing further work to proceed more rapidly.
Figure 3.4(a) shows the result of such an experiment. A Hind/// digested 
X.laevis mitochondrial plasmid was used as a positive control - the strong 
band at ~6.0kbp corresponds to the fragment containing the mitochondrial 
ribosomal RNA genes (Rastl and Dawid 1979). Since non poly(A)"1" RNAs 
contaminate poly(A) + selected RNAs by up to 50%, as judged by 3 H poly(U) 
hybridisation estimates of mRNA purity, it is not surprising that mitochondrial 
rRNA can be detected in this RNA preparation. However it is unclear why 
abundantly expressed polyadenylated mitochondrial RNAs are not detected. 
The non-specific hybridisation can be estimated by the intensity of the bands 
corresponding to vector sequences; this seems to be quite low (most vector 
sequences are at ~4.4kb on this gel) although slight partial digestion has given 



































Expression of oncogene related sequences in X.borealis RNA. (a) southern blots 
of digested oncogene plasmids probed with 32 P kinased labeled adult ovary 
poly(A) + RNA (specific activity ~2.6 x 10 6 cpm/vig). Plasmid DNA had ~1.0 - 2.0 
Ug insert (which should be in excess for the hybridisation since <1ug RNA was 
used). Mito = X.laevis mitochondrial genome plasmid Hind3 digested, other 
plasmids are as described in chapter 2. Stringency 2x SSPE, 37°C, 7 day 
exposure, (b), (c), (d), and (e) are northern blots with various probes. 4 - 5 ug 
of poly(A) + RNA was used per track. Bl = blood, Li = liver, Ki = kidney, He = 
heart, Lu = lung, Mu = muscle, Ad.ov = adult ovary, Pv.ov = previtellogenic 
ovary, Te = testes and Sp = spleen. All probes had specific activities of ~7 x 
10 8 - 1.5 x 10 9 cpm/ug. Sizes were estimated from X.borealis 18S and 28S 
rRNAs. (b) chicken c-myc second exon probe, stringency 0.5x SSPE, 50°C, 14 
day exposure; (c) cytoskeletal actin probe, stringency 0.2x SSPE, 65°C, 1 day 
exposure; (d) human c-myc third exon probe, stringency 0.5x SSPE, 50°C, 4 day 
exposure; (e) chicken c-myc second exon probe, stringency 0.5x SSPE, 50°C, 6 
day exposure.
band in sis is due to an unknown trace contaminant in that plasmid 
preparation. Bearing these reservations in mind the results suggest that myc, 
abl, ha-ras, ki-ras, re/ and fos are quite highly expressed in the ovary whereas 
src, fms, erb A/B and sis are expressed at a low level or not at all. These 
results provide some guidelines in selecting sequences for further study.
To further characterise these putative oncogene transcripts a series of 
northern blots were performed using poly(A) + RNA from a variety of different 
X.borealis tissues. It was found when total RNA was used under non-stringent 
conditions there was a very high level of background bands especially due to 
the ribosomal RNAs therefore poly(A) + RNA was used to reduce this problem. 
By using poly(A) + RNA mRNAs also have been effectively concentrated by ~100 
fold thereby making the detection of lowly expressed mRNAs easier.
Figure 3.4(b) shows the expression of c-myc related sequences as detected 
by a chicken c-myc second exon probe. The same filter was then probed with 
a cytoskeletal actin probe and is shown in figure 3.4(c) and shows the integrity 
of the RNA preparations. The 2.3kb band is due to cytoskeletal actin, the 1.6kb 
band is due to cardiac and skeletal muscle actins detected by cross-reaction of 
the probe and the intermediate bands are probably other cytoskeletal actins 
(Mohun et a/1984). In this experiment approximately equal amounts of poly(A) + 
RNA were used (~4-5ug). The differences in actin intensity can be explained 
partly in terms of expression. Cytoskeletal actin is expressed in all adult 
tissues but in muscle it is expressed 50 times less and in oocytes it is highly 
expressed (Mohun et al 1984, Gurdon et al \ 985). Therefore this suggests that 
roughly similar amounts of RNA have been loaded except maybe for blood and 
heart RNA.
Using the chicken c-myc second exon probe I can detect a ~2.9kb 
sequence quite strongly in adult ovary RNA. Kidney RNA shows a weaker 
signal and very weak signals can be detected on the original autoradiograph in 
blood, liver, lung, testes and spleen RNA. I cannot detect any signal from heart 
RNA. These differences in intensities may be due to different expression levels 
and differences in amount of RNA loaded. Figure 3.4(e) shows that the level of 
expression of this gene appears to be similar in adult and previtellogenic ovary 
RNA.
To reinforce the fact that this ~2.9kb band is due to c-myc related
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sequences a northern blot was performed with a human c-myc third exon 
probe. Figure 3.4(d) shows that this probe detects a similar band in 
previtellogenic ovary RNA. The ~2.9kb RNA is probably due to the expression 
of a c-myc related RNA since it is detected with two different exon probes. 
Using these heterologous probes requires exposures of 1-2 weeks compared 
with the homologous probes which need exposures of 3-5 days (compare 
northern blots in Chapter 4 with these). Hence the sensitivity is dependent on 
the level of expression and the probe used (for example the cytoskeletal actin 
filter was only exposed for 1 day compared with the 2 weeks exposure of the 
chicken myc filter).
C-myc RNA can be detected in a wide variety of adult tissues and organs 
(Chapter 1, Gonda et al 1982, Stewart, Bellve and Leder 1984, Zimmerman et al 
1986). Therefore it is not surprising that I can detect weak c-myc related 
transcripts with a heterologous probe in most tissues examined. The use of a 
homologous probe makes this analysis simpler (see Chapter 4). It is interesting 
that a high level of c-myc transcripts has been found in mouse ovary, uterus 
and thymus which may be correlated with cellular proliferation (Stewart, Bellve 
and Leder 1984) and I also detect a higher level of c-myc related transcripts in 
Xenopus adult and previtellogenic ovary.
The Xenopus c-myc related transcript is ~2.9kb which is larger than the 
2.4kb mouse, 2.5kb chicken 2.4-2.5kb human and 2.3kb trout c-myc transcripts 
although there is some disagreement about these sizes in the literature 
(Zimmerman et al 1986, Gonda et al 1982, Rabbitts et al 1985, Papas et al 1985, 
Van Beneden et al 1986). If the Xenopus protein product is roughly the same 
size as in other species then this implies that ~ 1.5Kb of the mRNA is 
non-coding (this is confirmed by sequence analysis described in Chapter 5). 
Other bands detected with the c-myc probes may be non-specific as they can 
vary between individual experiments but it is possible they are due to other 
c-myc related species.
Figure 3.5(a) shows the detection of N-myc related transcripts in X.borealis 
RNA. High levels of a ~4.9kb transcript appear to be expressed in 
previtellogenic ovary and liver whereas lower levels can be detected in kidney 
and lung. As described in Chapter 1 N-myc expression is much more 
restricted than that of c-myc (Zimmerman et a/1986, Jakobovits et al 1985). In 






























Northern blots using heterologous oncogene probes on X.borealis RNA. 4-5 
ug of poly(A)"1" RNA were used per track. Ad.ov = adult ovary, Pv.ov = 
previtellogenic ovary, Ki = kidney, Lu = lung, Li = liver. All probes had specific 
activities of ~7 x 10 8 - 1.5 x 10 9 cpm/ug. Sizes were estimated from X.borealis 
18S and 28S rRNAs. (a) N-myc probe, stringency 2x SSPE, 65°C, 3 day 
exposure; (b) v-fos probe, stringency 1x SSPE, 50°C, 21 day exposure; (c) 
v-ki-ras probe, stringency 1x SSPE, 50°C, 21 day exposure; (d) v-ha-ras probe, 
stringency 1x SSPE, 50°C, 7 day exposure.
hindbrain, kidney and intestine, but was reduced at least 20 fold in adult 
tissues. N-myc mRNA is expressed in the early stages of the differentiation of 
brain, kidney and haematopoietic cells in the mouse fetus. It is interesting that 
N-myc related expression in Xenopus is quite high in liver since the adult liver 
in Xenopus, unlike mouse, is still an active site of heamatopoiesis. Again the 
Xenopus N-myc related transcript appears to be larger than that of mouse or 
humans which is -3.0-4.0kb (Jakobovits ef a/1985, Michitsch and Melera 1985, 
Zimmerman efa/1986).
The expression of a fos related sequence is shown in figure 3.5(b). Weak 
signals can be detected in blood, kidney, lung, previtellogenic ovary and adult 
ovary, the size of this transcript is ~ 1.8kb which is slightly smaller than the 
mouse 2.2kb c-fos transcript (Muller and Verma 1984) but is still large enough 
to code for a protein of similar size to that of mouse (380aa). This 1.8kb band 
is very similar to the 18S ribosomal gene size but I do not think the sequence 
detected by the v-fos probe is due to non-specific hybridisation since no other 
tissue shows a strong fos transcript and yet 18S rRNA is present in each. The 
fos gene is rapidly induced in response to mitogens and differentiation agents 
(see Chapter 1, Verma 1986). In fetal mice high expression of the fos gene is 
found in anrm\orv, endoderm, mesoderm and visceral yolk sac (Muller, Verma 
and Adamson 1983, Muller and Verma 1984). Elevated levels of c-fos mRNA 
are also found in adult bone and skin. Also high mRNA levels are found during 
the late differentiation of myelomonocytic cells and during macrophage 
proliferation (Muller, Muller and Guilbert 1984, Gonda and Metcalf 1984, Muller 
et al 1985). It is difficult to assess the expression of the Xenopus c-fos gene 
in terms of these results since the signals, apart from previtellogenic ovary, are 
weak and since the tissues contain a wide variety of cell types.
The detection of ki-ras and ha-ras related transcripts in Xenopus RNA is 
shown in figure 3.5(c and d). Multiple transcripts are observed with both 
probes. Transcripts of 4.2, 2.6 and 2.2kb are found with v-ki-ras ptobe in adult 
ovary, previtellogenic ovary and kidney although there appear to be differences 
in the level of expression of each transcript. The v-ha-ras detects transcripts 
of 2.6kb and 1.7kb. The 2.6kb transcript is present in both adult and 
previtellogenic ovary but the 1.7kb transcript is present only in adult ovary. In 
mice and humans c-ha-ras and c-ki-ras seem to be expressed ubiquitously 
with multiple transcripts (Muller and Verma 1984, Hall 1984). The mouse 
c-ha-ras transcripts and 1.4kb and 4.3kb whereas the human c-ha-ras
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transcript is 1.2kb. The mouse c-ki-ras transcripts are 2.0kb and 4.4kb whereas 
the human c-ki-ras transcripts are 5.5, 3.8 and 1.2kb. The human N-ras 
transcripts are 5.2 and 2.2kb (Hall 1984). The multiple Xenopus ras transcripts 
which appear independent of each probe used (except the 2.6kb band) is 
entirely consistent with this data as is the expression in many tissues. It is 
interesting that both probes detect some different bands in northern blots yet 
the pattern of bands in southern blots is similar.
When probes for fms, re/, abl, erb B and src are used to probe northern 
blots of Xenopus RNA either very weak signals could be found (that could not 
be photographed) or no signal was detected. These signals may be 
non-specific although using v-src as a probe I detect a very weak ~3.4kb band 
in ovary RNA which is in agreement with Steele's results (Steele 1985). The 
discrepancies between the kinased labeled RNA experiment and the northern 
blotting experiments are not understood but it is likely the former results are 
subject to more artifacts.
3.4 Discussion
By using highly labeled probes and non-stringent hybridisation conditions I 
have extended the initial observations of Shilo that cellular oncogenes can be 
detected in a wide variety of organisms (Shilo and Weinberg 1981) to include 
amphibians. Table 3.1 summarise the data I have obtained using different 
oncogene probes on three species of Xenopus DNA. As table 3.1 indicates I 
can detect all the oncogenes I have looked for, at least to some extent, in the 
DNA of all three species of Xenopus. It is therefore likely that cellular 
oncogene homologs exist in Xenopus for most other oncogenes that I have not 
tested. Hence this study reaffirms the belief that cellular oncogenes are very 
highly conserved throughout evolution and provides a basis (albeit teleological) 
for saying cellular oncogenes play an important role in normal cell growth. 
This is supported by the fact, described previously, that cellular oncogenes 
have been isolated from yeast and Drosophila
From this study a general impression is gained that X.tropicalis DNA may be 
simpler than X.laevis or X.borealis DNA (with possible exceptions such as ras) 
and provides evidence for the genome doubling hypothesis discussed earlier. 
How this genome doubling event took place is unclear. It may have arisen by 
a failure of mitosis or meiosis leading to non-reduction generating
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Oncogene probe X.b X.I X.t Ov RNA
N-myc (human) ++ ++ ++ +++
v-erb B +++ +++ +++
c-myc (human 3rd exon) + +++ +++ ++
c-myc (chicken 2nd exon) +++ +++ +++ +++
v-ki-ras +++ +++ +++ +
v-ha-ras +++ +++ +++ +
v~src +++ +++ +++ +\-
v-abl +++ +++ +++ +\-
v-rel ++ ++ ++
v-fms + + ++
v-fos + + ++ +
v-sis + + ++
Table 3.1
Summary of heterologous probing southern and northern blotting data from 
figures 3.1, 3.2, 3.3, 3.4 and 3.5. X.b=X.borealis DNA, X.\=X./aev/s DNA, 
X.t=X.trop/ca//s DNA, Ov.RNA=ovary RNA, +++=strong signal, ++=moderade signal, 
+=weak signal, -=no signal.
autopolyploids. Alternatively genome doubling might have occurred by the 
crossing of two related species to generate allopolyploids. Mating with a 
haploid followed by further chromosome increases or mating with another 
tetraploid would give rise to the new tetraploid species. Gene conversion 
could then take place making two related genes similar and/or one gene could 
be silenced especially if there was pressure on the cell not to have two 
non-identical competing functional proteins.
A comparison of vitellogenin genes in Xenopus also supports a genome 
doubling of some kind (Wahli and Ryffel 1985). X.laevis has 4 vitellogenin 
genes. A1 and A2 are related by ~7% divergence as are B1 and B2. The A 
family are diverged ~20% from the B family suggesting a gene duplication 
before genome doubling. X.tropicalis has similarly two A genes but only one B 
gene suggesting the A gene duplicated soon after the laevis-tropicalis 
divergence and that they have been separated for the same period of 
evolutionary time. Therefore the divergence between X.laevis and X.tropicalis 
and the genome duplication in X.laevis probably occurred during the same 
period. Maybe the genome doubling led to the separation of the X.laevis 
lineage from X.tropicalis.
I can also detect expression of many cellular oncogenes using heterologous 
probes in X.borealis RNA. In general, the kinased RNA experiment in figure 
3.4(a) has borne out the results obtained with northern blotting with a few 
exceptions (e.g. rel and abl do not appear to be as highly expressed as 
suggested by the kinased RNA experiment). Therefore I think this kind of 
experiment can only be used as a guide to test a battery of sequences for 
expression. Since I am able to detect expression of at least some cellular 
oncogene sequences this makes me conpi^enV that at least some of the 
homologies I detect are real. It may be some are not real because the 
stringency is low and one might begin to detect families of functionally related 
genes such DNA binding proteins or protein kinases but rarely do non-identical 
probes which may have evolved from the same gene (e.g. src, abl, erb B) detect 
similar sized bands on southern blots.
Each oncogene sequence, that I find, expressed seems to be in many 
tissues and at different levels. Such an observation might be expected as it is 
true of other systems and since these genes probably have very specific 
functions in certain cell types (and may have more than one function or
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different functions in different ceils). But it is interesting to note that the best 
expression I detect, with many oncogene probes, tends to be in ovary RNA, 
maybe because Xenopus oocytes accumulate a large amount of mRNA for use 
during embryogenesis (see Chapter 1, Rosbash and Ford 1974). If cellular 
oncogene mRNAs are stored by the oocyte for subsequent development then it 
implies their protein products are involved in those processes of embryogenevs 
that do not require zygotic genome transcription (i.e. cell division, protein 
synthesis and cell lineage determination) although this does not preclude any 
possible function in later development.
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CHAPTER 4 
ISOLATION AND EXPRESSION OF C-MYC RELATED SEQUENCES IN X.BOREALIS
4.1 Introduction
Using heterologous probes to study cellular oncogenes in Xenopus is 
limited because the range of possible experiments is constricted by the 
sequence of divergence of the probes which may lead to artifacts. Therefore 
to pursue any further study of Xenopus cellular oncogenes requires the 
isolation of homologous sequences. Because conditions have been described 
that detect oncogene related sequences in southern and northern blots, it 
should be possible to use similar conditions to isolate related sequences from 
a Xenopus gene library. This rationale has already been proved by the isolation 
of c-src from X.laevis (Steele 1985) and by the isolation of other oncogene 
sequences from yeast and Drosophila.
A number of reasons influenced the decision to try and isolate c-myc 
related sequences from X.borealis. Firstly it seemed sensible to choose the 
c-myc gene because I had good southern blotting data suggesting it was 
closely related to higher vertebrate c-myc genes. Secondly my northern 
blotting data suggested that it may be moderately expressed in the ovary. This 
would make the isolation of the gene easier if a cDNA library was employed 
since less recombinants would have to be screened than a genomic library. 
Remembering that Xenopus has a genome size similar to humans, isolation of a 
single copy gene from a genomic library would require several million
recombinants whereas for a moderately expressed gene (say at least 0.01% of
cONA 
the total message population) only 50,000t recombinants would be required.
When using heterologous probes the signals obtained are likely to be weak 
therefore it is advisable to screen as few recombinants as possible since many 
false positives may be generated. When required, genomic clones can be 
obtained using the homologous cDNA clones as probes. Hopefully this strategy 
also saves on expense and time. Thirdly when I started this work I was 
unaware of anyone else who was trying to isolate c-myc from Xenopus.
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4.2 Isolation of C-myc Related Sequences from X.Borealis cDNA Libraries 
4.2.1 Construction of a cDNA Library
Since it appeared that X.borealis ovary had moderate expression of c-myc 
related sequences it was decided to build a previtellogenic ovary cDNA library 
in the vector ANM1149 and use heterologous c-myc probes from humans and 
chickens to screen for phages containing a Xenopus c-myc related sequence 
(an adult ovary cDNA library was already under construction in our laboratory). 
The previtellogenic ovary cDNA library was constructed as described in Chapter 
2 and as outlined in figure 4.1. This method has a number of advantages over 
other approaches (1) nearly full length clones should be generated due to the 
efficiency of the second strand reaction and the size selection, (2) in vitro 
packaging of X DNA is generally more efficient than transformation of E.coli 
with plasmids thereby increasing the number of recombinants obtained for 
equal amounts of cDNA, (3) a positive selection for recombinants exists by 
using the vector XNM1149 and plating the phages on E.coli NM514 and (4) X 
plaques can be screened at a much higher density than E.coli colonies.
Figure 4.1 summarises the construction of such a library, (a) shows the 
first strand products of reverse transcription appear to be quite long assuming 
the average size of the mRNA is 2.0kb (Rosbash and Ford 1974). Calculations 
(appendix 2) indicate that 30-50% of the input mass of RNA is converted to 
first strand products, (b) shows the second strand reactions have apparently 
gone to completion giving full size products. Calculations (appendix 2) indicate 
that -95-100% of the input mass of first strand product is converted to 
second strand products, (c) shows the size fractionated cDNA that was used 
for cloning into XNM1149 was mostly above ~0.7kbp in size and therefore 
should mostly contain full length cDNA clones. Using these procedures I 
generated a previtellogenic ovary cDNA library that contained ~4 x 104 - 6 x 
104 recombinants from ~50-100ng of double stranded cDNA.
4.2.2 Isolation of c-myc related cDNA clones
During the construction of the above library an adult ovary cDNA library 
from X.borealis became available (kindly supplied by D.Sleep), therefore it was 
decided to screen it with a human c-myc third exon probe under low 
stringency conditions similar to that previously described for southern and 









































































A: Analysis of the reaction products during the construction of a previtellogenic 
ovary cDNA library as described in chapter 2. (a) shows the size distribution of 
the first strand products (labeled with ot 32 dCTP in the reaction) run on a 1% 
alkaline-agarose gel. Similarly (b) shows the size distribution of the second 
strand products run on a 1% DNA agarose gel. (c) shows the size distribution 
of the fractionated cDNA from a Biogel A-50 column ran on a 1% DNA agarose 
gel and indicates the fraction used for cloning. Size markers were X DNA 
Hind3 digested.
FIGURE 4.2
B: Southern blot analysis of potential X.borealis c-myc clones, (a) shows the 
hybridisation of a XbmycA! probe to various c-myc exon clones and (b) 
similarly shows the hybridisation of a human c-myc third exon probe to a 
duplicate filter, (c) shows the hybridisation of a chicken c-myc second exon 
probe to various potential X.Borealis c-myc clones and similarly (d) shows a 
duplicate filter hybridised with a human c-myc third exon probe. All filters were 
hybridised under low stringency conditions with probes of specific activity of 
~5 x 10 7cpm/ug. Final washing stringency was 1x SSPE, 65°C with an 
overnight exposure. B1 = XbmycBI, A1 = XbmycAl, A2 = XbmycA2, A3 = 
XbmycAS, A4 = XbmycA4 and A5 = XbmycAS.
isolated. It was noted that on primary screening of the library the signals 
obtained were very weak which resulted in picking a high number of false 
positives (on subsequent rescreening these failed to produce any signal). The 
positive phage was called XbmycAl and contains an insert of - I.Skbp. 
Initially to show this insert contained c-myc related sequences southern 
blotting analysis was performed. Figure 4.2(a) shows that the human c-myc 
third exon probe hybridises with the XbmycAl insert and figure 4.2(b) shows 
that a XbmycAl insert probe hybridises with the human c-myc third exon and 
chicken c-myc third exon sequences but not the chicken c-myc second exon 
sequences. It was concluded that the XbmycAl sequence contained the 3' 
coding sequences of a X.borealis c-myc gene. This was subsequently 
confirmed by northern and southern blotting (see later) since the XbmycAl 
probe hybridised to similar bands that were picked up by the heterologous 
probe. DNA sequence analysis (chapter 5) showed that the XbmycAl insert 
contained sequences highly related to other c-myc genes (in fact it had SOObp 
of the 3 coding sequence).
Unfortunately when a XbmycAl probe was used to screen this library (a 
further ~4 x 104 phages) no more positive phages were found. The reasons 
for a failure to isolate any more clones are unclear. Therefore I screened my 
previtellogenic ovary cDNA library, when it was successfully completed, with a 
XbmycAl probe. Using this probe meant I could use higher stringency 
conditions and that positive plaques were much easier to identify.
On screening ~4 x 104 phages of this library with a XbmycAl probe I 
obtained 3 strong (XbmycA2, 4, 5) and 3 not so strong (XbmycBI, 2, 3) positive 
plaques. Figures 4(c) and (d) showed that XbmycA2 had strong homology to 
both exon probes but XbmycB1-3 had only strong homology to the third exon 
probe (only XbmycBI is shown). Subsequent southern blotting analysis 
suggests XbmycA and XbmycB type sequences are actually different c-myc 
related genes. XbmycA4 and 5 appear to be short cDNAs from the 3' end of 
the mRNA and were not analysed any further.
Sequence analysis of XbmycA2 (chapter 5) confirmed that it contained a 
X.borealis c-myc gene that lacked the 5 end of the coding sequence. To 
obtain more 5' sequences a single strand M13 probe from the 5 end of 
XbmycA2 was used to screen this library. From ~2 x 104 unamplified and ~6 
x 104 amplified phages 1 further strong positive (XbmycA3) and 11 less strong
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positives (XbmycB4-14) were found. Figures 4(c) and (d) shows that XbmycAS 
has strong homology to the second exon probe and sequencing (chapter 5) 
confirms it contains 5' coding sequences of a X.borealis c-myc gene. All 
XbmycB1-14 phages showed a similar hybridisation described for XbmycBL 
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Table 4.1 Summary of cDNA clones obtained
From the above data and the southern analysis described later it appears 
that I have isolated two different families of c-myc genes. The XbmycA class 
are closely related to the human c-myc third exon and chicken c-myc second 
exon sequences but the XbmycB class are only closely related to the human 
c-myc third exon sequence.
It may be that the XbmycA mRNA is difficult to reverse transcribe because I 
have isolated no complete cDNAs. The first strand reaction appears to have 
gone to completion since all the XbmycB cDNAs are nearly full length. 
Secondary structure in the XbmycA mRNA may block the passage of enzyme. 
During the initial screen I obtained roughly equal numbers of phages from each 
class which roughly agrees with the expectation from northern blotting in 4.3.1 
suggesting both types of genes may be expressed about the same level. The 
second screen with a 5'probe mainly isolated B type genes thereby suggesting 
that many A type genes lack a 5' end, again pointing to a difficulty in the 
reverse transcription of the XbmycA mRNA.
XbmycAS does contain 5'sequences yet it has no 3' sequences. It does 
not contain a poly(A) tail (chapter 5) hence it is not a cDNA clone for a short
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mRNA. Probably this clone was generated by an incomplete second strand 
synthesis or by an internal priming event from the mRNA during first strand 
synthesis. XbmycA2 has a 5' end which is a naturally occurring EcoRI site 
(chapter 5). Possibly this site was not methylated properly before EcoRI 
digestion during library construction but it is not impossible that the cDNA 
actually extends beyond this site by a very short sequence which I am unable 
to detect on an agarose gel.
Most of the further work I describe concerns the XbmycA type genes 
because I was confident that they contained c-myc related sequences. The 
XbmycB types gene obviously are c-myc related sequences but they seem to 
be further diverged from the probes I used to isolate them with than the 
XbmycA type genes.
4.3 Characterisation of C-myc Related cDNA Clones 
4.3.1 Northern blotting analysis
From heterologous probing I knew that the c-myc related transcript was 
~2.9kb in ovary RNA therefore if the cDNA clones I had isolated showed 
~2.9kb transcripts in northern blotting experiments then it would provide 
further evidence that the clones were derived from true c-myc mRNA. Any 
cDNA clone that contains more than one EcoRI fragment must also be tested 
to show that it is not derived from two independent cDNAs^W^ have been 
ligated into the same vector molecule.
The results of such experiments are shown in figure 4.3. It would appear 
each cDNA clone does hybridise to a similar sized ~ 2.9kb transcript as was 
detected by the heterologous probes. Furthermore both EcoRI fragments of 
XbmycA2 and 3 seem to derive from the same transcript. Close inspection 
suggests that the band is in fact a doublet. This may point to there being two 
independently transcribed c-myc genes or it may be due to transcription from 
two independent promoters on each gene or to post-transcriptional events 
such as differential splicing. It is known that the mouse c-myc gene is 
transcribed from two promoters 167bp apart (Stewart, Bellve and Leder 1984) 
and also that there is some transcription from further upstream of these 
promoters (Nepveu and Marcu 1986).












































































































A: Northern blot analysis of the various X.borealis c-myc clones under high 
stringency conditions with probes of specific activity of ~7 x 108 - 1.5 x 
109cpm/ng. About 5ug of previtellogenic ovary (P) or adult ovary (O) poly(A) + 
RNA was used per track. Final stringency of washing was 0.2x SSPE, 50°C with 
a 1 - 2 day exposure though the B1 filter had been exposed for 7 days since it 
had been reused a number of times. Sizes were estimated from X.borealis 18S 
and 28S rRNA. A1 = XbmycAl, A2U = XbmycA2 (large EcoRI fragment), A2L = 
XbmycA2 (small EcoRI fragment), A3U = XbmycAS (large EcoRI fragment), A3L = 
XbmycAS (small EcoRI fragment) and B1 = XbmycBL
B: Southern blot analysis of the various X.borealis c-myc clones under high 
stringency conditions with probes of specific activity of ~7 x 10 8 - 1.5 x 
109cpm/ug. 10u,g of X.borealis (B), X.laevis (L) or X.tropicalis (T) EcoRI digested 
DNA was used per track. Final stringency of washing was 0.2x SSPE, 65°C with 
a 3 - 4 day exposure. Sizes were estimated from X DNA Hind3 digested. Probes 
used are as described in A.
transcripts. I do not know to what extent the XbmycA and B probes 
cross-hybridise but southern analysis in 4.3.2 suggests this might be ~10% at 
the most. From figure 4.3 I roughly estimate the XbmycB genes are expressed 
at least 50% of the level of the XbmycA genes. This assumes that the probes 
were roughly the same specific activity and allows for the fact the XbmycB 
filter had been reused and the exposure is ~5x greater. Note that equal 
numbers of cDNA clones from each class were isolated from the int\&\ library 
screen using a 3' probe. S1 nuclease protection assays are required to confirm 
the above estimates.
The differences in signals between previtellogenic and adult ovary are 
probably due to differences in the amount of RNA loaded. The filter for 
XbmycAS had also been reused and probably explains the weaker bands. It 
must be emphasised that these exposures using homologous probes are 5-15x 
shorter than those using heterologous probes hence I have now greatly 
increased the sensitivity of my experiments.
4.3.2 Southern blotting analysis
To determine the relationship of the cDNA clones to each other and to try 
and work out a genomic structure for them a series of southern blots were 
performed as shown in figures 4.3. Each probe detects bands that are in 
common with the heterologous probes (figure 3.2) affirming the belief that the 
clones are c-myc related. Unfortunately it appears that in the filter probed 
with XbmycA! the X.borealis DNA was not completely digested as determined 
by band intensity and by comparison with the XbmycA2 (lower) filter since both 
probes span the same region hence the 4.3 and 9.4kbp bands should be 
ignored. The EcoRI site that splits XbmycA2 into two fragments is either due 
to an artifact generated during cloning or it is due to a polymorphism since the 
frog used for southern analysis was different from those used to make the 
cDNA library. Another cDNA clone, XbmycA4, has an EcoRI site roughly in a 
similar position therefore this may be a real polymorphism although XbmycAl 
and 5 do not possess an EcoRI site in this position.
My results show that there are at least two classes of c-myc genes in 
X.borealis and X.laevis. The hybridisation of XbmycA to X.borealis and X.laevis 
DNA is clearly different from that of XbmycB. There may be some 
cross-reaction of the probe since the probe hybridises weakly to the same
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sized bands as XbmycA1,2 and 3 (lower). Although it might be possible that 
there is a second B type gene, split by an EcoRI site and having the same 
fragment sizes as those detected by the A type probe. I think these other 
bands are probably due to cross-hybridisation for two reasons: 1) the XbmycA 
type genes pulled out the XbmycB type genes from the library and 2) there are 
no EcoRI sites in all 14 cDNA clones of the B type genes. I do not understand 
why the A type genes do not weakly hybridise to the B type gene fragments on 
these southern blots. It is interesting that the XbmycB probe does not 
hybridise at all well with X.tropicalis DNA. This suggests that the XbmycB gene 
has evolved since the split of X.borealis and X.laevis from X.tropicalis and may 
have arisen by gene duplication followed by divergence in the X.borealis and 
X.laevis lineage. A B type gene might exist in X.tropicalis but it might be too 
diverged from the X.borealis probe to detect it under the hybridisation 
conditions I used. Also because the B type gene hybridises to a ~3.0kb 
transcript then it cannot contain a very large intron since it appears to be 
contained within a single ~3.35kbp genomic fragment.
The simplest model for the XbmycA class genes is discussed below and 
takes into account some of the sequencing data described in chapter 5. Figure 
4.4 shows a hypothetical structure of a XbmycA gene and from where each 
probe is derived. It is assumed there is an intron present in the Xenopus gene 
at the approximate position indicated as one exists in the c-myc gene of all 
other species at approximately this position.
Probes XbmycA2 (upper and lower), XbmycAl, XbmycAS (lower) hybridise to 
the same sized fragments therefore this suggests that if an intron is present it 
does not contain an EcoRI site. The XbmycAS (upper) probe hybridises to one 
band that is similar in size (except X.tropicalis) and one band that is of a 
different size compared with the other probes. This different sized fragment is 
due to the presence of a natural EcoRI site in the 5'coding sequence which 
has apparently been conserved in X.laevis and X.tropicalis. I suggest that the 
14.0kbp and 6.0kbp fragments in X.borealis and the 9.0kbp and 3.25kbp 
fragments in X.laevis are physically linked to form on XbmycA type gene. I 
think that 2.0kbp fragment(s) in X.borealis and the 4.25kbp fragment in X.laevis 
form a second but different XbmycA type gene since they hybridise to all 
probes used. Therefore this would mean there are at least two different kinds 
of highly related XbmycA type genes in X.borealis and X.laevis but only one 









































A hypothetical structure of a XbmycA class gene (see text) from southern 
blotting data in Figure 4.3 and sequencing data described in chapter 5. The 
origin of each XbmycA cDNA clone is marked, U and L refering to the large and 
small fragments generated by EcoRI digestion respectively of XbmycAS and 
XbmycA2. The dotted line represents sequences not present in the XbmycA2 
cDNA clone (i.e. a potential intron sequence represented by a thin diagonal 
line). Boxes represent coding sequences, An represents the polyadenylation site 
and Rl represents EcoRI sites. Sizes are in kilobase pairs and the diagram is not 
to scale. Question marks refers to sizes that are impossible to estimate from 
the data.
has also been a gene duplication to generate both A type and B type genes in 
X.b ore alls and X.laevis,
If the the above model is correct then it has to explain how the A type 
gene that is contained in the 2.0kb fragment in X.borealis can be shorter than 
the mRNA size. It could be that it is an unexpressed pseudogene; it could be 
the 5' end of the mRNA is completely unrelated to the other gene and is split 
by an EcoRI site from this fragment (this means if an intron is present it must 
be very small) or it is possible that the gene is divided into two EcoRI 
fragments of a similar size. The XbmycAS (lower) probe overlaps the XbmycA2 
(upper) probe and is highly homologous to it but it does not detect both bands 
in X.laevis with equal intensity yet it does in X.borealis. If one assumes that 
the region spanned by the XbmycAS (lower) probe has diverged in one of the 
X.laevis genes then this would explain the results since this probe is much 
shorter that the XbmycA2 (upper) probe and might hybridise less well, also the 
rest of the XbmycA2 (upper) probe might be closely related to both X.laevis 
genes.
If there was one A type gene in X.tropicalis and two A type genes in 
X.borealis and X.laevis then it would be expected that the intensity of signal 
from X.tropicalis would be double compared with that from each of the 
X.borealis and X.laevis genes since twice as many genome equivalents 
X.tropicalis DNA was used. From figure 4.3 it is obvious this is not true and 
the intensities are roughly equal. Possibly this is a reflection of poorer 
hybridisation of the X.borealis probes to X.tropicalis DNA (as is true of XbmycB) 
or that the genes have became duplicated in X.borealis and X.laevis such that 
they give fragments of exactly the same size.
One could imagine other models that would fit the data in figure 4.3 for 
example the fragments I have suggested that are linked to each other may not 
be which would lead to other interpretations of the results. More extensive 
southern blotting analysis is needed to determine the exact genomic structure 
of these genes. Isolation of genomic clones and heteroduplex analysis would 
also be required to define the precise gene structure.
4.4 Expression of X.borealis C-myc Genes
Most of the following work describes the expression of the XbmycA type 
genes since these are highly related to the c-myc genes of other species.
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Sometimes filters were reused for probing with the XbmycB sequences. This 
was not always totally successful but the results are shown since they can be 
informative.
4.4.1 Tissue specific expression
XbmycAl was used to probe a northern blot of different tissue poly(A) + 
RNAs similar to that already described for heterologous probing. Figure 4.5 
shows that c-myc RNA can be detected in most tissues. Adult ovary RNA 
shows the strongest signal; kidney shows a moderate signal; muscle, testes, 
spleen, blood and lung show weak signals whereas liver and heart do not show 
a detectable signal. Figure 4.3 shows that both adult and previtellogenic ovary 
have similar expression levels of c-myc RNA. These results confirm those 
already described for heterologous probes in figure 3.3(c) i.e. c-myc RNA is 
expressed in a wide variety of tissues. Note that by using the homologous 
probe the exposure required for a good signal has been reduced 5 fold. 
Bearing in mind that different amounts of poly(A) + RNA might have been used 
and the fact there is heterogeneity of cell populations in tissues my results 
suggest that most tissues express c-myc RNA at a low level which is 
agreement with the expression of c-myc in other systems (Stewart, Bellve and 
Leder 1984). My results also suggest that c-myc levels are quite high in ovary. 
This might point to a storage of c-myc RNA in the protracted period of 
oogenesis for subsequent use by the egg and embryo during the rapid 
cleavage stages of development that are transcriptionally inactive.
4.4.2 Level of expression in stage II oocytes
To quantitate the level of expression of the XbmycA type genes in stage II 
oocytes a northern blotting experiment was performed that used in vitro 
synthesised antisense XbmycA RNA to compare with in vivo levels of XbmycA 
RNA. A short 205 bp EcoR//Pst\ fragment of the coding sequence of XbmycAl 
was subcloned into the transcription vector pGEM1. Truncated 3 H antisense. 
message was synthesised with T7 polymerase and known amounts were mixed 
with the same amount of stage II oocyte total RNA (5 oocytes worth). Mixed 
RNAs were run on a formaldehyde gel, transferred to hybond-N and probed 
with the complete XbmycAl fragment.
The result of such an experiment is shown'm figure 4.6. Assuming that the 
















































































A: Expression of XbmycAl in different tissue RNA. 4 - 5 ug of X.borealis 
poly(A)+ RNA was used per track. Bl = blood, Li = liver, Ki = kidney, He = heart, 
Mu = muscle, Lu = lung, Ad.Ov = adult ovary, Te = testes and Sp = spleen. The 
probe had a specific activity of ~1 x 10 9cpm/ug. Final stringency of washing 
was 0.5x SSPE, 50°C with a 4 day exposure. Sizes were estimated from 
X.borealis 18S and 28S rRIMA.
FIGURE 4.6
B: Level of expression of XbmycA RNA in stage II oocytes. 5 ooctyes worth of 
total RNA were mixed with known amounts (indicated above each lane) of an in 
vitro synthesised 205bp 3 H XbmycAl EcoRI/Pstl sense RNA. Samples were 
then ran on an RNA gel transfered to nitrocellulose and probed with the 
complete XbmycAl probe (specific activity 1 x 109cpm/ug) under high 
stringency conditions. Final washing conditions were 0.2x SSPE, 60°C with a 3 
day exposure. Densitometry was then performed and calculations indicate that 
one stage II oocyte contains ~19pg of XbmycA RNA.
FIGURE 4.7
C: Expression of XbmycA during oogenesis. For each stage (as described by 
Dumont 1972) the total RNA from 5 oocytes was loaded per track. Fer 
represents fertilised eggs. All probes had roughly the same specific activity of 
~1 x 109cpm/ug and were used under high stringency conditions. Final 
washing conditions were 0.2x SSPE, 60°C and each filter was exposed for 4 
days, (a) XbmycA2 probe, (b) the filter from (a) stripped and reprobed with a 
cytoskeletal actin probe, (c) the same filter stripped and reprobed with 
XbmycBL
5 stage II oocytes contain ~95pg of XbmycA RNA. There is 1.6ug of total RNA 
in 5 stage II oocytes as judged by optical density and 140ng of poly(A) 
containing RNA as judged by 3 H poly(U) hybridisations which agrees well with 
previous reports (Rosbash and Ford 1974). Therefore XbmycA type RNA is 
expressed at a moderately high level of ~0.07% of the maternal mRNA 
population in stage II previtellogenic oocytes.
4.4.3 Expression during oogenesis and development
Gene expression of XbmycA during oogenesis and development was 
examined by northern blotting using manually staged oocytes and embryos. 
Filters first were probed with XbmycA2 and then reprobed with cytoskeletal 
actin (and then XbmycBI). The results of these experiments are shown in 
figures 4.7 and 4.8. Densities of band intensities from overnight exposures of 
the autoradiographs were plotted versus stage of development as shown in 
figure 4.9 calibrating each experiment for the fertilised egg values. The 
relative expression of XbmycA against cytoskeletal actin is only a guide and 
assumes the specific activity of the probes were the same and hybridisation 
rates similar. Since the experimental scatter of the points is quite high the 
cytoskeletal actin graph was drawn first bearing in mind the previously 
determined developmental expression of the gene (Mohun et al 1984) then the 
XbmycA graph was drawn as a best fit of the experimental points. Hopefully 
this represents a true reflection of the expression of these genes.
Both XbmycA and cytoskeletal actin are made early in oogenesis, 
cytoskeletal actin always being expressed at a higher level (maybe at least by 2 
fold). The maximal level of expression is at the beginning of vitellogenesis 
(stage II oocytes) which has dropped by ~50% in stage VI oocytes. Golden 
reports similar results that most mRNAs accumulate early in oogenesis but 
then remain at a constant steady state level for the rest of oogenesis (Golden, 
Schafer and Rosbash 1980). These results are surprising since lampbrush 
chromosomes are maximally extended in stage III oocytes (Macgregor 1980) yet 
the highest levels of expression prece<Le. this event. It has been suggested that 
poly(A)* RNA synthesised early is conserved to the end of oogenesis and 
eventually inherited by the embryo whereas the poly(A) + RNA synthesised in 
the latter months of oogenesis turns over (Ford, Mathieson and Rosbash 1977, 
Dawid, Kay and Sargent 1983). Therefore it may mean that XbmycA and 






















































































Expression of XbmycA during development. Embryo stages are as described by 
Nieukoop and Faber 1956. E represents ovulated eggs; E5 and E10 represent 
ovulated eggs stored for 5 and 10 hours respectively without being fertilised. 
Per represents fertilised eggs. Development preceded at ~22°C and the first 
cleavage took ~1 hour with subsequent cleavages taking ~30 minutes each. 
Probes had roughly the same specific activity of ~ 1 x 10 9cpm/ug and were 
used under high stringency conditions. Final washing conditions were 0.2x 
SSPE, 60°C. (a) XbmycA2 probe, 7 day exposure, (b) the filter from (a) stripped 
and reprobed with a cytoskeletal actin probe, 1 day exposure, (c) the same filter 
stripped and reprobed with a XbmycBI probe, 7 day exposure.
EXPRESSION (arbitrary units)
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FIGURE 4.9
Expression of XbmycA during oogenesis and development. Densities from 1 day 
exposures of the filters from Figure 4.7 and 4.8 were plotted (in arbritary units) 
against each stage of oogenesis (experiment 1) or development (experiment 2). 
E refers to newly fertilised eggs and since it was present in both experiments it 
was used to calibrate experiment 1 with experiment 2 so that one graph could 
be plotted. Oocyte stages are as described By Dumont 1972: stage II oocytes 
are tate previtellogenic oocytes and stage VI oocytes are fully grown oocytes. 
Embryo stages are as described by Nieukoop and Faber 1956: stages 1 - 9 are 
blastula, stages 10 - 13 are gastrula, stages 14 - 24 neurula and stages 25 
onwards are tailbud through to swimming tadpole. The midblastula transition 
occurs about stage 8 of development at ~22°C and no new transcription 
occurs until this stage. From Figure 4.6 I estimate a stage II oocyte contains 
~19pg of XbmycA RNA. Similarly the developmental expression of cytoskeletal 
actin was plotted using the densities from overnight exposures of the filters in 
Figure 4.7 and 4.8. This profile is almost the same as that described by Mohun 
et al 1984 given the limits of experimental variation. Although both probes had 
roughly the same specific activity it is difficult to compare the results 
quantitatively between the two different probes due to many factors such as 
differences in probe length, hybridisation rates and conditions etc. and since 
the filters had been reused but a general picture is gained through the 
comparison.
would be difficult to reconcile this with the fact c-myc RNA is highly unstable 
in other systems.
Cytoskeletal actin mRNA is inherited by the embryo and is steadily 
degraded until just after gastrulation (stage 13-14) when new transcription of 
cytoskeletal actin mRNA begins. Transcripts accumulate as cell number 
increases probably because most cells in the embryo begin to synthesise 
cytoskeletal actin mRNA. Cell numbers double between stage 14 (gastrula) and 
stage 26 (tailbud) embryos whereas there is at least an 8 fold increase in 
cytoskeletal actin levels. This developmental profile is similar to that already 
described (Mohun et al 1984), therefore one can assume that the general 
activation of RNA synthesis at the midblastula transition (Newport and 
Kirschner 1982) happens at a similar stage of embryogenesis in these 
experiments (stage 8, 10,000 cells).
XbmycA mRNA is also inherited by the embryo but seems to be degraded 
in two waves till at stage 9 over 90% of maternal mRNA has disappeared. This 
may reflect specific degradation of XbmycA mRNA in different germ layers 
therefore it is possible that specific factors control the degradation of XbmycA 
RNA. New XbmycA transcription starts around late gastrula which is slightly 
earlier than cytoskeletal actin transcription. Since so much of the maternal 
XbmycA2 mRNA has been degraded it may mean new XbmycA transcription 
has to start sooner to allow proper cell division.
The accumulation of XbmycA mRNA during later development is quite 
different from that for cytoskeletal actin mRNA. Maximal levels of XbmycA 
mRNA are reached by late neurula to tailbud (stage 20-24) which then drop by 
~50% and remain roughly constant during later development. The main body 
organs have been mapped by stage 20 therefore maybe XbmycA is involved in 
organ differentiation. At stages 20-24 this would correspond to nervous 
system differentiation. The drop in expression of XbmycA later in development 
may be due to a smaller set of differentiating cells requiring XbmycA or it may 
be it is no longer involved in differentiation per se but rather is required in low 
amounts for cell division. Note in adult tissues XbmycA mRNA can be detected 
in many tissues. It is likely the XbmycA protein has many functions and will be 
involved in both processes.
The maximal level of XbmycA expression during development is of the
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same order as that in stage II oocytes. It seems that the embryo inherits 
enough XbmycA mRNA to last until it reaches -50,000 cell stage. Because 
there is no transcription until stage 8 it should be possible to make an 
estimate of the half life of XbmycA mRNA but this is confused by the 
apparently biphasic nature of the XbmycA mRNA degradation. Also figure 4.8 
shows that unfertilized eggs that have been incubated for 5 hours have only 
lost 25% of their XbmycA mRNA but when incubated for a further 5 hrs 
XbmycA mRNA becomes undetectable. It also seems cytoskeletal actin is much 
more stable over the first five hour period. There is not enough data to 
estimate a half life of XbmycA mRNA but it can be said it appears to be a lot 
longer than other systems (hours rather than minutes) but this may partly 
reflect differences in temperature as well as cell type.
Another point to note from these experiments and those in 4.4.1 is that the 
XbmycA transcripts are always the same size i.e. the oocyte XbmycA transcript 
is the same size as the somatic and embryoinic XbmycA transcripts. Anderson 
has reported that 70% of oocyte poly(A) + RNA carries interspersed repeats 
(Anderson et al 1982). Therefore it might be expected that oocyte XbmycA 
mRNA would be larger than somatic or embryoiVic. transcripts: this is obviously 
not true and supports the results of Golden (Golden, Schafer and Rosbash 
1980). I am actually unaware of any cloned sequence from Xenopus that has a 
larger transcript in oocytes.
The experiments using XbmycB as a probe are not very good since the 
filters had been reused several times prior to probing but from figure 4.8 one 
can see that XbmycB follows a similar developmental profile as 
XbmycA. Therefore both XbmycA and B might be regulated in a similar fashion.
4.4.4 Expression in dissected embryos
The previous results show XbmycA mRNA peaks during the late neurula to 
tailbud stages. This might mean XbmycA is involved in the development of the 
nervous system and the brain. During the post-natal development of the 
murine cerebellum high levels of c-myc mRNA have been found in proliferating 
granule cells and differentiating Purkinje cells (Ruppert, Goldowitz and Wille 
1986). To see if there is any localised expression of XbmycA mRNA in embryos 
a series of northern blots were done using dissected embryos from stages 24, 
26 and 33/34. The embryos were cut into 3 pieces : the head piece containing
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the developing brain and eyes ; a gut piece containing primitive body organs 
such as liver, heart, kidney, gut etc ; and a neural tube piece containing the 
developing spinal chord and somites. Note that each of these pieces do not 
derive from a single germ layer (i.e. either, endoderm, ectoderm or mesoderm 
alone). The results of such experiments are shown in figure 4.10 Densitometry 
was performed on overnight exposures of the autoradiographs and graphs were 
plotted of band intensity (in arbitrary units) versus stage for each tissue piece 
(see figure 4.11).
The total expression pattern for complete embryos (when the individual 
values of head, gut and neural tube are add together for each stage) is similar 
to previous results except that XbmycA expression turns down slightly later at 
stage 26 rather than stage 24. This may be due to batch variation or other 
variables therefore care must be taken when interpreting these results. Also 
intact undissected embryo results were ambiguous therefore the experiments 
should be repeated and complementary techniques such as in situ hybridisation 
should be performed to localise the expression of XbmycA precisely in tissues 
during development.
For each tissue piece cytoskeletal actin expression increases as the embryo 
stage increases which might be expected since the cell number is increasing. 
The increase between stages 24 and 26 might not be as dramatic as that 
between stages 26 and 33/34 since the former development takes ~3 hours 
whereas the latter takes ~15 hours and therefore has had more time to 
accumulate cytoskeletal actin mRIMA. This increase in expression only 
approximates to what was previously described.
For gut and neural tube tissue XbmycA expression increases between stage 
24 and 26 then decreases between stage 26 and 33/34 as well as between 
stage 24 and 26. Since the total expression of XbmycA is similar to the 
previous experiment (figure 4.9) and since cytoskeletal actin expression 
increases at all stages it seems likely this is a true result. Therefore this 
suggests that many cell types in late neurula/early tailbud require XbmycA for 
their growth but as the embryo grows older only a limited set of cells in the 
head require XbmycA. Thus it may be that XbmycA is involved in the early 
proliferation and differentiation of many cell types in specifically in the early 
differentiation and/or proliferation in Xenopus brain which may be analogous to 









Expression of XbmycA in dissected embryo pieces. Embryos were grown to the 
indicated stage of development (Nieukoop and Faber 1956) then dissected into 
a head (H), gut (G) and neural tube (N) piece or left intact (I). Total RNA from 5 
embryo pieces or 5 intact embryos were used for each lane in northern 
analysis. All probes had roughly the same specific activity of ~ 1 x 10 9cpm/ug 
and were used under high stringency conditions. Final washing conditions were 
0.2x SSPE, 60°C. Sizes were estimated from X.borealis 18S and 28S rRNA. (a) 
XbmycA2 probe, 1 day exposure, (b) the filter from (a) stripped and* reprobed 
with cytoskeletal actin, 1 day exposure, (c) the same filter stripped and 






















Expression of XbmycA in dissected embryos. Densities from overnight 
exposures of the filters from Figure 4.10 were plotted (in arbitrary units) for 
each tissue piece at each embrvionic stage indicated. Stage 24 is late neurula, 
stage 26 is tailbud and stage 33/34 is a swimming tadpole stage (Nieukoop and 
Faber 1956). The total densities of all three separate embryo pieces at each 
stage is also shown. Similarly the expression of cytoskeletal actin is also 
plotted. For both probes the expression of all three embryo pieces together 
roughly parallels that shown in Figure 4.9 although it it seems to be delayed 
slightly which is probably due to batch variation. Again for the reasons 
described previously in Figure 4.9 in and the text it is difficult to quantitate the 
absolute expression levels between the two probes used.
Once again experiments on the above filters using XbmycB as a probe have 
not ben very successful but examination of figure 4.10 suggest it follows a 
similar pattern to XbmycA. Again this may point to both genes being regulated 
in a similar manner.
4.5 Attempts to Analyse XbmycA Protein Expression
In order to study the expression of XbmycA protein I tried to make 
antibodies to the IM-terminal region of the coding sequence for use in western 
blotting analysis. The 1.3kbp XbmycAl EcoRI fragment was end repaired and 
then subcloned into the Smal site of pEX2 (Stanley and Luzio 1985) giving a 
construction which has the 100 amino acids of XbmycAl fused, in frame, onto
E.coli
the N-terminus of 8 galactosidase. When'pop 2136 is transformed it expresses 
a XbmycA1-|3 galactosidase fusion protein under the control of a temperature 
sensitive cro represser.
Figure 4.12 indicates that the XbmycA1-$ galactosidase fusion protein has 
an increase in molecular weight of roughly 12kD compared with 3 
galactosidase alone which would be expected from sequence of XbmycAl. 
This figure also shows the products to be inducible and that cells alone do not 
express these products. Finally this figure shows that when the XbmycAl 
insert is cloned into pEX2 in the reverse orientation it does induce a fusion 
protein which is slightly bigger than (3 galactosidase but seems to be more 
unstable probably due the poly(A) tail giving rise to a poly-lysine tract in the 
protein.
The fusion protein was used to immunise three rabbits as described in 
Chapter 2 and sera obtained were used in western blotting analysis. All rabbits 
used reacted in an apparently similar manner hence representative western 
filters are shown in figure 4.12. PreVmmune sera did not react with any 
Xenopus ovary proteins. When an anti-$ galactosidase serum (supplied by 
A.Khan) was used this reacted with both the vector and fusion E.coli proteins 
as expected but this serum also reacted with two Xenopus protein bands 
weakly (~55, -90kD) therefore this had to be remembered when judging the 
results of the anti-XbmycA1-8 galactosidase experiments.
All the anti-fusion sera when used in western blot analysis reacted with 
E.coli fusion and vector proteins in a similar manner to the anti-B 
galactosidase serum. No specific reaction was found in the Xenopus ovary
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Generation of a XbmycA - B galactosidase fusion protein and western blotting 
analysis with antisera generated against it. All proteins and antisera were 
prepared as described in chapter 2. (a) Coomassie blue stained 7.5% protein gel 
of pop2136 cell proteins uninduced (C) and induced (Cl); pop2136 containing 
pEX2 (vector) cell proteins uninduced (V) and induced (VI); pop2136 containing 
pEX2 - XbmycAl in frame fusion (see text) cell proteins uninduced (F) and 
induced (Fl); pop2136 containing pEX2 - XbmycA in the reverse orientation (see 
text) cell proteins uninduced (-F) and induced (-FI). The vector pEX2 \generates 
a B galactosidase protein of ~117kD and the pEX2 - XbmycA construct 
generates a ~129kD 8 galactosidase - XbmycA fusion protein. Sizes were 
estimated from BRL protein molecular weight markers, (b) Western blot 
analysis of the proteins described above plus a X.borealis oocyte protein 
extract (X). 1:200 dilution of rabbit preimmune serum. Antibody - antigen 
interactions were visualised as described in chapter 2. (c) Similarly western blot 
analysis using a rabbit anti B galactosidase antiserum (kindly supplied by 
A. Khan) at a 1:200 dilution, (d) Similarly western blot analysis using a rabbit 
anti B galactosidase - XbmycAl antiserum generated as described in chapter 2. 
This antiserum was affinty purified against the fusion protein before use as 
described in chapter 2.
protein tracks; in fact many non-specific bands were present in the 60-70kD 
range. To overcome this problem the anti-fusion sera were affinity purified 
against the fusion protein as described in chapter 2. When such affinity 
purified sera were used reaction with the E.coli vector and fusion proteins was 
observed, but not with any Xenopus ovary proteins (figure 4.12). The presence 
of many bands is due to breakdown products of these large fusion proteins.
The reasons why I have not obtained an anti-XbmycAl antiserum are 
unclear. It could be that the rabbits were not injected enough times. Since 
the epitope I am interested in is so much smaller than the $ galactosidase 
moiety (which is an excellent antigen) rabbits may take longer time to produce 
a response also if the rabbit c-myc protein sequence is very similar to the 
Xenopus XbmycAl protein sequence this too may mean that it is less 
immunogenic. I would expect that the Xenopus sequence to be sufficiently 
different to be a good immunogen since good antisera to the closely related 
human c-myc protein has been raised in rabbits previously (Persson et a/1984, 
Ramsay, Evan and Bishop 1984). It may be that the XbmycAl carboxyl terminus 
is not large enough or not well exposed in the fusion protein to be available 
for immunisation, though a similar region in the protein was used to generate a 
human antisera (Persson et al 1984). The production of other fusion constructs 
might solve this problem. Another possibility is that I have generated 
anti-XbmycA1 antibodies but they are either not high titre or have a low 
avidity. Therefore if the western technique was used with greater sensitivity 
(e.g. using alkaline phosphatase or streptavidin amplification systems) it may 
then detect the XbmycA protein. Possibly immunoprecipitation instead of 
western blotting would detect the XbmycA protein but since the antisera were 
raised against denatured proteins I would expect western blotting to have 
worked well.
4.6 Discussion
In this chapter I described the succes^ul isolation of two different types of 
c-myc genes from X.borealis. The XbmycA gene appears to be the equivalent 
of c-myc in other species whereas the relationship of XbmycB to other myc 
genes is unclear although it is c-myc related at its 3'end. The X.borealis frogs 
are not genetically inbred therefore it is vital to obtain the complete coding 
sequence of XbmycA on a single clone incase genetic variation complicates 
sequence analysis. Indeed chapter 5 indicates the XbmycA clones I have
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obtained do differ in sequence which may be due to different alleles or due to 
different genes and will be discussed in chapter 5.
The southern analysis I describe suggests the genomic structure of XbmycA 
in X.borealis and X.laevismay be similar to other c-myc genes. This may imply 
that this kind of genomic structure is important for the regulation of this type 
of gene. Indeed an analysis of c-myc genes that have been altered in genetic 
structure by chromosomal translocations suggests the post-transcriptional 
stability of the mRNA is determined by the genomic organisation of the c-myc 
locus (Piechaczyk et al 1985, Eick et al 1985, Piechaczyk et al 1986). The 
genomic structure of XbmycA would become readily available by the isolation 
of a clone from a genomic library.
Interestingly it appears that X.tropicalis does not have an equivalent to 
XbmycB. This may point to an event creating a gene duplication in the 
X.borealis and X.laevis lineage which may have occurt«A as described in the 
previous chapter. Sequence analysis of XbmycB will show how similar the 
protein products of XbmycA and B are and will show if it is actually a 
functional gene. Understanding the relationship of these genes is important 
because if they are very similar then why have two genes evolved or if they 
are quite distinct then what is the functional basis for these differences. Also, 
since X.tropicalis develops in an apparently similar fashion to X.borealis and 
X.laevis, it is important to determine if both XbmycA and B are fully functional 
to help understand the selection pressure on genes apparently involved in cell 
division control. Both XbmycA and B give rise to similar sized transcripts 
which implies both genes are functional in transcription but XbmycB might not 
be as highly expressed as XbmycA. Sometimes these transcripts appear as 
doublets therefore it is necessary to see if both size classes come from the 
same gene with more than one promoter or from different genes and what 
factors govern their regulation. Assessment of the regulation of these genes 
will be difficult due to post-transcriptional controls apparently involved (see 
chapter 1).
XbmycA is expressed in many tissues in agreement with results on c-myc 
expression in other vertebrates (Stewart, Bellve and Leder 1984). The highest 
level of expression is in the ovary which is probably a reflection on storage of 
mRNA in the oocyte for embryogenesis or the extremely high levels of gene 
expression in these cells. Expression levels of c-myc are low in most other
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tissues which may reflect the fact that only a small number of cells in these 
tissues are actually dividing and expressing XbmycA in a cell cycle dependent 
manner. C-myc has been regarded as a cell-cycle "enabling" signal whose 
presence is required either continually or else during a sensitive temporal 
window to allow a cell to progress through the cell cycle (Evan et al 1986) and 
hence c-myc transcripts would only be present in dividing cells. The tissue 
specific expression of XbmycB remains to be determined.
XbmycA is made early in oogenesis and some of this maternal message is 
inherited by the dividing embryo. XbmycA is probably also required for the 
growth of the oocyte since its expression drops during oogenesis. It remains 
to be determined if XbmycA transcripts turns over or if it is made only once 
during oogenesis. If it was made only once then it would be of great interest 
to find what factors stabiW the message such that it can be inherited by the 
embryo. Many factors govern the maturation of stage VI oocytes into eggs. 
Progesterone is the in vivo signal and exposure to progesterone in vitro will 
also cause oocyte maturation (Wasserman, Houle and Samuel 1984). 
Interestingly another oncogene protein, the ha-ras protein, can induce 
maturation of Xenopus oocytes upon microinjection (Birchmeier, Broek and 
Wigler 1985). It would also be interesting to determine if high levels of 
XbmycA protein induce maturation thereby implying a role in signalling division 
control.
The amount of XbmycA maternal message inherited by the dividing embryo 
is just enough to last until the gene is transcriptiotv^N reactivated at stage 
11-12. This suggests that dividing cells in the embryo only require low 
amounts of the XbmycA product hinting at a role of XbmycA in the actual cell 
division process. If one could block the translation of XbmycA by the injection 
of antisense message then it would be exciting to see if the cells in the 
embryo are still competent to divide or if there are other determinants 
governing the decision to divide (antisera to XbmycA may also have to be 
injected to block the function of any maternal protein that is inherited). Since 
XbmycA mRNA is not detecVoioV^ accumulated soon after the midblastula 
transition when a general activation of RNA synthesis occurs (Newport and 
Kirschner 1982) then this supports the idea that dividing embryonic cells only 
require low amounts of c-myc protein.
The highest levels of XbmycA expression are at mid-late neurula stages
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20-24 which may imply a role in neural development. Experiments on 
dissected embryos suggest that XbmycA is expressed at similar levels in each 
piece analysed (head, gut and neural tube). This may be because there is a 
rapid burst of transcription to replace the XbmycA that was lost in earlier 
development and therefore XbmycA might not be involved in the processes of 
differentiation at these stages but rather in cell division. As the embryo grows 
older there does appear to be a greater level of XbmycA expression in the 
head piece hence it may be involved in the later differentiation of the brain.
C-myc RNA levels are increased during the differentiation of mouse Purkinje 
and granule cells in the brain (Ruppert, Goldowitz and Wille 1986) therefore this 
correlates with the localisation of XbmycA expression in the Xenopus head at 
stage 33/34. Purkinje cells have undergone their last cell division (Miale and 
Sidman 1961) hence this implies that c-myc may also be involved in 
differentiation as well as cell division. Indeed in neuronal-pheochromocytoma 
(PC12) and erythroleukemia tissue culture cells that have been induced to 
differentiate by NGF and DMSO respectively there is a transient increase in 
c-myc RNA levels before repression of c-myc RNA synthesis (Lachman and 
Skoultchi 1984, Curran and Morgan 1985). Therefore c-myc might be involved 
in signalling pathways that are involved in brain and erthyroid cell development. 
In situ hybridisation of XbmycA to early Xenopus embryos would provide a 
clear insight to the functions of c-myc in the differentiation of the brain and 
other tissues.
The isolation of a genomic clone of XbmycA would allow an analysis of the 
regulatory regions of the gene. Injection of plasmid constructs into Xenopus 
eggs would help to determine which sequences are responsible for the 
transcriptional activation of these genes at stage 11-12 and may help elucidate 
what factors are responsible for this. Expression of XbmycA under the control 
of other promoters that are differentially activated during development may 
help us to understand the role of XbmycA. For example by putting the XbmycA 
gene under control of the promoter for GS17 would see what effect the early 
transcriptional activoA\orv of XbmycA at gastrulation (stage 9) would have on 
the dividing embryo (Krieg and Melton 1985).
I have prelttv>ir\o.r>f evidence that XbmycB is expressed in a similar fashion to 
XbmycA though this needs further testing. If both genes appear to be 
regulated in the same manner then the question remains why both genes
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appear to be different from each other. It is possible that they both carry out 
similar functions but they may respond to slightly different stimuli in a large 
regulatory network. Possibly having two slightly different proteins makes them 
more sensitive to changes in enviroment than having only one protein hence 
growth control decisions can be accurately controlled.
The expression of XbmycA could be further analysed by obtaining 
antibodies to the protein. This would open up a whole series of experiment 
which would help us understand XbmycA function. The expression of myc 
protein could be followed during development, the localisation of protein within 
cells and embryos could be determined, the blocking of XbmycA function could 
be attempted, the isolation of XbmycA protein from cells would be possible 
and the isolation XbmycA complexes with other proteins and nucleic acids 
could be done as well as many other experiments.
I described my attempts to make antibodies to the XbmycA protein which 
were unsuccessful^ but other ways of detecting the Xenopus c-myc protein 
exist. For example it is quite possible that mouse or human an\\-c-myc 
antisera will react with the XbmycA protein indeed preliminary evidence 
suggests this may be the case (Persson et al 1984). Alternatively it is 
conceivable that an anti-peptide antiserum to a region that is conserved in all 
mammalian myc genes (c, N and L-myd) which has been prepared (Evan et al 
1986) will react with Xenopus myc proteins as this region is highly conserved 
in XbmycA (see chapter 5).
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CHAPTER 5
SEQUENCE ANALYSIS OF C-MYC RELATED CLONES FROM X.BOREALIS
5.1 Introduction
Chapters 3 and 4 describe evidence that the cDNA clones from X.borealis I 
have obtained are related to c-myc genes of other species. The best proof 
that these clones are c-myc related comes from sequence analysis described 
in this chapter. Sequencing these genes will provide a basis for determining 
which parts of the protein coding domain are conserved from species to 
species thereby implying these regions play an important functional role in the 
protein. Indeed two such domains have been previously defined in N-myc, 
L-myc and c-myc in a variety of species (Schwab et al 1983, Nau et al 1985, 
Schwab 1985, Van Beneden et al 1986). Comparison of the different clones 
with each other and with a X.laevis c-myc sequence which I recently obtained 
from M.King, Seattle may provide clues to the evolution of these sequences in 
Xenopus. Also having the sequence of these clones provides information that 
can be used in the design of future experiments.
5.2 XbmycA!
Initially part of the XbmycA! clone was sequenced to show it was c-myc 
related before going on to use it to isolate the other Xbmyc clones from my 
previtellogenic cDNA library. 500 bp of the 5' end of this clone were 
sequenced using the strategy shown in figure 5.1. Figure 5.2 shows the 
sequence determined from the XbmycAl clone and shows that it contains 301 
bp of coding sequence and therefore ~ 1.0kb of 3' non-coding sequence 
(although this remains to be proved conclusively for this clone).
To determine if the XbmycAl protein and nucleic acid sequences are 
related to the c-myc genes of other species they were compared to the 
chicken and human c-myc protein and nucleic acid sequences using the 
program BESTFIT Figure 5.3 shows the 100 carboxyl terminal amino acids 
encoded by this clone are highly homologous to the respective region in the 
chicken and human sequences. The human and XbmycAl sequences are -71% 
homologous and the chicken and XbmycAl sequences are ~79% homologous 
at the amino acid level with no insertions or deletions. Of 29 substitutions
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between the human and XbmycAl sequences 11 are conservative changes and 
of 21 substitutions between the chicken and XbmycAl sequences 14 are 
conservative changes (this assumes amino acids are similar as defined by the 
UWGCG programs where P,A,G,S,T are neutral, weakly hydrophobic; Q,N,E,D,B,Z 
are hydrophilic, acid amine; H,K,R are hydrophilic, basic; L,I,V,M are hydrophobic; 
F,Y,W hydrophobic aromatic and C is cross-link forming).
When the nucleic acid sequence of XbmycAl is compared to the human 
and chicken sequences as shown in figure 5.4 and 5.5 they are also found to 
be highly related especially over the coding regions. The human and XbmycAl 
sequences are 68% homologous over the first 304 by of coding sequence (i.e. 
to the stop codon). This homology breaks down after the stop codon although 
they are still related there are multiple deletions or insertions in the sequences. 
Similarly the chicken and XbmycAl sequences are 68% homologous over the 
coding region and the non-coding region is less homologous due to multiple 
insertions and deletions. The non-coding region of XbmycAl is slighHy more 
related to that of chickens than humans since it has 126 matches compared 
with 104 matches over this region.
From the above data I was confident that I had isolated a portion of a bona 
fide c-myc gene from X.borealis which seems more related to chicken c-myc 
than human c-myc. As described in chapter 4 this clone was used to isolate 
all the other Xbmyc clones I obtained in this study hence it was highly likely 
that they would also be c-myc related. The sequence analysis of XbmycA2 and 
3 is described in the following sections. No sequence of the XbmycB clones 
has been determined as of yet.
5.3 XbmycA2 and XbmycAS
Sequencing strategies for XbmycA2 and 3 are shown in figure 5.1. An 
oligonucleotide was used to help sequence XbmycA2 on both strands. Note 
that the sequencing does not span the internal EcoRI site of XbmycA2 
therefore the presence of a small EcoRI fragment cannot be ruled out. 
Sequences of XbmycA2 and 3 and their putative translation products are 
presented in figures 5.6 and 5.7.
The internal EcoRI site of XbmycA2 may be due to a polymorphism at this 
locus or due to a cloning artifact maybe created during reverse transcription. 
Since both fragments of XbmycA2 detect the same bands on southern blots
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(figure 4.3) and XbmycAl does not have an internal EcoRI site then this 
suggests that the internal XbmycA2 site is due to a cloning artifact. Evidence 
against this being a cloning artifact is that XbmycA2 and XbmycAl were 
isolated from different libraries and that each library was made from many 
frogs. Support for the internal EcoRI site in XbmycA2 being a polymorphism 
also comes from the fact XbmycA4 has an internal EcoRI site and that only a 
single frog was used in the southern analysis (remember the frogs are not 
inbred). Further southern analysis on different frogs from different matings 
would help resolve this problem.
Both XbmycAl and 3 DNA sequences overlap the XbmycA2 DNA sequence 
therefore they were compared to see if they had the same DNA sequences 
using the BESTFIT program. Figures 5.8 and 5.9 show that the regions of 
overlap are highly related but they are different. Comparing XbmycAl with 
XbmycA2 shows thttfthe coding regions differ by 7.2% but the non-coding 
regions differ by 13.8% including 4 small insertions. XbmycAS and 2 only 
overlap in coding sequences and have a sequence difference of 7.4% including 
a 6 bp insertion. Figure 5.10 shows that the putative protein coding sequences 
of XbmycA! and 2. have 4% difference whereas the XbmycAS and 2 protein 
coding sequences have 6.6% difference including an insertion of two amino 
acids. Some of the nucleotide changes therefore must be silent and also 3 of 
4 amino acid changes between XbmycAl and 2 and 3 of 6 amino acid changes 
between XbmycAS and 2 are conservative substitutions.
From the above data it is obvious that these clones do not arise from the 
same gene. For XbmycAl and 2 this might be partly explained by the fact that 
they come from different libraries and that each library was made from frogs 
from different matings. It is not so easy to explain the differences between 
XbmycAS and 2 as they were isolated from the same library. The library that 
these clones came from was made using the RNA of many frogs which were 
from the same mating. Considering that X.borealis is tetraploid and assuming 
that XbmycA is a single copy gene then it is possible that there will be a 
maximum of 8 different kinds of XbmycA gene in my library. I think it is 
unlikely that XbmycAS and 2 are different alleles from the same frog since a 
nucleic acid difference of 6.6% is quite a high value for pairs of alleles.
Another possibility exists that there could be two XbmycA genes. Indeed 
the southern data presented in the previous chapter suggests there may be
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two highly related XbmycA genes although their genomic organisation remains 
to be resolved. The sequence divergence between XbmycA2 and 3 is 6.6% 
which is similar to the sequence divergence between two A type vitellogenin 
(A1,A2) and the two B type vitellogenin genes (B1,B2) in X.laevis which is -7% 
for both types (Wahli and Ryffel 1985) hence it is possible that there are two 
highly related XbmycA genes. Isolation of genomic clones and further 
sequence and southern analysis should resolve how many XbmycA genes exist.
5.4 XbmycA and XlmycA
Recently I was very kindly send the nucleic acid sequence of a X.laevis 
c-myc cDNA clone (which I have named XlmycA) from M.King, Seattle. I have 
used the program BESTFIT to compare this sequence with the XbmycA2 and 3. 
To use the BESTFIT program I had to split the sequences into small pieces 
before the comparison since the program can only compare two 1000 bp 
sequences at the most. The combined data of these comparisons is shown in 
figure 5.11 and 5.12.
The nucleic acid sequences of XbmycAS and XlmycA show 6.6% divergence 
over the region they overlap. Homology between these two sequences breaks 
down rapidly upstream of the initiating methionine codon. Over the coding 
region XbmycA2 and XlmycA show 8.2% divergence and over the non-coding 
region they show 14.1% divergence which has multiple insertions and 
deletions. Therefore this analysis shows that the X.borealis and X.laevis c-myc 
genes are highly related especially across the coding regions. The 3' 
non-coding regions are also highly conserved but not as much as the coding 
regions. It is interesting that the 3' non-coding regions are so highly 
conserved since it is generally thought that non-coding sequences evolve 
rapidly accumulating many changes (this appears to be true of the 5' 
non-coding sequences) therefore this may mean these sequences are 
important in the regulation of these genes in this system. It is also interesting 
that the divergence between the XbmycA type genes and the XlmycA gene is 
as high as the divergence between the XbmycA type genes. A result which 
might indicate that a XbmycA gene duplication event took place around the 
same time as the divergence of the X.borealis and X.laevis lineages. This also 
suggests, because the sequence divergence is small, that this event was 
relatively recent, estimated to by -30MY by Wahli and Ryffel, 1985.
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Figure 5.13 shows that the putative translation products of XbmycA2 and 3 
and XlmycA are very highly related. The XbmycAS and XlmycA peptide 
sequences differ by 5.2% including a 4 amino acid insertion in XlmycA. The 
XbmycAZ and XlmycA peptide sequences have 6.2% divergence with a deletion 
of a single amino acid in XbmycA2. Again many of the changes are 
conservative substitutions (3 from 11 changes between XbmycA2 and XlmycA 
and 7 from 19 changes between XbmycAS and XlmycA). Hence these 
sequences are very closely related with the divergence between species similar 
to that within species. Therefore this also supports the X.borealis and X.laevis 
lineages arising from the same event and that this event was relatively recent.
The extra 4 amino acids in the XlmycA sequence compared with the 
XbmycA3 sequence are right at the N-terminus such that the initiating 
methionine of XbmycA3 matches a methionine residue at amino acid posiVvoA 5 
of XlmycA. It is not known which methionine is used in vivo by the XlmycA 
mRNA. Computer analysis of many eukaryoVVc mRNAs suggests the 5 proximal 
AUG triplet generally serves as the intiation codon and a consensus of CC A/G 
CCAUG has been proposed in which the A 3 bp upstream of the AUG is very 
highly conserved (Kozak 1984). If true, this might suggest that the second in 
frame AUG of XlmycA serves as the initiating codon because only the second 
AUG has an A 3 bp upstream. Note the initiating AUG in XbmycAS also has an 
A at a similar position. See figure (5.12) for the positions of the initiation AUG 
codons.
5.5 Features of XbmycA Nucleic Acid Sequences 
5.5.1 Poly(A) addition site
Most eukaryotic mRNAs are post-transcriptionally modified by the addition 
of a poly(A) tail of 100-250 nucleotides to their 3' ends by the action of a 
poly(A) polymerase. Part of the recognition sequence for this process has been 
defined as AAUAAA which lies about 20 nucleotides from the 3 end of the 
mRNA and has been found in most poly(A) containing mRNAs (Proudfoot and 
Brownlee 1976). The XbmycA2 sequence contains one copy of this sequence 
which lies 16 nucleotides from the 3'end of the mRNA (figure 5.6); also XlmycA 
has one such sequence 19 nucleotides from the 3 end of the mRNA. 
Therefore it seems that the XbmycA gene(s) have structures that typify them 
as normal eukaryotic mRNAs.
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5.5.2 Rapid degradation signals
Very recently it has been reported that the mRNA of transiently expressed 
genes contain a conserved a AU-rich sequence in their 3' untranslated regions 
(Shaw and Kamen 1986). The sequence AUUUA surrounded by AU-rich 
nucleotides has been defined as a possible sequence that mediates selective 
mRNA degradation and is found in the 3' untranslated regions of several 
lymphokine and cellular oncogene mRIMAs. As described in chapter 1 c-myc 
mRNA in a variety of cell types is highly unstable with a half life of 20-30 
minutes (Dani et al 1984, Rabbitts et al 1985). Shaw and Kamen note that 
c-myc mRNA does contain such an AUUUA consensus in an AU-rich region 
which may reflect the Instability of c-myc
It would appear that the X.borealis c-myc mRNA during embryogenesis has 
a longer half life than mammalian c-myc mRNAs (see chapter 4) but this may 
reflect the temperature difference between organisms and also the mode of 
embryogenesis that Xenopus exhibits. Also the X.borealis c-myc mRNA might 
be more stable during oogenesis (see chapter 6). Interestingly I have found six 
copies of the AUUUA consensus in the 3' untranslated region of XbmycA2 
(figure 5.6). All of these AUUUA sequences lie in relatively AU-rich regions. 
Therefore it seems that the X.borealis c-myc gene may contain signals that 
make the mRNA potentially highly unstable. The actual half life of c-myc 
mRNA in Xenopus remains to be determined both in embryonic and somatic 
cells. Note that the XlmycA mRNA also has six AUUUA sequences in its 3' 
untranslated region.
5.5.3 Comparison with other c-myc sequences
To compare the XbmycA sequences with the c-myc sequences from other 
species the programs COMPARE and DOTPLOT were used to provide a 
graphical representation of the homologies between the sequences. The 
XbmycA2 and 3 sequences were assembled together to form one XbmycA 
sequence (bases 1-564 of XbmycAS and bases 1-2011 of XbmycA2) to help 
simplify the analysis. This is justified on the basis that because the differences 
between XbmycA2 and 3 are so small (where they overlap) then they would 
have little effect when comparing the large differences that occur between 
species. I have used the COMPARE and DOTPLOT programs rather than the 
BESTFIT program multiple times because it is much easier to obtain an overall
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impression of the divergence between sequences using COMPARE and 
DOTPLOT especially since the sequences are so large. Also COMAPRE and 
DOTPLOT may show regions that are repeated within sequences and may show 
homologies that are present in regions such as introns. For this analysis I 
have used trout, chicken and human c-myc sequences (Van Beneden et 5/1986, 
Waston et al 1983, Shih et al 1984, Colby et al 1983, Gazin et al 1984) to 
compare with the XbmycA sequence. No extra information is gained by using 
the mouse and viral c-myc sequences since they are so similar to human and 
chicken c-myc sequences respectively. Each comparison was performed using 
a window of 21 and a stringency of 14.
Figures 5.14, 5.15 and 5.16 show the output generated by comparing 
XbmycA with human, chicken and trout c-myc sequences respectively. Where 
known the mRNA start sites, introns, exons and mRNA finish sites are shown 
on the diagram. From all these diagrams it can be seen that the XbmycA 
coding sequences are highly related to the c-myc coding sequences of other 
species. To obtain a rough estimate of the extent of homology between each 
sequence the length of the breaks in the diagonal that is plotted where the 
homologies occurs was divided by the total length of the diagonal. This only 
provides a rough guide to the divergence between the two sequences as a 
window of 21 was used with a stringency of 14. Table 5.1 summarises the 
results of this comparison and the data of Van Beneden et al 1986 for the trout 
vs human and chicken vs human comparisons and indicates that the way I 
have measured the divergence between two sequences is, as expected, an 
overestimate. So I have corrected all the values by multiplying by a factor of 
0.82 which accounts for the average discrepancy between the values measured 
from the DOTPLOT figures and the data of Van Beneden et al 1986. Again I 
must emphasise this is only an estimate of divergence and comparisons 
between amino acid sequences discussed later provide better estimates of this 
parameter.
The first point to note from this comparison is that the c-myc genes from 
many species are highly homologous which is extremely strong evidence that 
these genes play an important function that has been evolutionary conserved. 
Secondly the third exon shows the highest conservation in all comparisons and 
hence may be extremely important for c-myc function. Indeed the third exon 
protein sequences are implicated in DNA binding as it contains far more basic 
amino acids than the second exon protein sequences (Persson and Leder 1984).
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XbmycA vs XbmycA vs XbmycA vs Trout vs Chicken vs 




















Homologies between c-myc nucleic acid sequences using the output from 
figure 5.14, 5.15 and 5.16. * Data from Van Beneden et al 1986. Figures in 
brackets are values corrected for the discrepencies between the values 
obtained from dotplots and the values from Van Beneden et al 1986. All 
figures are the percentage homology between the two sequences under 
comparison.
This analysis also suggests that the Xenopus c-myc nucleic acid sequence 
is more closely related to the chicken and human c-myc nucleic acid 
sequences than to the trout c-myc nucleic acid sequence. It is not really 
possible to derive a phylogeny of the various species using the divergence, as 
derived above, of the c-myc genes but one can say that the Xenopus sequence 
is apparently more related to mammalian and avian c-myc sequences than fish 
c-myc sequences.
The intron/exon boundaries of the human, chicken and trout c-myc genes 
are clearly delimited as shown in figures 5.14, 5.15 and 5.16. It is interesting to 
note close to the end of exon 2 of the human and chicken c-myc genes and 
the presumptive second exon of the trout c-myc gene that the sequence of 
XbmycA diverges significantly from the other sequences. Also it is of interest 
that at the beginning of the third exon that there appears to be a cluster of 
short simple repeats which might suggest slippage-like mechanisms are a 
source of genetic variation at this position (Tautz, Trick and Dover 1986). It 
may also be that both the above points suggest that the protein sequences 
encoded by each exon form two different domains of the protein.
It would appear from figures 5.14, 5.15 and 5.16 that the 3' non-coding 
region of XbmycA is related most closely of the 3'non-coding regions of 
chickens but it has diverged by the presence of multiple insertions and 
deletions. The human and trout c-myc 3' non-coding sequences are also 
related to the same region of XbmycA but it seems they have diverged 
significantly. The XbmycA sequence has a 3"non-coding sequence of ~ 1.0kb 
which is significantly longer than the same region in other c-myc genes (-200 
bp). It is not clear what this increase in size of the 3' non-coding sequence of 
XbmycA means but it might be involved in the regulation of stability of c-myc 
mRNA in oocytes compared with somatic cells if indeed any difference does 
exist.
From figure 5.14, 5.15 and 5.16 it can be seen that the 5'non-coding 
sequences of XbmycA are unrelated to any other c-myc 5' non-coding 
sequences. Note size estimation of XbmycA mRNA by northern blotting in 
chapter 4 suggested that the XbmycA sequence is lacking ~400bp of 5' 
sequence information therefore it is possible that within this missing region the 
XbmycA gene does have 5' sequence information related to that of other 
c-myc genes. The c-myc genes of humans, mice and chickens contain an
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upstream exon (exon 1) which does not contribute to the coding information of 
the c-myc protein but may be involved in the regulation of the c-myc genes 
(see chapter 1, Bernard et al 1983, Gazin et al 1984, Shih et al 1984). This exon 
is ~76% homologous between humans and mice but not related at all to any 
chicken sequences (Bernard et al 1983, Shih et al 1984) therefore it could be 
possible that XbmycA has three exons but the first exon is completely 
unrelated to any other sequences (indeed a WORDSEARCH of the upstream 
sequence of XbmycA on the GENBANK and EMBL data bases finds no 
significantly related sequences). It has been reported that the human c-myc 
first exon sequence has a provocative open reading frame which could encode 
a protein of 30KD (Gazin et a/1984). Whether this frame is translated or not in 
vivo remains to be determined but is is possible that translation of this exon 
modulates the translation of exon 2 and 3. Interestingly the first —161 bp of 
the XbmycA sequence is an open reading frame as shown in figure 5.17 which 
shows all possible open reading frames (note the large open reading frame 
which encodes the putative c-myc protein). It remains to be determined if the 
5'open reading frame extends further upstream. Although it is not clear how 
the c-myc gene is regulated these results might suggest that a common 
mechanism exists for the regulation of the c-myc genes in many species.
5.6 Features of XbmycA Protein Sequences
5.6.1 Comparison with other c-myc protein sequences
The putative translation products of the XbmycA sequences were compared 
with the putative translation products of human, mouse, chicken, viral, trout and 
XlmycA c-myc sequences by using the program GAP reiterativly with the 
command line option out until no further gaps are introduced then using the 
program PRETTY to align the sequences. The alignment was then manually 
edited to increase the matches. Results of such a comparison are shown in 
figure 5.18, note that a consensus has been derived using a plurality of 5, to 
highlight the conservation between sequences (note this will be slightly biased 
where the XbmycA sequences overlap).
It can be seen from figure 5.18 that all the c-myc protein sequences are 
highly related to each other and often at positions of difference the changes 
are conservative. Residues 379-449 on this figure show the highest 
conservation between all the c-myc sequences and contains 26% basic amino
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acids which might reflect a DNA binding function. Residues 450-491 are also 
rich in basic amino acid: but there are many conservative changes between the 
protein sequences. Other regions are also very highly conserved, for example, 
the regions which span the proposed myc boxes (Schwab et al 1983, Nau et al 
1985, Van Beneden et al 1986) are also very homologous (this is discussed 
further in section 5.7).
It is of interest that each c-myc sequence has inserted regions that are 
unique to themselves in the second exon. For example residues 82-99 and 
242-262 are unique to the mammalian c-myc sequences and residues 174-193 
are specific for the chicken, viral and Xenopus c-myc sequences. The trout 
c-myc sequence also has residues that are specific for it alone at positions 
210-216 (Van Beneden et al 1986) but the alignment in figure 5.18 does not 
show this well. Indeed this region is actually specific for each type of c-myc 
sequence i.e. either mammalian, avian, amphibian or fish c-myc sequences are 
unique at this position. Other than these insertions and discounting other 
small insertions and deletions it appears that the c-myc coding sequences 
have gradually evolved by the accumulative acceptance of point mutations.
On comparing each amino acid sequence using the program GAP a value of 
the percentage similarity is generated which I have used to estimated the 
sequence divergence between c-myc sequences and is shown in table 5.2. 
These values agree quite closely with the data of Van Beneden et al 1986 
therefore this analysis may give clues to the evolution of the c-myc protein 
sequences. In this analysis I have used the assembled XbmycA protein 
sequence for reasons outlined earlier.
As expected (and as described earlier) the X.borealis c-myc protein 
sequence is most closely related to the X.laevis c-myc protein sequence again 
suggesting both lineages arose from the same, relatively recent, event. The 
XbmycA sequence is next most closely related to the chicken, human, mouse 
and viral c-myc sequences and is least related to the trout c-myc sequence. 
Since the divergence between the XbmycA and human, XbmycA and chicken 
and the human and chicken comparisons are similar, each protein may have 
large blocks of homology interspersed with regions that are unique and free to 
mutate. As discussed earlier this is apparently the case. This might suggest 
that all the c-myc proteins play a common and important function in each 
species.
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XbmycA vs human 
XbmycA vs mouse 
XbmycA vs chicken 
XbmycA vs viral 

















Homologies between c-myc protein sequences showing the percentage 
similarity generated from the program gap when two sequences are aligned. 
Figures in brackets refer to the data of Van Beneden et al 1986.
5.6.2 Nuclear location signals
The c-myc protein has been shown to localise to the cell nucleus though it 
is not clear if it is associated with the nuclear matrix or not (Persson and Leder 
1984, Ramsay, Evan and Bishop 1984, Eisenman et al 1985, Evan et al 1986). 
C-myc protein made in £.co//and microinjected into fibroblasts localises to the 
nucleus (Sullivan et al 1986). Therefore it is likely that the c-myc protein 
sequence contains motifs that localise it to the nucleus. The nuclear transport 
signal of SV40 large T antigen comprises of a highly basic stretch of amino 
acids (Pro-Lys-Lys-Lys-Arg-Lys-Val) with an absolute requirement for a 
positive charge at the second lysine (Smith et al 1985). Indeed a carrier 
protein cross-linked to a synthetic peptide with the above sequence when 
microinjected into cells transports to the nucleus (Lanford, Kanda and Kennedy 
1986).
A computer search of sequences related to the SV40 T antigen nuclear 
location signal has revealed this sequence may act as a nuclear location signal 
in other proteins including the chicken c-myc sequence which has the related 
sequence Lys-Glu-Gln-Leu-Arg-Arg-Arg-Arg-Glu (Smith et al 1985). It is 
questionable whether this is a true nuclear location signal because it does not 
contain a Pro or Gly preceding the basic amino acids but it is interesting that 
this sequence is partially conserved in the mouse and human p53 protein 
sequences which are also known to be located in the nucleus (Crawford 1985). 
I have analysed Xenopus c-myc protein sequence to see if it contains a 
proposed nuclear location signal. Figure 5.18 (marked NL1) shows the location 
of such a sequence in the Xenopus c-myc protein. Crawford suggests two 
other areas of the c-myc protein might be important in c-myc function 
(nuclear location?) because of the conservation of some amino acids between 
the human and mouse p53, adenovirus Ela and mouse c-myc proteins and 
since these are all located in the nucleus (Crawford 1985). These are marked 
NL2 and NL3 on figure 5.18 and lie in areas of good conservation between all 
the c-myc proteins with only a few conservative changes hence these could be 
important for the nuclear location of c-myc.
5.6.3 Rapid degradation signals
The human c-myc protein has a short half life of ~30 minutes in cells 
(Ramsay, Evan and Bishop 1984, Rabbitts et al 1985) which may indicate that
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the c-myc protein level is capable of being rapidly modulated in normal cells. 
Recently it has been reported that there are amino acid sequences common to 
rapidly degraded proteins and the human c-myc protein has such sequences 
(Rogers, Wells and Rechsteiner 1986). The amino acid sequences that signify 
rapid degradation are rich in proline, glutamic acid, serine and threonine (PEST) 
residues and these regions begin and end with positively charged residues, 
have no internal basic amino acids and tend to have clustering of negatively 
charged residues. Also the 'PEST stretches seems to be extre.^e\>y 
hydrophilic when analysed by hydropathy plots. In figure 5.18 I have underlined 
the 'PEST' regions that have been identified in the human c-myc protein (RD 
1-7). Many of the regions are quite highly conserved between all the c-myc 
proteins which might suggest the proteins are degraded in a similar manner.
5.6.4 The myc boxes
Sequence analysis of the c-myc, N-myc and L-myc genes has revealed that 
two short regions are highly conserved between all the myc genes (Schwab et 
al 1983, Nau et al 1985, Schwoio 1985). These so-called myc boxes are also 
conserved in the c-myc genes from different species (Van Beneden et al 1986 
and figure 5.18). This suggests that the protein domains encoded by the myc 
boxes serve an important conserved function between all myc genes. It is 
interesting that the A box overlaps one of the proposed rapid degradation 
signals described earlier which may hint at the function of these domains since 
the N-myc protein also has a short half life (Evan et al 1986).
It would be expected from the above data that the Xenopus c-myc proteins 
would also have highly conserved myc boxes. Figure 5.18 shows that for all 
the c-myc proteins that the A box has only 1 deviation in the viral sequence, 
and that for the B box there is 1 deviation in the mammalian, trout and 
Xenopus c-myc sequences. Figure 5.19 shows that the consensus sequence 
for the proposed A box c-myc sequence is ~95% and ~79% homologous to 
the proposed N-myc and L-myc A box sequences respectively and that the 
consensus sequence for the proposed B box c-myc sequence is ~71% and 
79% homologous to the proposed N-myc and L-myc B box sequences. Hence 
this shows there is strong evolutionary conservation of this protein domain 
which is likely to have a common function in all the c-myc proteins. Note that 
for the c-myc protein sequences alone there are other areas in the protein that 
have greater conservation than the myc box sequences, for example residues
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391-449 are very highly conserved (figure 5.19), which probably points to a 
very important domain in the c-myc protein unique for its function.
5.7 Discussion
In this chapter I describe that the DNA and putative protein sequences of 
the cDNA clones I have obtained from X.borealis cDNA libraries are almost 
definitely portions of c-myc genes from X.borealis. The initial clone I obtained, 
XbmycAl, is strongly homologous to the c-myc genes from other species and 
was used to isolate XbmycA2 and 3 which are also very homologous to other 
c-myc genes. Chapter 4 describes reasons why I might not have isolated full 
length cDNA clones but XbmycA2 and 3 do overlap to give a putative full 
length protein product although they are encoded by two slightly different 
genes. Since the XbmycA2 and 3 DNA and putative protein sequences are so 
similar to the X.laevis and other c-myc DNA and putative protein sequences it 
is likely that the full length X.borealis c-myc gene will have a coding sequence 
similar to the assembled XbmycA2 and 3 sequences though it is difficult to say 
if the non-coding regions will be similar (note the 5' region of XbmycAS is not 
so homologous to the corresponding region of XlmycA). If the divergence 
between XbmycA2 and 3 is as high as ~6.6% at the protein level then this 
raises the possibility that there are two very similar c-myc genes which are 
not alleles. Such a situation might reflect the tetraploid nature of the 
X.borealis genome or it might reflect an extended function of c-myc in 
Xenopus which may have evolved a requirement for two different protein 
products. It is interesting that in humans there are multiple forms of c-myc 
proteins but these are thought to involve post-translational modifications 
(Ramsay, Evan and Bishop 1984, Persson et al 1984, Persson et al 1986), 
however maybe there are as yet undiscovered c-myc genes in this system.
When the X.borealis c-myc DNA and putative protein sequences are 
compared with other available c-myc sec^et\<-e,s it is found they are highly 
conserved over the coding sequences. The X.borealis and X.laevis genes and 
protein are greater than 90% homologous showing that both species recently 
evolved from the same common ancestor. Compared with the other c-myc 
genes the X.borealis c-myc DNA and protein sequences are about 60 and 67% 
homologous respectively with the trout c-myc sequences being slightly less 
homologous. This demonstrates the existence of a conserved gene product 
which spans greater than 400 million years of evolutionary time and allows a
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confident extrapolation of the results obtained with Xenopus to mammals. 
Again such conservation implies the c-myc gene plays an important role in cell 
function. Some regions of extreme conservation exist between many kinds of 
myc proteins (for example the myc boxes) which is probably due to some 
common function between all the proteins. It is interesting that myc box A 
overlaps a potential sequence for rapid degradation and both c-myc and 
N-myc are rapidly degraded proteins (Evan et al 1986). Probably the diversity 
between the many different kinds of myc proteins arose through divergent 
evolution from a single progenitor gene, to those seen today. Therefore it is 
not surprising that areas of good conservation can be found.
Comparing the X.borealis c-myc non-coding DNA sequences with other 
c-myc non-coding sequences shows they are much more diverged than the 
coding regions with many insertions or deletions and substitutions. The 
highest conservation is between the X.borealis and X.laevis sequences but even 
in these closely related species the non-coding regions have diverged hence 
there may be less selection pressure to maintain the (probably) untranslated 
sequences. This might suggest that the non-coding sequences are not 
important for regulation of the c-myc gene. Sequence analysis of genomic 
c-myc clones from X.borealis would help in determining how the gene is 
regulated and whether it has features upstream of transcription initiation in 
common with other c-myc genes. It would be extremely interesting to see if 
the stability of c-/7?yc mRNA in Xenopus is similar in oocytes and somatic cells. 
If the oocyte c-myc mRNA is more stable it may mean that specific proteins 
interact with and control the degradation of the c-myc message. A class of 
poly(A) + mRNA binding proteins has been shown to exist in oocytes 
(Darnborough and Ford 1981) which may provide stabilising functions for 
mRNAs. Also it will be interesting to determine whether the putative rapid 
degradation signals of the c-myc mRNA play a role in the stability of the 
message in both oocytes and somatic cells. Conservation of a polyadenylation 
signal in the X.borealis DNA sequence suggests that 3' processing of the 
c-myc mRNA is similar in many systems. It is not surprising that a 
polyadenlyation signal was found since the clones I isolated were from a cDNA 
library and that most poly(A) containing mRNAs have such a signal.
As described the X.borealis protein sequences are highly conserved. The 
probable X.borealis protein would have roughly 419 amino acids with a 
molecular weight of ~47.5kD (taken from the assembled XbmycA2 and 3
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sequences). The human c-myc protein is a phosphoprotein and would have a 
molecular weight of ~48kD but has at least two forms of ~62 and 66kD when 
analysed on SDS gels (Ramsay, Evan and Bishop 1984). It would be interesting 
to see if the Xenopus protein is also a phosphoprotein and whether it also runs 
anomalously on SDS gels.
Like other c-myc proteins the Xenopus c-myc proteins are rich in basic 
amino acids in the carboxyl half of the protein. This region of the protein 
spans the supposed DNA binding domain of myc proteins (Persson and Leder 
1984). Indeed deletions of portions of this domain in v-myc fail to bind DNA 
but still localise to the nucleus and have a reduced capacity to transform 
macrophages but not fibroblasts when incorporated into MC29 virus (Enritto 
and Hayman 1985). This may suggest myc proteins have more than one 
function some of which require DNA binding and others do not. Interestingly 
these deletions do not disrupt the potential nuclear location signals of the 
proteins.
The identification of potential nuclear location signals and rapid degradation 
signals in the X.borealis c-myc proteins provides a starting point in testing 
their function directly. Since the c-myc protein could be made in E.coli with 
various mutations of these signals, then it is a relatively simple matter to 
microinject a Xenopus oocyte and analyse the effect of these mutations with 
the availability of a good antiserum. If more sophisticated apparatus was 
available then injection of oocyte and somatic cells could be compared to see, 
for example, if there are factors which stabilise c-myc protein in the oocyte. 
Hence powerful analysis of c-myc protein function can be carried out quite 































































































































































































































































































































Sequencing strategy of the XbmycA clones. Sequences were determined by the 
dideoxynucleotide sequencing method of Sanger as described in chapter 2. 
Both strands were sequenced as indicated by arrowheads, the dotted arrow 
refers to the sequence determined using an oligonucleotide primer as 
described in chapter 2. Six base pair recognition restriction enzymes used for 
cloning into M13 vectors are shown. R = Ecorl, Sm = Smal, P = Pstl, B = Bgl2, 
Sa = Sad, Sp = Sphl, D = Oral, Sc = Seal and H = Hind3 All sizes are in 
kilobase pairs.
XBMYCA1 DNA SEQUENCE AND PROTEIN TRANSLATION
CCGCAAGTGCGCCAGTCCCAGGTCCTCTGATTCCGAGGAGAACGACAAGAGGAAGACGCA























361 ———————— + ———————— + ———————— + ———————— + ————————————————— + 420
GCTCTGATGTTTCGACTTAAACATCTTGTACCTGTTGACGTACGTCTACTAAAGTGTTGA
ACACAACCTTGGCTTGGTCTCAAACAGATTCTGCCAGCACCTTAAAACTGCCTCAATACT






XbmycAl DNA sequence and putative protein translation. The potential stop 
codon is boxed.
COMPARISON OF XBMYCA1 AND HUMAN C-MYC PROTEIN SEQUENCES
1 RKCASPRSSDSEENDKRKTHNVLERQRRNELKLSFFALRDQVPEVANNEK 50
III MINI III II Illlllllimil MINIM II III!
340 RKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEK 389
• • • *
51 APKVVILKKATEYAISLQEDERRLIRETEQLKFRKEQLKQRLQQLRN 97
Mlllllllll I I I I II I II MM I MM
390 APKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRN 436
COMPARISON OF XBMYCA1 AND CHICKEN C-MYC PROTEIN SEQUENCES
1 RKCASPRSSDSEENDKRKTHNVLERQRRNELKLSFFALRDQVPEVANNEK 50
Ml Ml MIIIIMI MMMMMMIIMMIMM MUM
317 RKCSSPRTSDSEENDKRRTHNVLERQRRNELKLSFFALRDQIPEVANNEK 366
• • • •
51 APKVVILKKATEYAISLQEDERRLIRETEQLKFRKEQLKQRLQQLRN 97




A: Comparison of XbmycAl and human c-myc protein sequences using the 
program BESTFIT with a gap weight of 5.0 and a length weight of 0.3. The top 
sequence is XbmycAl and the lower sequence is human c-myc. The human 
c-myc sequence is from a translation of the human c-myc DNA sequence 
given in the GENBANK database release 40.0. % similarity = 73.196, quality = 
68.4 and quality ratio = 0.705.
B: Comparison of XbmycAl and chicken c-myc protein sequence^ using the 
program BESTFIT with a gap weight of 5.0 and a length weight of 0.3. The top 
sequence is XbmycAl and the lower sequence is chicken c-myc. The chicken 
c-myc sequence is from a translation of the chicken c-myc DNA sequence 
given in the GENBANK database release 40.0. % similarity = 82.474, quality = 
78.3 and quality ratio = 0.807.
COMPARISON OF XBMYCA1 AND HUMAN C-MYC DNA SEQUENCES
1 CCGCAAGTGCGCCAGTCCCAGGTCCTCTGATTCCGAGGAGAACGACAAGA 50
Ml II III MM Illllllllll II MINIUM I Mill
1587 CCGAAAATGCACCAGCCCCAGGTCCTCGGACACCGAGGAGAATGTCAAGA 1636
• • • » •
51 GGAAGACGCACAACGTTCTGGAGCGTCAGAGGCGGAACGAGCTCAAGTTG 100
M II Illlllll MINI Illlll MINIMI! II I
1637 GGCGAACACACAACGTCTTGGAGCGCCAGAGGAGGAACGAGCTAAAACGG 1686
. * • • •
101 AGTTTTTTCGCCTTGCGCGATCAGGTACCGGAGGTGGCGAACAACGAGAA 150
M Mill III MM II Ml I Illlll III Mill II II
1687 AGCTTTTTTGCCCTGCGTGACCAGATCCCGGAGTTGGAAAACAATGAAAA 1736
• • t • •
151 AGCCCCCAAAGTCGTCATCCTCAAAAAGGCAACGGAATACGCCATTTCTC 200
IMMMI II II Mill Mill II M I MM I I M
1737 GGCCCCCAAGGTAGTTATCCTTAAAAAAGCCACAGCATACATCCTGTCCG 1786
• • • * •
201 TGCAGGAGGATGAGCGACGGCTCATACGTGAAACAGAACAGTTAAAGTTC 250
MM II MM I Illlll MM II III I
1787 TCCAAGCAGAGGAGCAAAAGCTCATTTCTGAAGAGGACTTGTTGCGGAAA 1836
• • • • •
251 AGGAAAGAGCAGTTGAAACAGAGACTCCAACAGCTAAGGAACTTGGTTGT 300
I Ml Illllllllll I Ml IMIIIM Illlll II
1837 CGACGAGAACAGTTGAAACACAAACTTGAACAGCTACGGAACTCTTGTGC 1886
• • • • •
301 CfTA/JlTCA ........ TAAACACTTTATTATAAACTGTTGACAGTCTATA 342
Ml I MM II M III I
1887 GtTA^GGAAAAGTAAGGAAAACGATTCCTTCTAAC...............A 1921
343 TCAAGGTTGTCTCTTCCTCGAGACTACAAAGCTGAATTTGTAGAACATGG 392
M II I Ml II MM MM
1922 GAAATGT. ....... .CCTGAGCAATCACCTATGAACTTGT........T 1954
393 ACAACTGCATG..CAGATGATTTCACAACTACACAACCTTGGCTTGGTCT 440
Ml Illlll M III MM MIMMMMM MM
1955 TCAAATGCATGATCAAATG......CAACCTCACAACCTTGGCTGAGTCT 1998
• • • • •
441 CAA.....ACAGATTCTGCCAGCACCTTAAAACTGCCTCAATACTGGGAT 485
I I Mill MM I I IMIMIMM I I III
1999 TGAGACTGAAAGATTTAGCCATAATGT..AAACTGCCTCA..AATTGGAC 2044
•
486 TTTGGGTATTA 496 
2045 TTTGGGCATAA 2055
FIGURE 5.4
Comparison of XbmycA! and human c-myc DNA sequences using the program 
BESTFIT with a gap weight of 5.0 and a length weight of 0.3. The top sequence 
is XbmycAl and the lower sequence is human c-myc. Boxed are the potential 
stop codons. The human c-myc DNA sequence is from the GENBANK database 
release 40.0. % similarity = 70.705, quality = 139.2 and quality ratio = 0.297.
COMPARISON OF XBMYCA1 AND CHICKEN C-MYC DNA SEQUENCES
1 CCGCAAGTGCGCCAGTCCCAGGTCCTCTGATTCCGAGGAGAACGACAAGA 50
III II III Illlllll I Ml I! II Illlllllllllllll
3215 CCGAAAATGCTCCAGTCCCCGCACGTCAGACTCAGAGGAGAACGACAAGA 3264
• • • • •
51 GGAAGACGCACAACGTTCTGGAGCGTCAGAGGCGGAACGAGCTCAAGTTG 100
II Mlllllllll Mill! Ill I MM Mill III II
3265 GGCGAACGCACAACGTCTTGGAGCGCCAGCGAAGGAATGAGCTGAAGCTG 3314
. . . • •
L01 AGTTTTTTCGCCTTGCGCGATCAGGTACCGGAGGTGGCGAACAACGAGAA 150
Mill II III III! II III MM Illlllll MIMMIMI
3315 AGTTTCTTTGCCCTGCGTGACCAGATACCCGAGGTGGCCAACAACGAGAA 3364
• * • * *
151 AGCCCCCAAAGTCGTCATCCTCAAAAAGGCAACGGAATACGCCATTTCTC 200
M HIM II Illlllll HIM II Mill MM I III
3365 GGCGCCCAAGGTTGTCATCCTGAAAAAAGCCACGGAGTACGTTCTGTCTA 3414
• • • • •
201 TGCAGGAGGATGAGCGACGGCTCATACGTGAAACAGAACAGTTAAAGTTC 250
I M Ml MM I II II II I III Mill I I
3415 TCCAATCGGACGAGCACAGACTAATCGCAGAGAAAGAGCAGTTGAGGCGG 3464
• * • • •
251 AGGAAAGAGCAGTTGAAACAGAGACTCCAACAGCTAAGGAACTTGGTTGT 300
MM III Mlllllllll I III I Illllllllllll II 
3465 AGGAGAGAACAGTTGAAACACAAACTTGAGCAGCTAAGGAACTCTCGTGC 3514
• • * * •
301 CfTA. .... .AJTTCATAAACACTT. ....................... . TA 319
II M I HIM II
3515 AgA^GAACTCTTGGACATCACTTAGAATACCCCAAACTAGACTGAAACTA 3564
• * • * •
320 TTATAAACTGTTGACAGTCTATATCAAGGTTGTCTCTTCCTCGAG.ACTA 368
I HIM III III I I I I I I III I MM 
3565 TGATAAAATATT. . . AGTGTTTCTAA. ...... . TATCACTCATGAACTA 3603
• • • • •
369 CAAAGCTGAATT. . . TGTAGAACATGGACAACTGCATGCAG . ATGATTTC 414
M I III II MM IMIIMMM I II M
3604 CATCAGTCCATTGAGTATGGAACTATTGCAACTGCATGCTGTGCGACTTA 3653
.....
415 AC. . . .AACTACACAACCTTGGCTTGGTCTCAAACAGATTCTGCCAGCAC 460




II IMIIMMIM I II I MUM II I II
3704 CTCAAAACTGCCTCATAATTGATACTTTGGGCATAAGGG 3742
FIGURE 5.5
Comparison of XbmycAl and chicken c-myc DN/\ sequences using the program 
BESTFIT with a gap weight of 5.0 and a length weight of 0.3. The top sequence 
is XbmycAl and the lower sequence is chicken c-myc Boxed are the potential 
stop codons. The chicken c-myc DNA sequence is from the GENBANK database 
release 40.0. % similarity = 71.926, quality = 172.4 and quality ratio = 0.345.






































XbmycA2 DNA sequence and putative protein translation. The potential stop 
codon and the potential polyadenylation signal are boxed. Underlined are the 
potential rapid degradation signals.
TCTCATTCGCAGCCTTCCCGGCCTCACCACAGCCCATTGGTTCTGAAGCGGTGTCACGTT









































1201 ————————+————————+———————— +————————+————————+————————-i- 1260
AGGACCCTAAAACCCATAATACCCTGACAAACATTTTTTTAAAAAAAAAAAAGACGAACA
GGGGGGGTATATTTGCCAACTTTTTTCTTTGTTTGTTTGTTATTGTTTTACAACCTTTGT
1261 ————————+————————+————————+————————+————————+ ——————— + 1320
CCCCCCCATATAAACGGTTGAAAAAAGAAACAAACAAACAATAACAAAATGTTGGAAACA
ATTTAAAACATTTATTTTTCTTATAAACGAATTCCTGAAGTTTGCCTCTGAATAGCTTAA
1321 ————————+————————+————————+————————+————————+ ———————— + 1380
TAAATTTTGTAAATAAAAAGAATATTTGCTTAAGGACTTCAAACGGAGACTTATCGAATT
ATATATACATCATCGCTGACTCGTCTATAATATCATTAATAGGTCGTTATAGAAATTATT
1381 ——————— +————————+————————+————————+————————+ ———————— + 1440
TATATATGTAGTAGCGACTGAGCAGATATTATAGTAATTATCCAGCAATATCTTTAATAA
GTATTCACTTCTAACCGCTATGGCGCAAAAAAGAGAGAAGCAAAACTTTTTTTGTTTTTT






1561 ————————+———————+———————+———————+——————— +———————+ 1620
TTCTTCTCTCTTAAATTGTAAATAGATAGTTCAAAGTAAACCTATTAAGACATAACCTCG
TAGTCGTACCAGTTTCTGAAGAACTGATGAAGAAGGCACTGACCAACATGTAACTCAAAA


















1981 ———————+———————+——————— + ~ 2011 
CTTATTCGAAGTCTTTTATTTTTAGTTCAAA
XBMYCA3 DNA SEQUENCE AND PROTEIN TRANSLATION
GAATTCCCCCCCCCCCTTCCCAGAGCTGCCCCAAATCACAGGGGTCTCGCTCCATTCCAG
1 ———————— + ———————— + ———————— + --------- + --------- + ———————— + go
CTTAAGGGGGGGGGGGAAGGGTCTCGACGGGGTTTAGTGTCCCCAGAGCGAGGTAAGGTC
CCCCTTATGTGGGACCCCCCTTCCATAAAGTCAAGTATCTCTGAAAGAAAAGACTTTGCA 
61 ———————— + ———————— + ———————— + ———————— +———————— + ———————— -i- 120 
GGGGAATACACCCTGGGGGGAAGGTATTTCAGTTCATAGAGACTTTCTTTTCTGAAACGT
GACACAGATGAGGAAAACAAACATTCACTAATTGTTAATTAAGCAGGATAAGAGGGAGAC
121 ———————— + —————————————————— + ———————— + ———————— +———————— + 180
CTGTGTCTACTCCTTTTGTTTGTAAGTGATTAACAATTAATTCGTCCTATTCTCCCTCTG
TGGGAAATGCGATTGGGTTACGAAGACTCCGAGCGAGACTGTTCAGCTGCTCCGACGCAT
181 ———————— + ———————— +————————+ ———————— +————————+ ———————— + 240
ACCCTTTACGCTAACCCAATGCTTCTGAGGCTCGCTCTGACAAGTCGACGAGGCTGCGTA
CAAAGTGGATGAGCCCATCCTGAGACCTGCATCAGCCCCCGGGGACAGCGATAAAGTGAG
241 ———————— +———————— + ———————— + ———————— + ———————— + ———————— + 300
GTTTCACCTACTCGGGTAGGACTCTGGACGTAGTCGGGGGCCCCTGTCGCTATTTCACTC
ACCAATCGCAAGGGAGGAAAdATGlCCTCTTAATGCCAGTTTCCCCAGCAAGAACTACGAC











































901 ———————— + ———————— + ———— 925
GACTTGCTGTCGTAAAGGTTGAGGT
LNDSISNS




• • • • •
51 GGAAGACGCACAACGTTCTGGAGCGTCAGAGGCGGAACGAGCTCAAGTTG 100
M IIIIMIIMM IIMMIMI 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
764 GGCGGACGCACAACGTCTTGGAGCGTCAAAGGCGGAACGAGCTCAAGTTG 813
• • • • •
101 AGTTTTTTCGCCTTGCGCGATCAGGTACCGGAGGTGGCGAACAACGAGAA 150
MM! MMMMMMM MMMMMMMMI MMMMMI
814 AGTTTCTTCGCCTTGCGCGACCAGGTACCGGAGGTGGCCAACAACGAGAA 863




• • • • •
201 TGCAGGAGGATGAGCGACGGCTCATACGTGAAACAGAACAGTTAAAGTTC 250
MMMMM MMMMMMMMI IMMIMMMMMMI I
914 TGCAGGAGGACGAGCGACGGCTCATACGGGAAACAGAACAGTTAAAGTAC 963
• • * • •
251 AGGAAAGAGCAGTTGAAACAGAGACTCCAACAGCTAAGGAACTTGGTTGT 300










• • • • •
387 ACATGGACAACTGCATGCAGATGATTTCACAACTACACAACCTTGGCTTG 436
I MIMIMIMIIMI IIIMMIMMIMIMMIIIMM II
1113 AAATGGACAACTGCATGC..ATGATTTCACAACTACACAACCTTGGCATG 1160
• • • • •
437 GTCTCAAACAGATTCTGCCAGCACCTTAAAACTGCCTCAATACTGGGATT 486




I MM Ml Ml Ml 
1211 TTGGGTATTATGGG 1224
FIGURE 5.8
Comparison of XbmycAl and XbmycA2 DNA sequences using the program 
BESTFIT with a gap weight of 5.0 and a length weight of 0.3. The top sequence 
is XbmycAl and the lower sequence is XbmycA2. Boxed are the potential stop 
codons. % similarity = 93.763, quality = 413.0 and quality ratio = 0.826.




• * • • •
615 TGACGAAGCCTTGCTGAAGTCCATCGTCATACAGGACTGTATGTGGAGTG 664
I I I I I I I II I I I I I II I I I I I I I I I I I I I II I I I I I I I I I II I I I I I I I I 
51 TGACGAAGCCTTGCTGAAGTCCATCGTCATACAGGACTGTATGTGGAGTG 100
• • * • •
665 GTTTTTCAGCGGCGGCCAAGCTGGAGAAAGTGGTGTCTGAGAAGCTGGCA 714
I II II Illllllllllllllllllllllllllll Illlllllllll 
101 GCTTCTCGGCGGCGGCCAAGCTGGAGAAAGTGGTGTCGGAGAAGCTGGCA 150




• • * • •
765 AAGTCAACCGCCTCAGAGCCCACTCAAGTCTCCCTCATGCCACGG..... 809
MINIM M IIMIIII IMMMMMMMM I II
201 GAGTCAACCACCACAGAGCCCGATCAAGTCTCCCTCATGCGATGGGAGCC 250
• • * • *
810 .GAGTCTCGAAGGGACCCACAGGAGCAGCCATGCTTTTCTCCAGGACCCC 858
IMIIIM MMIM MMMMMIMM II IMIMMIIM
251 TGAGTCTCGGAGGGACCAACAGGAGCAGCCATGGATTCCTCCAGGACCCC 300
• • • • •
859 AGCTCGGATTGTGTTGACCCTTCCGTGGTCTTCCCATACCCACTGAACGA 908
MMMMMMMIMIII II 111 M 11 III 11 III III I I II I 11 I
301 AGCTCGGATTGTGTTGACCCATCAGTGGTCTTCCCATACCCACTGAACGA 350 
909 CAGCATTTCCAACTCCA 925 
351 CACCATTTCCAACGCCA 367
FIGURE 5.9
Comparison of XbmycAS and XbmycA2 DNA sequences using the program 
BESTFIT with a gap weight of 5.0 and a length weight of 0.3. The top sequence 
is XbmycAS and the lower sequence is XbmycA2. % similarity = 93.629, quality 
= 310.5 and quality ratio = 0.860.




• • • * •
51 APKVVILKKATEYAISLQEDERRLIRETEQLKFRKEQLKQRLQQLRNLVV 100
IIMIIMIIMI II Illllllllllllll Illllllllllllllll 
289 APKVVILKKATEYVISMQEDERRLIRETEQLKYRKEQLKQRLQQLRNLVV 338
COMPARISON OF XBMYCA3 AND XBMYCA2 PROTEIN SEQUENCES
82 EFLGGDMVNQSFICEADDEALLKSIVIQDCMWSGFSAAAKLEKVVSEKLA 131
MMMIMIIMIIIIIIIIIMIIMIIIMIIMIIIIIIIIIIIII
1 EFLGGDMVNQSFICEADDEALLKSIVIQDCMWSGFSAAAKLEKVVSEKLA 50 
132 SYQASRKESALSSSQCPSQPPQSPLKSPSCHG. . SLEGTHRSSHAFLQDP 179
M Mill MINIM I III MM Mill I II M MM HIM






A: Comparison of XbmycAl and XbmycA2 protein sequences using the program 
BESTFIT with a gap weight of 5.0 and a length weight of 0.3. The top sequence 
is XbmycA! and the lower sequence is XbmycA2. % similarity = 96.000, quality 
= 95.6 and quality ratio = 0.956.
B: Comparison of XbmycAS and XbmycA2 protein sequences using the program 
BESTFIT with a gap weight of 5.0 and a length weight of 0.3. The top sequence 
is XbmycAS and the lower sequence is XbmycA2. % similarity = 94.118, quality 
= 105.7 and quality ratio = 0.888.








• • • • *
101 GCTTCTCGGCGGCGGCCAAGCTGGAGAAAGTGGTGTCGGAGAAGCTGGCA 150
I M Mill I I! HIM' I !i! illMil I Ml UlllllMII
485 GATTTTCGGCTGCGGCCAAGCTGGAGAAAGTGGTGTCTGAGAAGCTGGCG 534
• • • * •
151 TCGTACCAGGCTTCTAGGAAAGAGAGTGCTCTG. . . TCTTCTTCTCAGTG 197
M IIIMIIIIIIIMIIIIMIMIIIIIM MIMIIIM III
535 TCCTACCAGGCTTCTAGGAAAGAGAGTGCTCTGTCTTCTTCTTCTCCGTG 584
• • • • •
198 CCAGAGTCAACCACCACAGAGCCCGATCAAGTCTCCCTCATGCGATGGGA 247
MIIIIIIIIIIMM Illllll I IIIMIIIMI II MINI
585 TCAGAGTCAACCACCACCGAGCCCGCTTAAGTCTCCCTCGTGTCATGGGA 634 
248 GCCTGAGTCTCGGAGGGACCAACAGGAGCAGCCATGGATTCCTCCAGGAC 297
MIMIIIM MIMIMI MMMIMMIMM II IMIIIIM
635 GCCTGAGTCTGGGAGGGACCCACAGGAGCAGCCATGGTTTTCTCCAGGAC 684
• - • • * •
298 CCCAGCTCGGATTGTGTTGACCCATCAGTGGTCTTCCCATACCCACTGAA 347
MMMMMMMMMIMM I 1 1 1 M M M M M II 1 1 M 1 1 M 1 1
685 CCCAGCTCGGATTGTGTTGACCCTTCAGTGGTCTTCCCATACCCACTGAA 734
• • • • •
348 CGACACCATTTCCAACGCCAGCTCACCATGCCAAGATCTCATGTTGGAAA 397
MMI MMMMMMMMM M Illlllllllllll MMIM
735 CGACAGCATTTCCAACGCCAGCTCTCCTTGCCAAGATCTCATTTTGGAAA 784
• * • * •
398 CACCACCCATCAGCAGTAACAGCAGCAGTAGTGAATCAGAAGAGGAACAG 447
I II MMMMMMMMMIMM IIMIMI MINIUM
785 CTCCGCCCATCAGCAGTAACAGCAGCAGCAGTGAATCTGAAGAGGAACCA 834
• • • • •
448 GAAGATGATGATGAAGACTGTGACGAGGAAGAGGAGATTGATGTGGTCAC 497
MM IMMMIMI MMMMMMMIMMI II Mill
835 GAAGATGAGGATGAAGACTGCGACGAGGAAGAGGAGATTGACGTTGTCAC 884
• • • * •
498 GGTAGAAAAGAGACAGACTGCGTCCAGGCGGATGGAATCCAGTTCTCATT 547
M M M 1 1 M. Ml I M 1 1 1 1 II 1 1 1 1 1 II I II 1 1 1 1 1 II I II
885 AGTAGAAAAAAGGCAGTCGGCATCCAAGCGGGTGGAATCCAGTTCTCATT 934
• • • • ,
548 CGCAGCCTTCCCGGCCTCACCACAGCCCATTGGTTCTGAAGCGGTGTCAC 597
MMMI Mill M Ml Illllll II MMMMMIMIMM
935 CGCAGCCCTCCCGACCCCACTACAGCCCTTTAGTTCTGAAGCGGTGTCAC 984
• • • • .
598 GTTCCCATTCACCAACACAACTACGCAGCGTCCCCCTCAACCAAAGTGGA 647
MMMMMMMMMMMIMI MMI Mill IMIMMIM
985 GTTCCCATTCACCAACACAACTACGCGGCGTCTCCCTCGACCAAAGTGGA 1034
FIGURE 5.11
Comparison of XbmycA2 and XlmycA DNA sequences using the program GAP 
with a gap weight of 5.0 and a length weight of 3.0. To compare the whole 
sequences they first were divided into three parts and then each comparison 
was run (since at a maximum only two 1000 bp sequences can be compared). 
The combined output of these comparisons is shown in this figure. Boxed are 
the potential stop codons. The XlmycA DNA sequence was kindly provided by 
M. King. The average % similarity = 93.763, quality = 413.0 and quality ratio = 
0.826 over the whole sequences.
648 CTATGTTTCTTCCAAGAGGGCGAAACTAGAAAGCAACGCCAGGGTCCTCA 697




Mllll Mill II IIII III 11 Mill III I MINIUM III Ml
1085 AACAGATCAGCAACAACCGCAAGTGCGCCAGTCCCAGGTCCTCGGATTCC 1134
• * • * •
748 GAAGAGAACGACAAGAGGCGGACGCACAACGTCTTGGAGCGTCAAAGGCG 797
MIMIIMIMMIIM IMMIMIMI IMMM II Mill
1135 GAAGAGAACGACAAGAGGAAGACGCACAACGTTCTGGAGCGCCAGAGGCG 1184
• • • • •
798 GAACGAGCTCAAGTTGAGTTTCTTCGCCTTGCGCGACCAGGTACCGGAGG 847
Ml Ml III IIIIIIIIIIII II I III III I III MMIMMMM
1185 GAACGAGCTCAAGTTGAGTTTTTTTGCCTTGCGCGATCAGGTACCGGAGG 1234
• * • • *
848 TGGCCAACAACGAGAAGGCCCCCAAAGTCGTCATCCTCAAAAAGGCAACG 897




MM III IMMM IMIMMMMI II MMMMMMMIM
1285 GAATACGCCATTTCTCTGCAGGAGGACGAACGGCGGCTCATACGGGAAAC 1334










* • • * *
1097 AAACTGAATTTGTAGAAAATGGACAACTGCATGC..ATGATTTCAC-AACT 1144
II II I II II I II II II I I II II II I II II II I I 11111111111111 
1481 AAACTGAATTTGTAGAACATGGACAACTGCATGCAGATGATTTCACAACT 1530
• . • • • •
1145 ACACAACCTTGGCATGGTCTCAACCGGATTCTGCCAGCACCTTAAAACTG 1194
MMIIIIMMMMMIMM I IIII111 II IIIIIIII1111III
1531 ACACAACCTTGGCATGGTCTCAAACAGATTCTGCCAGCACCTTAAAACTG 1580
* • • * •
1195 CCTCAATCCTGGGATTTTGGGTATTATGGGACTGTTTGTAAAAAAATTTT 1244
IMMM Mllll IMMMMIIMIIMI I I MM
1581 CCTCAATACTGGGA.TTTGGGTATTATGGGACTTTGT. ....... .TTTT 1620
• * • • •
1245 TTTTTTTTCTGCTTGTGGGGGGGTATATTTGCCAACTTTTTTCTTTGTTT 1294
MIMMIM • II MMMIMMMMMIM IMMM
1621 TTTTTTTTCTTGCT.TGAGGGGGTATATTTGCCAACTT.....TTTGTTT 1664





MINI Illllllllllllll MM IMMM IMMMMII INI
1715 ATAAACAAATTCCTGAAGTTTGGCTCTGAATAGCTTAAATATATATATCA 1764
• * • * •
1393 TCGCTGACTCGTCTATAATATCATTAATAGGTCGTTATAGAAATTATTGT 1442
MIIIIMMIIIMIMMIMM III! I 1111111111111III
1765 TCGCTGACTCGTCTATAATATCATTGATAGAACATTATAGAAATTATTGT 1814
• • * • •
1443 ATTCACTTCTAACCGCTATGGCGCAAAAAAGAGAGAAGCAAAACTTTTTT 1492
IMIIIIIMIIMIIIIIIIIIMIMI I I MMIMI
1815 ATTCACTTCTAACCGCTATGGCGCAAAAA..AAAAAAGCAAAA....... 1855
• • • • *
1493 TGTTTTTTGCCAATTAATACCATGAATGCATTTAACAAACTTGTTTTTTT 1542
Illllll MM Illlllll! MINIMI III I
1856 ACGTTTTTGCTAATTCGTACCATGAACGCATTTAACGAACCT........ 1897
• * • • *
1543 TTATTTTTTGTTTATTTTAAGAAGAGAGAATTTAACATTT.ATCTATCAA 1591
Illllllllllllll I II Illllll MM MM 
1898 ..........TTTATTTTAAGAAGAAAAAA...AACATTTAATCTTTCAA 1934




• • • • •
1642 AACTGATGAAGAAGGCACTGACCAACATGTAACT..CAAAACAAATTACT 1689
MMMMMIMIIIMIMMMMIMM I MM Ml MM
1985 AACTGATGAAGAAGGCACTGACCAACATGTAATTTAAAAAAGAAAATACT 2034
• • • • •
1690 AAAAGTACTTAATATTATCCCATACCCCTCTATCCTTGTCATGTGAAAAC 1739
MMMIMMMII IIMM MM Illllllllllllll MM
2035 AAAAGTACTTAATAT..CCCCATA.CCCTGTATCCTTGTCATGTGGAAAC 2081
• • • • •
1740 CTCAAACCTGCTGGCTGCTTATGGCGTCCTATTGTAGTAATTGCAGCAGG 1789
III MMMMMIMM III HIM HIM II Illlllll
2082 CTCTAACCTGCTGGCTGCTCCTGGTGTCCTGTTGTAATAGCAGCAGCAGG 2131
• • • * •
1790 ATTGTGGTCTTTCCTAGTAACACAGAAGCAGTCTGCTGTTTCTATATTGA 1839
II M Ml M M I I M Ml I I MM MMM I IMMIMMIII IM
2132 ATCTTGGTCTTTCCTAGTAACACAGAAGCAGTCTGCTGTTTCTATATTGA 2181
• • • * •
1840 ATCTCTTAAAGATATTATAACATGCTGGTCTG.......AAAAATTCATC 1882
M MM IM M MMMI MMMMMMIM MM HIM
2182 TTCTCTTAAAGATATTATAACATGCTGGTCTGAAAAAAAAAAAACTCATC 2231
• • • * *
1883 ATTTGTTTATTGTAAGGCTTGTTTTTGCTTAAGATGAAACTATTCATGTG 1932




Ml I M MMM Illlllll MIMMMIMIMM




COMPARISON OF XBMYCA3 AND XLMYCA DNA SEQUENCES
294 AAGTGAGACCAATCGCAAGGGAGGAAAGJATGlCCTCTTAATGCCAGTTTCC 343
I I Mill 11II Ml I M MIMMIIMIMMMIMM Ml I
114 ACGGGAGACCAATCGdATGteCAGGAAAGSAYGlCCTCTTAATGCCAATTTTC 163
• * • • *
344 CCAGCAAGAACTACGACTACGACTATGACTTGCAGCCCTGCTTCTTCTTC 393
MMMIMMMMIIIMM 11II11IIIIIIIIIII M II M M I
164 CCAGCAAGAACTACGACTACGATTATGACTTGCAGCCCTGCTTCTTCTTT 213








• * • • •
494 TGTCGCCCAGCCGCAGATCCAGCCAGTCCAGCCTTTTCCCCTCTACTGCC 543
MM MMMMMMMMMMIMMIMMMMMM II II
314 TGTCACCCAGCCGCAGATCCAGCCAGTCCAGCCTTTTCCCCTCCACGGCT 363
• • • * •
544 GATCAGCTGGAGATGGTGACCGAATTCCTGGGAGGGGACATGGTCAACCA 593
: ! ! I ! i !! I i I I , ! I , ; I I i I I I MM ! M M I I I ! I I I Mi liiM i!
364 GATCAGCTGGAGATGGTGACCGAATTCCTGGGAGGGGACATGGTCAACCA 413
• • • • •
594 GAGCTTTATCTGCGAGGCGGATGACGAAGCCTTGCTGAAGTCCATCGTCA 643
MMMMMMMMMMMMIMMMMIIMIMMMIMIM
414 GAGCTTTATCTGCGAGGCGGATGACGAAGCCTTGCTGAAGTCCATCGTCA 463 
644 TACAGGACTGTATGTGGAGTGGTTTTTCAGCGGCGGCCAAGCTGGAGAAA 693
MMMIMMMMMIMM Mill M M 1111 M 11 M 1111 11
464 TACAGGACTGTATGTGGAGTGGATTTTCGGCTGCGGCCAAGCTGGAGAAA 513
• • • * •
694 GTGGTGTCTGAGAAGCTGGCATCATACCAGGCTTCTAGGAAAGAGAGTGC 743
MMIMMMMMIMM II 11 M M M M I M III11111111 M
514 GTGGTGTCTGAGAAGCTGGCGTCCTACCAGGCTTCTAGGAAAGAGAGTGC 563
• • • • •
744 TCTG...TCTTCTTCTCAGTGTCCAAGTCAACCGCCTCAGAGCCCACTCA 790
MM MM MUM INN I M 11111 11 I 111111 11 I
564 TCTGTCTTCTTCTTCTCCGTGTCAGAGTCAACCACCACCGAGCCCGCTTA 613
• • • • *
791 AGTCTCCCTCATGCCACGG......GAGTCTCGAAGGGACCCACAGGAGC 834
IIMMIMI II II M IMIM I MMIMMMIMM
614 AGTCTCCCTCGTGTCATGGGAGCCTGAGTCTGGGAGGGACCCACAGGAGC 663
• • • • •
835 AGCCATGCTTTTCTCCAGGACCCCAGCTCGGATTGTGTTGACCCTTCCGT 884
MIMM MMMMMMMMMMMMMIMIMMMIM M





Comparison of XbmycAS and XlmycA DNA sequences using the program 
BESTFIT with a gap weight of 0.5 and a length weight of 0.3. The top sequence 
is XbmycAS and the lower sequence is XlmycA. Boxed are the potential start 
codons. The XlmycA DNA sequence was kindly provided by M. King. % 
similarity = 94.462, quality = 552.8 and quality ratio = 0.875.
COMPARISON OF XBMYCA2 AND XLMYCA PROTEIN SEQUENCS




• • • * •
51 SYQASRKESAL.SSSQCQSQPPQSPIKSPSCDGSLSLGGTNRSSHGFLQD 99
IIIMIIIMI III Illlll II INN MINIM MINIM!
136 SYQASRKESALSSSSPCQSQPPPSPLKSPSCHGSLSLGGTHRSSHGFLQD 185
• • • • •
100 PSSDCVDPSVVFPYPLNDTISNASSPCQDLMLETPPISSNSSSSESEEEQ 149
I I I II I II I I I II 11 II I I II I I I II I I I II II I II I II II II II I I 
186 PSSDCVDPSVVFPYPLNDSISNASSPCQDLILETPPISSNSSSSESEEEP 235
• • • * *
150 EDDDEDCDEEEEIDVVTVEKRQTASRRMESSSHSQPSRPHHSPLVLKRCH 199
M IIMMIMMMMMM II I 11 MM I HIM MM Ml I
236 EDEDEDCDEEEEIDVVTVEKRQSASKRVESSSHSQPSRPHYSPLVLKRCH 285
• • • • •
200 VPIHQHNYAASPSTKVDYVSSKRAKLESNARVLKQISNNRKCASPRSSDS 249
IM IMMMNiM MMIMIMM III I I I IIII I I M III I M
286 VPIHQHNYAASPSTKVDYVSSKRAKLESNIRVLKQISNNRKCASPRSSDS 335 
250 EENDKRRTHNVLERQRRNELKLSFFALRDQVPEVANNEKAPKVVILKKAT 299




M M M I I I I MM MM !MM: I M M M MM i M I
386 EYAISLQEDERRLIRETEQLKYRKEQLKQRLQQLRNFV 423








• • . . . 
101 ALLKSIVIQDCMWSGFSAAAKLEKVVSEKLASYQASRKESAL.SSSQCPS 149
MMMMMMIMMIMMMMIIIIMMIMIMM III I I
105 ALLKSIVIQDCMWSGFSAAAKLEKVVSEKLASYQASRKESALSSSSPCQS 154
• 
150 QPPQSPLKSPSCHG. . SLEGTHRSSHAFLQDPSSDCVDPSVVFPYPLNDS 197







A: Comparison of XbmycA2 and XlmycA protein sequences using the program 
BESTFIT with a gap weight of 5.0 and a length weight of 0.3. The top sequence 
is XbmycA2 and the lower sequence is XlmycA. The XlmycA sequence is a 
translation from the XlmycA DNA sequence kindly supplied by M. King. % 
similarity = 96.000, quality = 310.8 and quality ratio = 0.922.
B: Comparison of XbmycA3 and XlmycA protein sequences using the program 
BESTFIT with a gap weight of 5.0 and a length weight of 0.3. The top sequence 
is XbmycAS and the lower sequence is XlmycA. The XlmycA sequence is a 
translation from the XlmycA DNA sequence kindly supplied by M. King. % 



































Comparison of human c-myc and XbmycA DNA sequences. Bases 1 - 564 of 
XbmycAS were added to the 5' end of XbmycA2 to form the assembled 
XbmycA sequence as described in the text. The COMPARE program was used 
with a window size of 21 and a stringency of 14 to generate the points which 
were then plotted using che DOTPLOT program. El, E2 and E3 represent the 
three exons of the human c-myc gene. CDS represents the putative coding
sequence of XbmycA. An indicates the polyadenylation site in both genes. S1
\\ 
and S2 indicate the mRNA start sites of the human c-myc gene. Intervening
sequences in the human c-myc gene are represented by the thin diagonal lines 








































































Comparison of chicken c-myc and XbmycA DNA sequences. Bases 1 - 564 of 
XbmycAS were added to the 5' end of XbmycAZ to form the assembled 
XbmycA sequence as described in the text. The COMPARE program was used 
with a window size of 21 and a stringency of 14 to generate the points which 
were then plotted using the DOTPLOT program. El, E2 and E3 represent the 
three exons of the chicken c-myc gene. CDS represents the putative coding 
sequence of XbmycA. An indicates the polyadenylation site in both genes. 
Intervening sequences in the chicken c-myc gene are represented by the thin 
diagonal lines between the exons. The limits of the first exon and the mRNA 
start sites of the chicken c-myc gene have not yet been precisely defined. 
Sizes are marked in base pairs. The chicken c-myc DNA sequence is from the 
GENBANK database release 40.0.
E 2 ? E 3 ?
J-

















Comparison of trout c-myc and XbmycA DNA sequences. Bases 1 - 564 of 
XbmycAS were added to the 5' end of XbmycA2 to form the assembled 
XbmycA sequence as described in the text. The COMPARE program was used 
with a window size of 21 and a stringency of 14 to generate the points which 
were then plotted using the DOTPLOT program. E2 and E3 represent at least 
two of the exons of the trout c-myc gene. CDS represents the putative coding 
sequence of XbmycA. An indicates the polyadenylation site of XbmycA. 
Intervening sequences in the trout c-myc gene are represented by the thin 
diagonal line between exons. The number of exons, the mRNA start sites and 
the polyadenylation site of the trout c-myc gene have not yet been defined. 
Sizes are marked in base pairs. The trout c-myc DNA sequence is from Van 
















































Possible open reading frames of the XbmycA DNA sequence. Bases 1 - 564 of 
XbmycAS were added to the 5' end of XbmycA2 to form the assembled 
XbmycA sequence as described in the text. Open reading frames were found 
using the program FRAMES. Boxes represent open reading frames in each of 
the six possible frames with start codons represented with ticks above the 
boxes and stop codons represented by ticks below the boxes. The filled box 
represents the putative XbmycA c-myc coding sequence.
COMPARISON OF C-MYC PROTEIN SEQUENCES
50
HUM v ftnr 1 v ycd 
MOU vn ftnr 1 v icd 
CHK sa Ip v yf. ee la 
VIR aaaa sa Ip v yf. ee la 
TRO ... s la i yvd n ded. 
XLA magk an fp .1 c ffl 
XB2 - - - - - -
XB3 a fp 
XB1
1 c ffl








XB2 .......... .......... . .
XB3 
XB1 .......... ..........
CON P^PSEDIWKK FELLPTPPLS PS"
101 . RD2
HUM Sf 1 
MOU nf ml 
CHK 1 
VIR 1 
TRO f d v 
XLA f 




g c p syvav tpfs 
g c p syvavatsfs 
s aaa s 
s aaa s 





q qq e 
h qq e 
a rg e 
a rg e 
h pgq 
h . r














p s v 
p s v 
a y sqt 1 
ea all v 
ea all v 
ea all v
CON FPSTADQLEM VTE-LGGDMV NQSFICD-D. DE-F-<SIII
RD 3
151
HUM ... ad 
MOU ... ad 
CHK t r g 
VIR t r g 





CON AAKLEKVVSE KLASYQASRK ES 
201 
HUM h vcs ssly Iqd saa e 
MOU h vcs ssly Iqd taa e 
CHK ag ...... y Ihd gaa a
VIR ag ...... y Ihd gaa a
TRO Iqdpn sase cigpnts e 
XLA 1 gg hrss hgf qdps \ 
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Comparison of c-myc protein coding sequences using the program GAP (with 
command line option OUT) reiteratively, with a gap weight of 5.0 and a length 
weight of 3.0, until no more gaps are introduced between comparisons. Initial 
alignments were performed using the program PRETTY then the alignments 
were manually edited to increase the maximum number of matches.Hum = 
human, mou = mouse, chk = chicken, vir = viral, tro = trout, XIA = XlmycA, Xb2 
= XbmvcA2, Xb3 = XbmycAS and Xb1= XbmycAl c-myc protein coding 
sequences. Con = a consensus sequence generated using a plurality of 5. The 
putative myc boxes A and B are boxed (see 5.6.4). Underlined are the potential 
nuclear location signals, NL1 - 3 (see 5.6.2) and the potential rapid degradation 
signals, RD1 - 7 (see 5.6.3). The human, mouse, chicken and viral sequences 
are translations from the respective DNA sequences given in the GENBANK 
database release 40.0. The trout sequence is a translation of the trout c-myc 
DNA sequence given in Van Beneden et al 1986 and the XlmycA sequence is a 
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FIGURE 5.19
Alignment of myc box A and B amino acid sequences (see 5.6.4). The c-myc 
sequences are from a consensus generated from Figure 5.18 and in brackets is 
shown the deviation in the c-myc consensus: in myc box A a methionine is 
present as shown in the viral sequence and in myc box B a valine is present as 
shown in the Xenopus sequences and a threonine is present as shown in the 
trout sequence. The myc boxes are as described by Schwab et al 1983, Nau et 
al 1985 and Schwab 1985.
CHAPTER 6
DISCUSSION
6.1 Oncogene Homologies in Xenopus
Low stringency hybridisation conditions and highly labeled probes were 
employed to show the presence of many oncogene related sequences in the 
genome of three species of Xenopus and in some cases in the RNA of 
X.borealis. This result, in itself, is not too surprising since it is expected that 
genes important for development or normal cell growth might be conserved 
between a variety of organisms. Indeed the isolation of many oncogene 
related sequences from Drosophila (see chapter 1) supports such a view. 
Conversely the isolation, from many species, genes related to those in 
Drosophila development (i.e. the homeo box containing genes) also supports 
this view. Only organisms, such as yeast, which exhibit a radically different life 
style from insects and vertebrates appear not to have the full complement of 
oncogene related genes though this might reflect a high degree of divergence 
between the probe that is used and the yeast gene rather than differences in 
the mode of cell growth. Obviously some oncogene related sequences that are 
involved in cell type specific processes or in development might not be 
required in lower organisms hence they will not be present in their genomes 
(in a functional form?). Since cellular oncogenes are so highly conserved 
throughout evolution it seems to me that an analysis of cellular oncogene 
function is best carried out in the organism that can be best exploited for the 
particular question one is trying to answer. Xenopus is one organism that is 
ideal (in many respects) for studying cellular oncogene function during 
development and I have demonstrated the potential for isolating many such 
sequences from Xenopus.
6.2 The X.borealis C-myc Genes
I have described the isolation of X.borealis cDNA clones that represent 
genes homologous to the mammalian and avian c-myc genes. Nucleotide 
sequence analysis and preliminary southern blot analysis suggests there are at 
least two distinct types of c-myc genes in X.borealis and X.laevis (represented 
by XbmycA and B in X.borealis) and only one type in X.tropicalis. Also this
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analysis showed that the XbmycA genes may have been duplicated to give rise 
to two related genes. As discussed previously this is consistent with a total 
genome duplication within the genus Xenopus. These studies also showed that 
the nudeotide and predicted amino acid sequences of the XbmycA type genes 
have a great degree of homology with other c-myc sequences which suggests 
the gene products have an important common function. Preliminary evidence 
suggests that at least one of the XbmycA genes may have a similar structure 
to avian and mammalian c-myc genes which may point to the structure of the 
c-myc gene being important in its regulation. Further sequence analysis of 
both genomic and cDNA clones along with southern blotting and expression 
data would help determine the precise relationship of the c-myc gene family 
members in X.borealis and would help us to understand whether each gene is 
infact functional. If more than one c-myc gene is functional it would be 
extremely interesting to see if they play different roles. For example there may 
be c-myc equivalents of somatic and oocyte type genes like in the 5S gene 
system, but this is unlikely for the c-myc genes I have isolated (unless 
translational regulation or other controls are evoked) since they were all 
isolated from ovary cDNA libraries. An understanding of the c-myc gene family 
in Xenopus might actually be better done using the diploid species X.tropicalis 
since both X.borealis and X.laevis are tetraploid they should have an increased 
gene number which might complicate matters.
6.3 Expression of X.borealis C-myc Genes
The c-myc gene XbmycA of X.borealis is an example of a maternal mRNA 
that is made early in oogenesis and then subsequently inherited by the 
fertilised egg. The stage II previtellogenic oocyte appears to have maximal 
levels of synthesis with around 19 pg of XbmycA mRNA which subsequently 
declines to around 8 pg in the stage VI oocyte. I calculate that the 
non-dividing stage II oocyte has ~1.2 x 107 molecules of XbmycA mRNA per 
cell therefore the stage VI oocyte has ~5x 10 6 molecules of XbmycA mRNA per 
cell which only decreases slightly on fertilisation. After fertilisation there is a 
period of extremely active cell division without detectable RNA synthesis 
(Newport and Kirschner 1982 a) during which the XbmycA mRNA is degraded 
such that by the time RNA synthesis begins (stage 8) there are only <40 
XbmycA mRNA molecules per cell. New transcription of the XbmycA gene is 
not detected till late gastrula (stage 11) by which time the inherit XbmycA 
mRNA has been degraded even further. There is then an increase in XbmycA
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mRNA in the embryo during neurulation to about 130 copies of XbmycA mRNA 
per cell, followed by a decrease to ~30 copies per cell in the stage 33/34 
tadpole. These calculations use cell numbers estimated by Gurdon, 1974 and 
averaged values over the embryo as a whole, which do not allow for the 
possibility that certain cell types may have localised increased expression of 
the XbmycA gene(s).
The total amount of poly(A)+ RNA has reached its final abundance in 
previtellogenic oocytes (Rosbash and Ford 1974, Cabada et a/1977, Dolecki and 
Smith 1979), does not turnover significantly within a 18 month period (Ford, 
Mathieson and Rosbash 1977) and many individual poly(A) + RNAs cease to 
accumulate after stage II of oogenesis (Golden, Schafer and Rosbash 1980). 
Such observations suggest that c-myc RNA itself in a Xenopus oocyte is 
extremely stable with a half life in the order of several weeks, contrasting 
starkly with c-myc RNA half life of only a few tens of minutes in other systems 
(Dani et al 1984). This is supported by calculations of the type described by 
Perlman and Rosbash, 1978 which show (assuming that (1) the newly made 
RNA is stable, (2) there are 8 genes that are fully active, (3) the RNA 
polymerase transit time is 15 bases/second and (4) there are 10 RNA 
polymerases loaded/kilobase) that it would take nearly 100 days to synthesise 
the 19 pg of XbmycA mRNA in a stage II oocyte which is about half the time 
required to reach sexual maturity. Therefore without direct evidence of the 
XbmycA mRNA half life in oocytes it seems probable that it is in fact 
essentially stable. Masking proteins of the type described in chapter 1 may 
stabilise the RNA. Using in vivo labeled oocytes (Ford, Mathieson and Rosbash
1977) in conjunction with a sensitive RNase protection assay (Zinn, Dimaio and 
Manaitis 1983) might help to demonstrate the half life of XbmycA mRNA in 
oocy^es. This might be not possible since XbmycA mRNA seems to represent 
one of the low abundance classes of poly(A)+ RNAs (Perlman and Rosbash,
1978). Injection of in vitro synthesised XbmycA RNA directly into oocytes may 
also answer the same question and might provide a basis for determining what 
sequences (or other factors) are important in the stabilisation of XbmycA RNA 
in oocytes.
Upon fertilisation degradation of XbmycA mRNA is induced. It is difficult to 
estimate the half life of the XbmycA mRNA during early cleavage due to the 
kinetics of degradation but it is of the order of 5 hours. These experiments 
should be repeated to determine this precisely. Even this half life is several
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times greater than that described for mammalian systems (Dani et a/1984). If 
in Xenopus somatic cells c-myc mRNA has a half life (which remains to be 
determined) similar to mammalian systems and if during embryogenesis 
mechanisms that degrade c-myc mRNA are similar to somatic cells then 
factors that influence c-myc degradation may be limiting early in development. 
Such factors may be stored in the oocyte then activated on fertilisation or they 
may become newly made during development. Also it may be that c-myc 
mRNA is only released fortranslation slowly in embryos and after doing so 
becomes degraded. After stage 11 XbmycA mRNA assumes a more typical 
somatic level with slightly greater expression during neurulation. I have 
prelimioojfv evidence that XbmycA mRNA is expressed to a higher level in the 
developing brain and nervous system, which might parallel observations in 
mouse development (Rupport, Goldowitz and Wille 1986). Further northern 
analysis with more finely dissected embryos in conjunction with in situ 
hybridisation experiments may define the localisation of expression of the 
XbmycA gene during early development. Also int\oi experiments suggest that 
the XbmycA genes are expressed in a variety of tissues at a low level which is 
similar to results for mammalian c-myc (Stewart, Bellve and Leder 1984). This 
analysis could be extended to other Xenopus tissues and known numbers of 
cells could be used to determine if any adult tissue has an unusually high level 
of c-myc expression; for example it would be of interest to determine c-myc 
expression in the developing brain compared with the adult brain.
As described in chapter 1 there is a strong correlation of c-myc mRNA 
expression with cell proliferation and a downregulation of c-myc mRNA 
expression upon differentiation. Obviously from the experiments I described 
c-myc mRNA expression is uncoupled from cellular proliferation during 
Xenopus oogenesis. Undoubtably this is a reflection on the mode of 
embryogenesis that Xenopus exhibits. There are two possible interpretations 
of the high levels of c-myc mRNA in the early oocyte. Firstly it may be 
required to sustain oocyte metabolism and therefore may be involved in the 
regulation of ribosomal RNA synthesis which is a major metabolic event 
occurring maximally after stage II of oogenesis (Rosbash and Ford 1974). 
Secondly it may be required to provide protein products to sustain embryo 
division through its early phase of transcriptional quiescence. This may mean 
the c-myc protein is involved in DNA synthesis, RNA processing or ribosome 
assembly. Possibly the c-myc protein has a variety of functions with different
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roles in the developing oocyte or neuron to the proliferating embryonic or 
somatic cell.
6.4 The X.borealis C-myc Protein
In chapter 4 I described my attempts to make an antiserum against the 
XbmycA protein which were unsuccessfX To further study the expression of 
the protein in Xenopus and to attempt biochemical experiments desperately 
requires the availability of a homologous antiserum to the protein (I have 
previously described ways how this might be achieved). An immediate 
question to be asked with the availability of such an antiserum would be a 
study of XbmycA protein synthesis during oogenesis. It would be interesting 
to see if protein synthesis is coupled to mRNA expression or if there is a delay 
in synthesis due to translational control. Also it could be determined whether 
the XbmycA protein is synthesised in a stable fashion during oogenesis or 
does it turnover; this could also be compared with the protein half life in 
embryonic and somatic cells. Expression of the XbmycA protein during 
development could also be studied to see if it parallels the expression of 
XbmycA mRNA.
Many studies with such an antiserum using immunofluorescence in situ 
could be done to determine both the localisation of the XbmycA protein within 
a cell and its localisation between a variety of cell types. It is expected, 
providing the XbmycA protein has a function similar to other c-myc proteins, 
that it would be localised in the cell nucleus though possibly some becomes 
sequestered into the oocyte cytoplasm in a storage form for future use. 
Previously it has been shown that injection of DNA into the oocyte cytoplasm 
leads to the production of nucleus like structures suggesting the oocyte is rich 
in nuclear structural components (Forbes, Kirschner and Newport 1983). In situ 
hybridisation to different embryo stages using an anti-XbmycA antiserum 
would also help confirm whether the protein product indeed has a role in 
neural development.
An anti-XbmycA antiserum could also be used to study the characteristics 
of specifically modified XbmycA proteins. The antiserum could be used to 
analyse the fate of bacterially synthesised XbmycA protein containing specific 
deletions injected into oocytes or to analyse the fate of specif»to\ly deleted 
XbmycA proteins synthesised from mRNA made in vitro that has been injected
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into oocytes. These experiments may address the question of which 
sequence(s) are responsible for nuclear location of the XbmycA protein and 
might help understanding of post-translational modifications on the protein 
structure and function. Similar experiments could be done to see if injection of 
XbmycA protein has any effect on oocyte maturation for instance by 
influencing cAMP levels. An early response of Xenopus oocytes to 
progesterone is a drop in cAMP levels which is the possible signal for 
induction of meiosis (Mailer 1983) therefore such experiments may show a link 
between c-myc and meiotic cell divisions. If the oocyte does contain a large 
store of c-myc protein it is difficult to see a role for it in me'iosi«> unless it is 
stored in an inactive form hence the previous experiment might not be 
particularly informative.
6.5 Some Other Future Experiments
Apart from the experiments eluded to above and in other chapters an 
analysis of c-myc function could be attempted by trying to block its function in 
early embryos. There are three possible ways that this might be carried out. 
Firstly if homologous antiserum was available this could be injected into 
oocytes and embryos to try and block c-myc function. It is known that 
injected antibodies are relatively stable and retain their antigenic specificity and 
they can inactivate certain nuclear enzymes such as RNA polymerase I (see 
Scheer 1986 for review). Hence a careful analysis of the effect of injected 
ant\-c-myc antibodies might help elucidate the c-myc protein function in early 
development. Also injection of such antibodies into specific blastomeres might 
show whether the c-myc protein is required for the differentiation of certain 
cell types (e.g. neural development).
A second approach would attempt to achieve the same outcome as the first 
but involves injection of antisense message into oocytes and embryos to 
hopefully block translation of c-myc mRNA. This technology appears to work 
in oocytes as the translation of exogenously introduced globin mRNA can be 
blocked by the injection of antisense globin RNA (Melton 1985) and the 
translation of an endogenous ribosomal protein L1 gene can be blocked by the 
injection of antisense L1 RNA (Wormington 1986). As yet the technology 
cannot be used to block translation of specific mRNAs during development as 
many factors appear to influence the stabilisation/degradation and localisation 
of the injected antisense RNA in cleavage cells (Colman and Drummond 1986,
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Melton and Rebagliati 1986), though these problems may be overcome soon. 
There are also two other points to note: 1) it is not clear how 'leaky' these 
treatments will be and 2) any c-myc protein inherited from the egg may 
complicate the analysis hence antibodies may also have to be employed.
The third approach is actually a modification of the second type of 
experiment and is based on the injection of cloned DNA into oocytes and 
embryos to direct the endogenous synthesis of antisense c-myc RNA to try 
and block the translation of c-myc mRIMA. Previously it has been demonstrated 
that the expression of a thymidine kinase gene injected into mouse L cells is 
significantly reduced by co-injection of a plasmid that directs the synthesis of 
antisense thymidine kinase RNA (Izant and Weintraub 1984). Plasmid DNAs 
injected into fertilised Xenopus eggs can persist, in an episomal form, beyond 
the neurula stage of development (e.g. Krieg and Melton 1985, Mohun, Garrett 
and Gurdon 1986), providing the prospect for injection of plasmids into 
Xenopus fertilised eggs which direct the synthesis of antisense c-myc RNA. 
Such plasmid constructs could be designed to express antisense RNA at 
particular stages of development or in particular cell types. For example 
plasmids which direct antisense c-myc RNA under the control of the gastrula 
specific promoter from the GS17 gene (Krieg and Melton 1985) may block the 
translation of c-myc mRNA during early neurulation or under the control of the 
cardiac actin gene promoter (Mohun, Garrett and Gurdon 1986) may block the 
translation of c-myc mRNA in embryonic muscle cells. Experiments along 
these lines may be very revealing about the function of c-myc. Parallel 
experiments to try and over-express c-myc mRNA could also be done to try 
and see what effect high levels of c-myc protein have at a particular 
developmental stage or cell type. It should be borne in mind that transgenic 
mice containing c-myc gene constructs showed no developmental defects 
(Stewart et al 1985, Adams et al 1985, Leder et al 1986) hence experiments 
using plasmids directing synthesis of sense c-myc RNA in Xenopus embryos 
may not show any gross effect on development.
6.6 Recent Publications on the X.laevis C-myc Gene
Within the last two weeks of writing the bulk of this thesis three 
independent papers describing the c-myc gene in X.laevis have appeared (King, 
Roberts and Eisenman 1986, Godeau et al 1986, Taylor et al 1986). This 
obviously reflects the potential of Xenopus for studying cellular oncogene
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function and overall the results described therein are in agreement with mine. 
Two studies have isolated homologous c-myc cDNA probes from X.laevis cDNA 
libraries (King, Roberts and Eisenman 1986, Taylor et al 1986) and one used 
heterologous probes (with inherent difficulties) to look at c-myc mRNA 
expression (Godeau et al 1986). As described in chapter 5 I have shown that 
the X.laevis and X.borealis c-myc cDNA sequences are very closely related.
Each of the above studies show a temporal pattern of c-myc mRNA 
expression during oogenesis and development which approximately agrees with 
my data. King and co-workers do not give any densitometric estimates of 
expression levels but from the original paper it looks very similar to my data. 
There is some disagreement on the expression of c-myc mRNA during 
oogenesis. I find a gradual decrease during oogenesis, Taylor et al find a 
gradual increase till stage III of oogenesis which subsequently declines and 
Godeau et al find an almost constant level of expression through all stages. 
This discrepancy could be due to individual batch variation and would be 
resolved by repeating the experiments. I find it difficult to believe that c-myc 
mRNA accumulates until stage III of oogenesis since as discussed previously 
no poly(A)+ RNAs have ever been shown to accumulate after stage II of 
oogenesis. The estimated levels of expression of the c-myc gene during 
oogenesis and development by Taylor et al are almost exactly the same as my 
estimates, this study also showed a small peak of expression during 
neurulation. King and co-workers report a higher level of c-myc mRNA in the 
ventral mesoderm of stage 13 neurula embryos but they did not analyse any 
dorsal tissue so this result might not disagree with the observed peak during 
neurulationdescribed by myself and Taylor et al.
All three studies use anti-human c-myc antisera to study the expression of 
X.laevis c-myc proteins. Taylor and co-workers show the presence, in a 
Xenopus kidney cell line, of two nuclear phosphoprotein species with molecular 
weights of 61 and 64 kD which have a short half of about 30 minutes. The 
oocyte appears only to have the 64 kD species which is located both in the 
nucleus and cytoplasm; also since it was impossible to detect this protein by 
immunoprecipitation in the oocyte they suggest it has a very long half life. 
Godeau et al show the presence of a single 65 kD species and using 
immunofluorescence they show in follicle cells it is only located in the nucleus 
but in oocytes it is located mainly in the nucleus with some cytoplasmic 
staining which may be due to sequestering of nuclear product in the
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cytoplasm. Also they demonstrate that the maximal levels of the putative 
c-myc protein synthesis occur in stage V oocytes hence invoking some kind of 
translational regulation of the c-myc mRNA. Taylor et al detect the presence 
of putative c-myc proVe\c\ species of 62 and 77 kD and show again that maximal 
synthesis occurs in stage V oocytes. It seems the 77 kD species may be an 
artifact since it is not detected from proteins synthesised from hybrid selected 
c-myc mRNA and only two out of five antisera used detect the larger product. 
Hence although there are differences between each protein study, probably due 
to the different heterologous antiserum used, the overall conclusions appear to 
be similar: the c-myc protein is synthesised from mRNA that is translationaly 
regulated in the oocyte and is mainly localised in the nucleus with some 
cytoplasmic storage and is apparently stable. In contrast it is only nuclear and 
has a short half life in Xenopus somatic cells.
6.7 Conclusions
My own work and the recent work described in 6.6 has shown that it is 
possible to undertake an analysis of c-myc function during early development 
in Xenopus. This work is basically at the preliminary stages with only a 
descriptive analysis of the Xenopus c-myc gene and product being described 
so far, hopefully the future will bring some real insight to how this mysterious 
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APPENDIX 1
CALCULATION OF AMOUNT OF POLY(A)+ RNA AS ESTIMATED BY 
3H POLY(U) HYBRIDISATION
If 3H poly(U) has specific activity of S cpm/ng and 
n = cpm poly(U) bound in the reaction - background 
then total poly(A) per reaction = n/S ng.
Assuming the average length of a poly(A) + containing RNA is 2.0kb with a 
poly(A) tail length of 50 nucleotides then the poly(A) content is equivalent to 
1/40 of the weight of poly(A) + containing RNA,
Hence ng poly(A) + per reaction containing RNA = 40 x ng poly(A).
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APPENDIX 2
CALCULATION OF THE AMOUNT OF CDNA PRODUCTS SYNTHESISED
For both first and second strand reactions the weight of cDNA synthesised in 
ng is given by the general formula:
ng of product made = (total incorporated - background cpm in the reaction) x 
total moles NTP (both labeled and unlabeled) x 10 9 / total cpm in the reaction x 
molecular weight NTP x fractional base composition of the nucleic acid. Where 
NTP is used as the labeled nucleotide(s) in the reaction.
Example
For first strand reaction described in chapter 2 containing 120 nmoles dCTP 
and 20 uCi a 32 P dCTP (from which the number of moles is insignificant) and 
the fraction of CTP in the RNA is 0.22 the amount of first strand cDNA made is
(5132 - 174) x (120 x 10~ 9) x (340) x 10 9 / (194222) x (0.22) = 4734ng.
Since 10jag of poly(A)"1" RNA was used this represents 47% first strand 
synthesis.
Similarly for second strand reaction described in chapter 2 containing 5 nmoles 
dCTP, 20 u.Ci a 32 P dCTP and 100ng of first strand cDNA the amount of second 
strand cDNA made is
(2065 - 515) x (5 x 10~9) x (340) x 10 9 / (129150) x (0.22) = 92.7ng.
Since 100ng of first strand cDNA was used this represents 93% second strand 
synthesis.
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